Reagent sets and gene signatures for renal tubule injury

ABSTRACT

The invention discloses reagent sets and gene signatures for predicting onset of renal tubule injury in a subject. The invention also provides a necessary set of 186 genes useful for generating signatures of varying size and performance capable of predicting onset of renal tubule injury. The invention also provides methods, apparatuses and reagents useful for predicting future renal tubule injury based on expression levels of genes in the signatures. In one particular embodiment the invention provides a method for predict whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 11/184,272, filed on Jul. 18, 2005, which claims priority from U.S. Provisional Application No. 60/589,409, filed Jul. 19, 2004, each of which is hereby incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

This invention relates to reagent sets and gene signatures useful for predicting the onset of renal tubule injury (RTI) in a subject. The invention also provides methods, apparatuses and kits useful for predicting occurrence of renal tubule injury based on expression levels of genes in the signatures. In one embodiment the invention provides a method for predicting whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.

BACKGROUND OF THE INVENTION

Renal tubule injury (also referred to herein as, “tubular nephrosis”) is a common drug-induced toxicity that includes degenerative lesions of the renal tubules, such as acute tubular dilation, vacuolation and necrosis. Necrotic lesions of the tubules can arise as a consequence of septic, toxic or ischemic insult, and is a frequent cause of renal failure among hospitalized patients. Recognition is hampered by the lack of accurate markers and the shortcomings and over-reliance of serum markers of impaired glomerular filtration rate (i.e., serum creatinine and blood urea nitrogen) (see e.g., Schrier et al., “Acute renal failure: definitions, diagnosis, pathogenesis, and therapy,” J Clin Invest, 114(1):5-14 (2004)). Drugs associated with the development of tubular nephrosis include aminoglycoside antibiotics, antifungals, antineoplastics, immunosuppresants and radiocontrast dyes, among others.

Similarly to the human clinical setting, long-term treatment of rats during preclinical drug development with relatively low doses of aminoglycoside antibiotics, heavy metal toxicants or antineoplastic drugs, for example, leads to the development of degenerative lesions of the renal tubules. However, histopathological or clinical indications of kidney injury are not readily apparent in the early course of treatment, thus necessitating expensive and lengthy studies.

The development of methods to predict the future onset of renal tubule injury (RTI) and gain a greater understanding of the underlying mechanism, would facilitate the development more reliable clinical diagnostics and safer therapeutic drugs. In addition, improved preclinical markers for RTI would dramatically reduce the time, cost, and amount of compound required in order to prioritize and select lead candidates for progression through drug development.

SUMMARY OF THE INVENTION

The present invention provides methods, reagent sets, gene sets, and associated apparatuses and kits, that allow one to determine the early onset of renal tubule injury (or nephrotoxicity) by measuring gene expression levels. In one particular embodiment, the invention provides a RTI “necessary set” of 186 genes mined from a chemogenomic dataset. These genes are information-rich with respect to classifying biological samples for onset of RTI, even at sub-acute doses and time points of 5 days or earlier, where clinical and histopathological evidence of RTI are not manifested. Further, the invention discloses that the necessary set for RTI classification has the functional characteristic of reviving the performance of a fully depleted set of genes (for classifying RTI) by supplementation with random selections of as few as 10% of the genes from the set of 186. In addition, the invention discloses that selections from the necessary set made based on percentage impact of the selected genes may be used to generate high-performing linear classifiers for RTI that include as few as 4 genes. In one embodiment, the invention provides several different linear classifiers (or gene signatures) for RTI. For all of the disclosed embodiments based on the necessary set of 186 genes, the invention also provides reagent sets and kits comprising polynucleotides and/or polypeptides that represent a plurality of genes selected from the necessary set.

In one embodiment, the present invention provides a method for testing whether a compound will induce renal tubule injury in a test subject, the method comprising: administering a dose of a compound to at least one test subject; after a selected time period, obtaining a biological sample from the at least one test subject; measuring the expression levels in the biological sample of at least a plurality of genes selected from those listed in Table 4; determining whether the sample is in the positive class for renal tubule injury using a classifier comprising at least the plurality of genes for which the expression levels are measured. In one embodiment, the method is carried out wherein the test subject is a mammal selected from the group consisting of a human, cat, dog, monkey, mouse, pig, rabbit, and rat. In one preferred embodiment the test subject is a rat. In one embodiment, the biological sample comprises kidney tissue. In one embodiment, the method is carried out wherein the test compound is administered to the subject intravenously (IV), orally (PO, per os), or intraperitoneally (IP). In one embodiment, the method is carried out wherein the dose administered does not cause histological or clinical evidence of renal tubule injury at about 5 days, about 7 days, about 14 days, or even about 21 days. In one embodiment, the method is carried out wherein the expression levels are measured as log₁₀ ratios of compound-treated biological sample to a compound-untreated biological sample. In one embodiment, the method of the invention is carried out wherein the classifier is a linear classifier. In alternative embodiments, the classifier may be a non-linear classifier. In one embodiment, the method is carried out wherein the selected period of time is about 5 days or fewer, 7 days or fewer, 14 days or fewer, or even 21 days or fewer. In one embodiment of the method, the selected period of time is at least about 28 days.

In one embodiment, the method is carried out wherein the classifier comprises the genes and weights corresponding to any one of iterations 1 through 5 in Table 4. In one embodiment, the method of the invention is carried out wherein the classifier for renal tubule injury classifies each of the 64 compounds listed in Table 2 according to its label as nephrotoxic and non-nephrotoxic.

In one embodiment, the method is carried out wherein the linear classifier for renal tubule injury is capable of classifying a true label set with a log odds ratio at least 2 standard deviations greater than its performance classifying a random label set. In preferred embodiments of the method, the linear classifier for renal tubule injury is capable of performing with a training log odds ratio of greater than or equal to 4.35. In another embodiment, the plurality of genes includes at least 4 genes selected from those listed in Table 4, the four genes having at least having at least 2, 4, 8, 16, 32, or 64% of the total impact of all of the genes in Table 4.

The present invention also provides a gene sets, and reagent sets based on those gene sets, that are useful for testing whether renal tubule injury will occur in a test subject. In one embodiment, the invention provides a reagent set comprising a plurality of polynucleotides or polypeptides representing a plurality of genes selected from those listed in Table 4. In one embodiment, the reagent set comprises a plurality of genes includes at least 4 genes selected from those listed in Table 4, the 4 genes having at least 2% of the total impact of all of the genes in Table 4. In another embodiment, the reagent set comprises a plurality of genes includes at least 8 genes selected from those listed in Table 4, the 8 genes having at least 4% of the total impact of all of the genes in Table 4. Other embodiments include reagent sets based on subsets of genes randomly selected from Table 4, wherein the subset includes at least 4 genes having at least 1, 2, 4, 8, 16, 32, or 64% of the total impact. In preferred embodiments, the reagent sets of the invention include represent as few genes as possible from Table 4 while maximizing percentage of total impact. In preferred embodiments, the reagent sets of the invention include fewer than 1000, 500, 400, 300, 200, 100, 50, 20, 10, or even 8, polynucleotides or polypeptides representing the plurality of genes from Table 4. In one embodiment, the reagent sets consist essentially of polynucleotides or polypeptides representing the plurality of genes from Table 4. Further, the invention comprises kits comprising the reagent sets as components. In one embodiment, the reagent set is packaged in a single container consisting essentially of polynucleotides or polypeptides representing the plurality of genes from Table 4.

In one embodiment, the reagent sets of the invention comprise polynucleotides or polypeptides representing genes comprising a random selection of at least about 10% of the genes from Table 4, wherein the addition of said randomly selected genes to a fully depleted gene set for the renal tubule injury classification question increases the average logodds ratio of the linear classifiers generated by the depleted set to at least about 2.5. In another embodiment, a random selection of at least 20% of the genes from Table 4, wherein the addition of said randomly selected genes to a fully depleted gene set for the renal tubule injury classification question increases the average logodds ratio of the linear classifiers generated by the depleted set to at least about 3.3. In another embodiment, a random selection of at least 40% of the genes from Table 4, wherein the addition of said randomly selected genes to a fully depleted gene set for the renal tubule injury classification question increases the average logodds ratio of the linear classifiers generated by the depleted set to at least about 4.0. In other embodiments, reagent sets of the present invention comprise random selections of at least about 5%, 30%, 50%, 60%, 70%, 80%, 90%, or even 99% of the genes from Table 4, each which are capable of substantially increasing the average performance of a depleted set for generating classifiers RTI.

In one embodiment, the invention provides a reagent set for classifying renal tubule injury comprising a set of polynucleotides or polypeptides representing a plurality of genes selected from Table 4, wherein the addition of a random selection of at least 10% of said plurality of genes to the fully depleted set for the renal tubule injury classification question increases the average logodds ratio of the linear classifiers generated by the depleted set by at least 2-fold. In another embodiment, the reagent set includes at least 40% of said plurality of genes to the fully depleted set for the renal tubule injury classification question increases the average logodds ratio of the linear classifiers generated by the depleted set by at least 3-fold.

In another preferred embodiment the plurality of genes are selected from the variables of a linear classifier capable of classifying renal tubule injury with a training log odds ratio of greater than or equal to 4.35. In one preferred embodiment, the plurality of genes is the set of genes in any one of iterations 1 through 5 in Table 4. In another embodiment, the plurality of genes is the set of genes in any one of Tables 7, 8, 10, and 11. In one embodiment the reagents are polynucleotide probes capable of hybridizing to a plurality of genes selected from those listed in Table 4, and in a preferred embodiment, the polynucleotide probes are labeled.

In another embodiment, the reagents are primers for amplification of the plurality of genes. In one embodiment the reagents are polypeptides encoded by a plurality of genes selected from those listed in Table 4. Preferably the reagents are polypeptides that bind to a plurality proteins encoded by a plurality of genes selected from those listed in Table 4. In one preferred embodiment, the reagent set comprises secreted proteins encoded by genes listed in Table 4.

The present invention also provides an apparatus for predicting whether renal tubule injury will occur in a test subject comprising a reagent set as described above. In preferred embodiments, the apparatus comprises a device with reagents for detecting polynucleotides, wherein the reagents comprise or consist essentially of a reagent set for testing whether renal tubule injury will occur in a test subject as described above.

In one embodiment, the apparatus comprises at least a plurality of polynucleotides or polypeptides representing a plurality of genes selected from those listed in Table 4. In one embodiment the apparatus comprises a plurality of genes includes at least 4 genes selected from those listed in Table 4, the four genes having at least 2% of the total impact of the genes in Table 4. In another preferred embodiment the plurality of genes are variables in a linear classifier capable of classifying renal tubule injury with a training log odds ratio of greater than or equal to 4.35. In one embodiment, the apparatus comprises the plurality of genes listed in any one of iterations 1 through 5 in Table 4. In one preferred embodiment, the apparatus comprises polynucleotide probes capable of hybridizing to a plurality of genes selected from those listed in Table 4. In preferred embodiments, the apparatus comprises a plurality of polynucleotide probes bound to one or more solid surfaces. In one embodiment, the plurality of probes are bound to a single solid surface in an array. Alternatively, the plurality of probes are bound to the solid surface on a plurality of beads. In another preferred embodiment, the apparatus comprises polypeptides encoded by a plurality of genes selected from those listed in Table 4. In one preferred embodiment, the polypeptides are secreted proteins encoded by genes listed in Table 4.

The present invention also provides a method for predicting renal tubule injury in an individual comprising: obtaining a biological sample from the individual after short-term treatment with compound; measuring the expression levels in the biological sample of at least a plurality of genes selected from Table 4; and determining whether the sample is in the positive class for renal tubule injury using a linear classifier comprising at least the plurality of genes for which the expression levels are measured; wherein a sample in the positive class indicates that the individual will have renal tubule injury following sub-chronic treatment with compound. In one preferred embodiment, the method for predicting renal tubule injury is carried out wherein the genes encode secreted proteins. In a preferred embodiment, the individual is a mammal, and preferably a rat. In another preferred embodiment, the biological sample is selected from blood, urine, hair or saliva. In another preferred embodiment of the method, the expression log₁₀ ratio is measured using an array of polynucleotides.

In another embodiment, the invention provides a method for monitoring treatment of an individual for renal tubule injury, or with a compound suspected of causing renal tubule injury, said method comprising: obtaining a biological sample from the individual after short-term treatment with compound; measuring the expression levels in the biological sample of at least a plurality of genes selected from Table 4; and determining whether the sample is in the positive class for renal tubule injury using a linear classifier comprising at least the plurality of genes for which the expression levels are measured; wherein a sample in the positive class indicates that the individual will have renal tubule injury. In a preferred embodiment, the individual is a mammal, and preferably a rat. In another preferred embodiment, the biological sample is selected from blood, urine, hair or saliva. In another preferred embodiment of the method, the expression log₁₀ ratio is measured using an array of polynucleotides.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the 35 genes in the first iteration RTI signature derived according to the method of Example 3, their corresponding weights, and their average expression log₁₀ ratio in the 15 compound training positive class.

FIG. 2 depicts a plots of training and test logodds ratios for prediction of renal tubule injury for 20 subsets of genes randomly selected from the necessary set. A training or test LOR of 4.00 could be achieved by signatures of as few as 4 and 7 genes, respectively.

DETAILED DESCRIPTION OF THE INVENTION

I. Overview

The present invention provides methods for predicting whether compound treatments induce future renal tubular injury following sub-chronic or long-term treatment using expression data from sub-acute or short-term treatments. The invention provides necessary and sufficient sets of genes and specific signatures comprising these genes that allow gene expression data to be used to identify the ability of a compound treatment to induce late onset renal tubule injury before the actual histological or clinical indication of the toxicity. Further, the invention provides reagent sets and diagnostic devices comprising the disclosed gene sets and signatures that may be used to deduce compound toxicity using short term studies, and avoiding lengthy and costly long term studies.

II. Definitions

“Multivariate dataset” as used herein, refers to any dataset comprising a plurality of different variables including but not limited to chemogenomic datasets comprising logratios from differential gene expression experiments, such as those carried out on polynucleotide microarrays, or multiple protein binding affinities measured using a protein chip. Other examples of multivariate data include assemblies of data from a plurality of standard toxicological or pharmacological assays (e.g., blood analytes measured using enzymatic assays, antibody based ELISA or other detection techniques).

“Variable” as used herein, refers to any value that may vary. For example, variables may include relative or absolute amounts of biological molecules, such as mRNA or proteins, or other biological metabolites. Variables may also include dosing amounts of test compounds.

“Classifier” as used herein, refers to a function of a set of variables that is capable of answering a classification question. A “classification question” may be of any type susceptible to yielding a yes or no answer (e.g., “Is the unknown a member of the class or does it belong with everything else outside the class?”). “Linear classifiers” refers to classifiers comprising a first order function of a set of variables, for example, a summation of a weighted set of gene expression logratios. A valid classifier is defined as a classifier capable of achieving a performance for its classification task at or above a selected threshold value. For example, a log odds ratio≧4.00 represents a preferred threshold of the present invention. Higher or lower threshold values may be selected depending of the specific classification task.

“Signature” as used herein, refers to a combination of variables, weighting factors, and other constants that provides a unique value or function capable of answering a classification question. A signature may include as few as one variable. Signatures include but are not limited to linear classifiers comprising sums of the product of gene expression logratios by weighting factors and a bias term.

“Weighting factor” (or “weight”) as used herein, refers to a value used by an algorithm in combination with a variable in order to adjust the contribution of the variable.

“Impact factor” or “Impact” as used herein in the context of classifiers or signatures refers to the product of the weighting factor by the average value of the variable of interest. For example, where gene expression logratios are the variables, the product of the gene's weighting factor and the gene's measured expression log₁₀ ratio yields the gene's impact. The sum of the impacts of all of the variables (e.g., genes) in a set yields the “total impact” for that set.

“Scalar product” (or “Signature score”) as used herein refers to the sum of impacts for all genes in a signature less the bias for that signature. A positive scalar product for a sample indicates that it is positive for (i.e., a member of) the classification that is determined by the classifier or signature.

“Sufficient set” as used herein is a set of variables (e.g., genes, weights, bias factors) whose cross-validated performance for answering a specific classification question is greater than an arbitrary threshold (e.g., a log odds ratio≧4.0).

“Necessary set” as used herein is a set of variables whose removal from the full set of all variables results in a depleted set whose performance for answering a specific classification question does not rise above an arbitrarily defined minimum level (e.g., log odds ratio≧4.00).

“Log odds ratio” or “LOR” is used herein to summarize the performance of classifiers or signatures. LOR is defined generally as the natural log of the ratio of the odds of predicting a subject to be positive when it is positive, versus the odds of predicting a subject to be positive when it is negative. LOR is estimated herein using a set of training or test cross-validation partitions according to the following equation, ${LOR} = {\ln\frac{\left( {{\sum\limits_{i = 1}^{c}{TP}_{i}} + 0.5} \right)*\left( {{\sum\limits_{i = 1}^{c}{TN}_{i}} + 0.5} \right)}{\left( {{\sum\limits_{i = 1}^{c}{FP}_{i}} + 0.5} \right)*\left( {{\sum\limits_{i = 1}^{c}{FN}_{i}} + 0.5} \right)}}$ where c (typically c=40 as described herein) equals the number of partitions, and TP_(i), TN_(i), FP_(i), and FN_(i) represent the number of true positive, true negative, false positive, and false negative occurrences in the test cases of the i^(th) partition, respectively.

“Array” as used herein, refers to a set of different biological molecules (e.g., polynucleotides, peptides, carbohydrates, etc.). An array may be immobilized in or on one or more solid substrates (e.g., glass slides, beads, or gels) or may be a collection of different molecules in solution (e.g., a set of PCR primers). An array may include a plurality of biological polymers of a single class (e.g., polynucleotides) or a mixture of different classes of biopolymers (e.g., an array including both proteins and nucleic acids immobilized on a single substrate).

“Array data” as used herein refers to any set of constants and/or variables that may be observed, measured or otherwise derived from an experiment using an array, including but not limited to: fluorescence (or other signaling moiety) intensity ratios, binding affinities, hybridization stringency, temperature, buffer concentrations.

“Proteomic data” as used herein refers to any set of constants and/or variables that may be observed, measured or otherwise derived from an experiment involving a plurality of mRNA translation products (e.g., proteins, peptides, etc) and/or small molecular weight metabolites or exhaled gases associated with these translation products.

III. General Methods of the Invention

The present invention provides a method to derive multiple non-overlapping gene signatures for renal tubule injury. These non-overlapping signatures use different genes and thus each may be used independently in a predictive assay to confirm that an individual will suffer renal tubule injury. Furthermore, this method for identifying non-overlapping gene signatures also provides the list of all genes “necessary” to create a signature that performs above a certain minimal threshold level for a specific predicting renal tubule injury. This necessary set of genes also may be used to derive additional signatures with varying numbers of genes and levels of performance for particular applications (e.g., diagnostic assays and devices).

Classifiers comprising genes as variables and accompanying weighting factors may be used to classify large datasets compiled from DNA microarray experiments. Of particular preference are sparse linear classifiers. Sparse as used here means that the vast majority of the genes measured in the expression experiment have zero weight in the final linear classifier. Sparsity ensures that the sufficient and necessary gene lists produced by the methodology described herein are as short as possible. These short weighted gene lists (i.e., a gene signature) are capable of assigning an unknown compound treatment to one of two classes.

The sparsity and linearity of the classifiers are important features. The linearity of the classifier facilitates the interpretation of the signature—the contribution of each gene to the classifier corresponds to the product of its weight and the value (i.e., log₁₀ ratio) from the microarray experiment. The property of sparsity ensures that the classifier uses only a few genes, which also helps in the interpretation. More importantly, the sparsity of the classifier may be reduced to a practical diagnostic apparatus or device comprising a relatively small set of reagents representing genes.

A. Gene Expression Related Datasets

a. Various Useful Data Types

The present invention may be used with a wide range of gene expression related data types to generate necessary and sufficient sets of genes useful for renal tubule injury signatures. In a preferred embodiment, the present invention utilizes data generated by high-throughput biological assays such as DNA microarray experiments, or proteomic assays. The datasets are not limited to gene expression related data but also may include any sort of molecular characterization information including, e.g., spectroscopic data (e.g., UV-Vis, NMR, IR, mass spectrometry, etc.), structural data (e.g., three-dimensional coordinates) and functional data (e.g., activity assays, binding assays). The gene sets and signatures produced by using the present invention may be applied in a multitude of analytical contexts, including the development and manufacture of detection devices (i.e., diagnostics).

b. Construction of a Gene Expression Dataset

The present invention may be used to identify necessary and sufficient sets of responsive genes within a gene expression dataset that are useful for predicting renal tubule injury. In a preferred embodiment, a chemogenomic dataset is used. For example, the data may correspond to treatments of organisms (e.g., cells, worms, frogs, mice, rats, primates, or humans etc.) with chemical compounds at varying dosages and times followed by gene expression profiling of the organism's transcriptome (e.g., measuring mRNA levels) or proteome (e.g., measuring protein levels). In the case of multicellular organisms (e.g., mammals) the expression profiling may be carried out on various tissues of interest (e.g., liver, kidney, marrow, spleen, heart, brain, intestine). Typically, valid sufficient classifiers or signatures may be generated that answer questions relevant to classifying treatments in a single tissue type. The present specification describes examples of necessary and sufficient gene signatures useful for classifying chemogenomic data in liver tissue. The methods of the present invention may also be used however, to generate signatures in any tissue type. In some embodiments, classifiers or signatures may be useful in more than one tissue type. Indeed, a large chemogenomic dataset, like that exemplified in the present invention may reveal gene signatures in one tissue type (e.g., liver) that also classify pathologies in other tissues (e.g., intestine).

In addition to the expression profile data, the present invention may be useful with chemogenomic datasets including additional data types such as data from classic biochemistry assays carried out on the organisms and/or tissues of interest. Other data included in a large multivariate dataset may include histopathology, pharmacology assays, and structural data for the chemical compounds of interest.

One example of a chemogenomic multivariate dataset particularly useful with the present invention is a dataset based on DNA array expression profiling data as described in U.S. patent publication 2002/0174096 A1, published Nov. 21, 2002 (titled “Interactive Correlation of Compound Information and Genomic Information”), which is hereby incorporated by reference for all purposes. Microarrays are well known in the art and consist of a substrate to which probes that correspond in sequence to genes or gene products (e.g., cDNAs, mRNAs, cRNAs, polypeptides, and fragments thereof), can be specifically hybridized or bound at a known position. The microarray is an array (i.e., a matrix) in which each position represents a discrete binding site for a gene or gene product (e.g., a DNA or protein), and in which binding sites are present for many or all of the genes in an organism's genome.

As disclosed above, a treatment may include but is not limited to the exposure of a biological sample or organism (e.g., a rat) to a drug candidate (or other chemical compound), the introduction of an exogenous gene into a biological sample, the deletion of a gene from the biological sample, or changes in the culture conditions of the biological sample. Responsive to a treatment, a gene corresponding to a microarray site may, to varying degrees, be (a) up-regulated, in which more mRNA corresponding to that gene may be present, (b) down-regulated, in which less mRNA corresponding to that gene may be present, or (c) unchanged. The amount of up-regulation or down-regulation for a particular matrix location is made capable of machine measurement using known methods (e.g., fluorescence intensity measurement). For example, a two-color fluorescence detection scheme is disclosed in U.S. Pat. Nos. 5,474,796 and 5,807,522, both of which are hereby incorporated by reference herein. Single color schemes are also well known in the art, wherein the amount of up- or down-regulation is determined in silico by calculating the ratio of the intensities from the test array divided by those from a control.

After treatment and appropriate processing of the microarray, the photon emissions are scanned into numerical form, and an image of the entire microarray is stored in the form of an image representation such as a color JPEG or TIFF format. The presence and degree of up-regulation or down-regulation of the gene at each microarray site represents, for the perturbation imposed on that site, the relevant output data for that experimental run or scan.

The methods for reducing datasets disclosed herein are broadly applicable to other gene and protein expression data. For example, in addition to microarray data, biological response data including gene expression level data generated from serial analysis of gene expression (SAGE, supra) (Velculescu et al., 1995, Science, 270:484) and related technologies are within the scope of the multivariate data suitable for analysis according to the method of the invention. Other methods of generating biological response signals suitable for the preferred embodiments include, but are not limited to: traditional Northern and Southern blot analysis; antibody studies; chemiluminescence studies based on reporter genes such as luciferase or green fluorescent protein; Lynx; READS (GeneLogic); and methods similar to those disclosed in U.S. Pat. No. 5,569,588 to Ashby et. al., “Methods for drug screening,” the contents of which are hereby incorporated by reference into the present disclosure.

In another preferred embodiment, the large multivariate dataset may include genotyping (e.g., single-nucleotide polymorphism) data. The present invention may be used to generate necessary and sufficient sets of variables capable of classifying genotype information. These signatures would include specific high-impact SNPs that could be used in a genetic diagnostic or pharmacogenomic assay.

The method of generating classifiers from a multivariate dataset according to the present invention may be aided by the use of relational database systems (e.g., in a computing system) for storing and retrieving large amounts of data. The advent of high-speed wide area networks and the internet, together with the client/server based model of relational database management systems, is particularly well-suited for meaningfully analyzing large amounts of multivariate data given the appropriate hardware and software computing tools. Computerized analysis tools are particularly useful in experimental environments involving biological response signals (e.g., absolute or relative gene expression levels). Generally, multivariate data may be obtained and/or gathered using typical biological response signals. Responses to biological or environmental stimuli may be measured and analyzed in a large-scale fashion through computer-based scanning of the machine-readable signals, e.g., photons or electrical signals, into numerical matrices, and through the storage of the numerical data into relational databases. For example a large chemogenomic dataset may be constructed as described in U.S. patent publication 2005/0060102, published Mar. 17, 2005, which is hereby incorporated by reference for all purposes.

B. Generating Valid Gene Signatures from a Chemogenomic Dataset

a. Mining a Large Chemogenomic Dataset

Generally classifiers or signatures are generated (i.e., mined) from a large multivariate dataset by first labeling the full dataset according to known classifications and then applying an algorithm to the full dataset that produces a linear classifier for each particular classification question. Each signature so generated is then cross-validated using a standard split sample procedure.

The initial questions used to classify (i.e., the classification questions) a large multivariate dataset may be of any type susceptible to yielding a yes or no answer. The general form of such questions is: “Is the unknown a member of the class or does it belong with everything else outside the class?” For example, in the area of chemogenomic datasets, classification questions may include “mode-of-action” questions such as “All treatments with drugs belonging to a particular structural class versus the rest of the treatments” or pathology questions such as “All treatments resulting in a measurable pathology versus all other treatments.” In the specific case of chemogenomic datasets based on gene expression, it is preferred that the classification questions are further categorized based on the tissue source of the gene expression data. Similarly, it may be helpful to subdivide other types of large data sets so that specific classification questions are limited to particular subsets of data (e.g., data obtained at a certain time or dose of test compound). Typically, the significance of subdividing data within large datasets become apparent upon initial attempts to classify the complete dataset. A principal component analysis of the complete data set may be used to identify the subdivisions in a large dataset (see e.g., US 2003/0180808 A1, published Sep. 25, 2003, which is hereby incorporated by reference herein.) Methods of using classifiers to identify information rich genes in large chemogenomic datasets is also described in U.S. Ser. No. 11/114,998, filed Apr. 25, 2005, which is hereby incorporated by reference herein for all purposes.

Labels are assigned to each individual (e.g., each compound treatment) in the dataset according to a rigorous rule-based system. The +1 label indicates that a treatment falls in the class of interest, while a −1 label indicates that the variable is outside the class. Thus, with respect to the 64 compound treatments shown in Table 2 (see Example 2 below) used in generating an RTI signature, the “nephrotoxic” treatments were labeled +1, whereas the “non-nephrotoxic” were labeled −1. Information used in assigning labels to the various individuals to classify may include annotations from the literature related to the dataset (e.g., known information regarding the compounds used in the treatment), or experimental measurements on the exact same animals (e.g., results of clinical chemistry or histopathology assays performed on the same animal). A more detailed description of the general method for using classification questions to mine a chemogenomic dataset for signatures is described in U.S. Ser. No. 11/149,612, filed Jun. 10, 2005, and PCT/US2005/020695, filed Jun. 10, 2005, each of which is hereby incorporated in its entirety by reference herein.

b. Algorithms for Generating Valid Gene Signatures

Dataset classification may be carried out manually, that is by evaluating the dataset by eye and classifying the data accordingly. However, because the dataset may involve tens of thousands (or more) individual variables, more typically, querying the full dataset with a classification question is carried out in a computer employing any of the well-known data classification algorithms.

In preferred embodiments, algorithms are used to query the full dataset that generate linear classifiers. In particularly preferred embodiments the algorithm is selected from the group consisting of: SPLP, SPLR and SPMPM. These algorithms are based respectively on Support Vector Machines (SVM), Logistic Regression (LR) and Minimax Probability Machine (MPM). They have been described in detail elsewhere (See e.g., El Ghaoui et al., op. cit; Brown, M. P., W. N. Grundy, D. Lin, N. Cristianini, C. W. Sugnet, T. S. Furey, M. Ares, Jr., and D. Haussler, “Knowledge-based analysis of microarray gene expression data by using support vector machines,” Proc Natl Acad Sci USA 97: 262-267 (2000)).

Generally, the sparse classification methods SPLP, SPLR, SPMPM are linear classification algorithms in that they determine the optimal hyperplane separating a positive and a negative class. This hyperplane, H can be characterized by a vectorial parameter, w (the weight vector) and a scalar parameter, b (the bias): H={x|w^(T)x+b=0}.

For all proposed algorithms, determining the optimal hyperplane reduces to optimizing the error on the provided training data points, computed according to some loss function (e.g., the “Hinge loss,” i.e., the loss function used in 1-norm SVMs; the “LR loss;” or the “MPM loss” augmented with a 1-norm regularization on the signature, w. Regularization helps to provide a sparse, short signature. Moreover, this 1-norm penalty on the signature will be weighted by the average standard error per gene. That is, genes that have been measured with more uncertainty will be less likely to get a high weight in the signature. Consequently, the proposed algorithms lead to sparse signatures, and take into account the average standard error information.

Mathematically, the algorithms can be described by the cost functions (shown below for SPLP, SPLR and SPMPM) that they actually minimize to determine the parameters w and b. SPLP ${{\min\limits_{w,b}{\sum\limits_{i}e_{i}}} + {\rho{\sum\limits_{i}{\sigma_{i}{w_{i}}{s.t.{y_{i}\left( {{w^{T}x_{i}} + b} \right)}}}}}} \geq {1 - e_{i}}$ e_(i) ≥ 0, i = 1, …  , N

The first term minimizes the training set error, while the second term is the 1-norm penalty on the signature w, weighted by the average standard error information per gene given by sigma. The training set error is computed according to the so-called Hinge loss, as defined in the constraints. This loss function penalizes every data point that is closer than “1” to the separating hyperplane H, or is on the wrong side of H. Notice how the hyperparameter rho allows trade-off between training set error and sparsity of the signature w. SPLR ${\min\limits_{w,b}{\sum\limits_{i}{\log\quad\left( {1 + {\exp\quad\left( {- {y_{i}\left( {{w^{T}x_{i}} + b} \right)}} \right)}} \right)}}} + {\rho{\sum\limits_{i}{\sigma_{i}{w_{i}}}}}$

The first term expresses the negative log likelihood of the data (a smaller value indicating a better fit of the data), as usual in logistic regression, and the second term will give rise to a short signature, with rho determining the trade-off between both. SPMPM ${{\min\limits_{w}\sqrt{w^{T}{\hat{\Gamma}}_{+}w}} + \sqrt{w^{T}{\hat{\Gamma}}_{-}w} + {\rho{\sum\limits_{i}{\sigma_{i}{w_{i}}\quad{s.t.\quad{w^{T}\left( {{\hat{x}}_{+} - {\hat{x}}_{-}} \right)}}}}}} = 1$

Here, the first two terms, together with the constraint are related to the misclassification error, while the third term will induce sparsity, as before. The symbols with a hat are empirical estimates of the covariances and means of the positive and the negative class. Given those estimates, the misclassification error is controlled by determining w and b such that even for the worst-case distributions for the positive and negative class (which we do not exactly know here) with those means and covariances, the classifier will still perform well. More details on how this exactly relates to the previous cost function can be found in e.g., El Ghaoui, L., G. R. G. Lanckriet, and G. Natsoulis, 2003, “Robust classifiers with interval data” Report # UCB/CSD-03-1279. Computer Science Division (EECS), University of California, Berkeley, Calif.

As mentioned above, classification algorithms capable of producing linear classifiers are preferred for use with the present invention. In the context of chemogenomic datasets, linear classifiers may be used to generate one or more valid signatures capable of answering a classification question comprising a series of genes and associated weighting factors. Linear classification algorithms are particularly useful with DNA array or proteomic datasets because they provide simplified signatures useful for answering a wide variety of questions related to biological function and pharmacological/toxicological effects associated with genes or proteins. These signatures are particularly useful because they are easily incorporated into wide variety of DNA- or protein-based diagnostic assays (e.g., DNA microarrays).

However, some classes of non-linear classifiers, so called kernel methods, may also be used to develop short gene lists, weights and algorithms that may be used in diagnostic device development; while the preferred embodiment described here uses linear classification methods, it specifically contemplates that non-linear methods may also be suitable.

Classifications may also be carried using principle component analysis and/or discrimination metric algorithms well-known in the art (see e.g., US 2003/0180808 A1, published Sep. 25, 2003, which is hereby incorporated by reference herein).

Additional statistical techniques, or algorithms, are known in the art for generating classifiers. Some algorithms produce linear classifiers, which are convenient in many diagnostic applications because they may be represented as a weighted list of variables. In other cases non-linear classifier functions of the initial variables may be used. Other types of classifiers include decision trees and neural networks. Neural networks are universal approximators (Hornik, K., M. Stinchcombe, and H. White. 1989. “Multilayer feedforward networks are universal approximators,” Neural Networks 2: 359-366); they can approximate any measurable function arbitrarily well, and they can readily be used to model classification functions as well. They perform well on several biological problems, e.g., protein structure prediction, protein classification, and cancer classification using gene expression data (see, e.g., Bishop, C. M. 1996. Neural Networks for Pattern Recognition. Oxford University Press; Khan, J., J. S. Wei, M. Ringner, L. H. Saal, M. Ladanyi, F. Westermann, F. Berthold, M. Schwab, C. R. Antonescu, C. Peterson, and P. S. Meltzer. 2001. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7: 673-679; Wu, C. H., M. Berry, S. Shivakumar, and J. McLarty. 1995. Neural networks for full-scale protein sequence classification: sequence encoding with singular value decomposition. Machine Learning 21: 177-193).

c. Cross-Validation of Gene Signatures

Cross-validation of a gene signature's performance is an important step for determining whether the signature is sufficient. Cross-validation may be carried out by first randomly splitting the full dataset (e.g., a 60/40 split). A training signature is derived from the training set composed of 60% of the samples and used to classify both the training set and the remaining 40% of the data, referred to herein as the test set. In addition, a complete signature is derived using all the data. The performance of these signatures can be measured in terms of log odds ratio (LOR) or the error rate (ER) defined as: LOR=ln(((TP+0.5)*(TN+0.5))/((FP+0.5)*(FN+0.5))) and ER=(FP+FN)/N;

where TP, TN, FP, FN, and N are true positives, true negatives, false positives, false negatives, and total number of samples to classify, respectively, summed across all the cross validation trials. The performance measures are used to characterize the complete signature, the average of the training or the average of the test signatures.

The SVM algorithms described above are capable of generating a plurality of gene signatures with varying degrees of performance for the classification task. In order to identify that signatures that are to be considered “valid,” a threshold performance is selected for the particular classification question. In one preferred embodiment, the classifier threshold performance is set as log odds ratio greater than or equal to 4.00 (i.e., LOR≧4.00). However, higher or lower thresholds may be used depending on the particular dataset and the desired properties of the signatures that are obtained. Of course many queries of a chemogenomic dataset with a classification question will not generate a valid gene signature.

Two or more valid gene signatures may be generated that are redundant or synonymous for a variety of reasons. Different classification questions (i.e., class definitions) may result in identical classes and therefore identical signatures. For instance, the following two class definitions define the exact same treatments in the database: (1) all treatments with molecules structurally related to statins; and (2) all treatments with molecules having an IC₅₀<1 μM for inhibition of the enzyme HMG CoA reductase.

In addition, when a large dataset is queried with the same classification question using different algorithms (or even the same algorithm under slightly different conditions) different, valid signatures may be obtained. These different signatures may or may not comprise overlapping sets of variables; however, they each can accurately identify members of the class of interest.

For example, as illustrated in Table 1, two equally performing gene signatures (LOR=˜7.0) for the fibrate class of compounds may be generated by querying a chemogenomic dataset with two different algorithms: SPLP and SPLR. Genes are designated by their accession number and a brief description. The weights associated with each gene are also indicated. Each signature was trained on the exact same 60% of the multivariate dataset and then cross validated on the exact same remaining 40% of the dataset. Both signatures were shown to exhibit the exact same level of performance as classifiers: two errors on the cross validation data set. The SPLP derived signature consists of 20 genes. The SPLR derived signature consists of eight genes. Only three of the genes from the SPLP signature are present in the eight gene SPLR signature.

Table 1: Two Gene Signatures for the Fibrate Class of Drugs Accession Weight Unigene name RLPC K03249 1.1572 enoyl-Co A, hydratase/3-hydroxyacyl Co A dehydrogenase AW916833 1.0876 hypothetical protein RMT-7 BF387347 0.4769 ESTs BF282712 0.4634 ESTs AF034577 0.3684 pyruvate dehydrogenate kinase 4 NM_019292 0.3107 carbonic anhydrase 3 AI179988 0.2735 ectodermal-neural cortex (with BTB-like domain) AI715955 0.211 Stac protein (SRC homology 3 and cysteine-rich domain protein) BE110695 0.2026 activating transcription factor 1 J03752 0.0953 microsomal glutathione S-transferase 1 D86580 0.0731 nuclear receptor subfamily 0, group B, member 2 BF550426 0.0391 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 AA818999 0.0296 muscleblind-like 2 NM_019125 0.0167 probasin AF150082 −0.0141 translocase of inner mitochondrial membrane 8 (yeast) homolog A BE118425 −0.0781 Arsenical pump-driving ATPase NM_017136 −0.126 squalene epoxidase AI171367 −0.3222 HSPC154 protein NM_019369 −0.637 inter alpha-trypsin inhibitor, heavy chain 4 AI137259 −0.7962 ESTs SPLR NM_017340 5.3688 acyl-coA oxidase BF282712 4.1052 ESTs NM_012489 3.8462 acetyl-Co A acyltransferase 1 (peroxisomal 3-oxoacyl-Co A thiolase) BF387347 1.767 ESTs K03249 1.7524 enoyl-Co A, hydratase/3-hydroxyacyl Co A dehydrogenase NM_016986 0.0622 acetyl-co A dehydrogenase, medium chain AB026291 −0.7456 acetoacetyl-CoA synthetase AI454943 −1.6738 likely ortholog of mouse porcupine homolog

It is interesting to note that only three genes are common between these two signatures, (K03249, BF282712, and BF387347) and even those are associated with different weights. While many of the genes may be different, some commonalities may nevertheless be discerned. For example, one of the negatively weighted genes in the SPLP derived signature is NM_(—)017136 encoding squalene epoxidase, a well-known cholesterol biosynthesis gene. Squalene epoxidase is not present in the SPLR derived signature but aceto-acteylCoA synthetase, another cholesterol biosynthesis gene is present and is also negatively weighted.

Additional variant signatures may be produced for the same classification task. For example, the average signature length (number of genes) produced by SPLP and SPLR, as well as the other algorithms, may be varied by use of the parameter p (see e.g., El Ghaoui, L., G. R. G. Lanckriet, and G. Natsoulis, 2003, “Robust classifiers with interval data” Report # UCB/CSD-03-1279. Computer Science Division (EECS), University of California, Berkeley, Calif.; and PCT publication WO 2005/017807 A2, published Feb. 24, 2005, each of which is hereby incorporated by reference herein). Varying ρ can produce signatures of different length with comparable test performance (Natsoulis et al., “Classification of a large microarray data set: Algorithm comparison and analysis of drug signatures,” Gen. Res. 15:724-736 (2005)). Those signatures are obviously different and often have no common genes between them (i.e., they do not overlap in terms of genes used).

C. “Stripping” Signatures from a Dataset to Generate the “Necessary” Set

Each individual classifier or signature is capable of classifying a dataset into one of two categories or classes defined by the classification question. Typically, an individual signature with the highest test log odds ratio will be considered as the best classifier for a given task. However, often the second, third (or lower) ranking signatures, in terms of performance, may be useful for confirming the classification of compound treatment, especially where the unknown compound yields a borderline answer based on the best classifier. Furthermore, the additional signatures may identify alternative sources of informational rich data associated with the specific classification question. For example, a slightly lower ranking gene signature from a chemogenomic dataset may include those genes associated with a secondary metabolic pathway affected by the compound treatment. Consequently, for purposes of fully characterizing a class and answering difficult classification questions, it is useful to define the entire set of variables that may be used to produce the plurality of different classifiers capable of answering a given classification question. This set of variables is referred to herein as a “necessary set.” Conversely, the remaining variables from the full dataset are those that collectively cannot be used to produce a valid classifier, and therefore are referred to herein as the “depleted set.”

The general method for identifying a necessary set of variables useful for a classification question involved what is referred to herein as a classifier “stripping” algorithm. The stripping algorithm comprises the following steps: (1) querying the full dataset with a classification question so as to generate a first linear classifier capable of performing with a log odds ratio greater than or equal to 4.0 comprising a first set of variables; (2) removing the variables of the first linear classifier from the full dataset thereby generating a partially depleted dataset; (3) re-querying the partially depleted dataset with the same classification question so as to generate a second linear classifier and cross-validating this second classifier to determine whether it performs with a log odds ratio greater than or equal to 4. If it does not, the process stops and the dataset is fully depleted for variables capable of generating a classifier with an average log odds ratio greater than or equal to 4.0. If the second classifier is validated as performing with a log odds ratio greater than or equal to 4.0, then its variables are stripped from the full dataset and the partially depleted set if re-queried with the classification question. These cycles of stripping and re-querying are repeated until the performance of any remaining set of variables drops below an arbitrarily set LOR. The threshold at which the iterative process is stopped may be arbitrarily adjusted by the user depending on the desired outcome. For example, a user may choose a threshold of LOR=0. This is the value expected by chance alone. Consequently, after repeated stripping until LOR=0 there is no classification information remaining in the depleted set. Of course, selecting a lower value for the threshold will result in a larger necessary set.

Although a preferred cut-off for stripping classifiers is LOR=4.0, this threshold is arbitrary. Other embodiments within the scope of the invention may utilize higher or lower stripping cutoffs e.g., depending on the size or type of dataset, or the classification question being asked. In addition other metrics could be used to assess the performance (e.g., specificity, sensitivity, and others). Also the stripping algorithm removes all variables from a signature if it meets the cutoff. Other procedures may be used within the scope of the invention wherein only the highest weighted or ranking variables are stripped. Such an approach based on variable impact would likely result in a classifier “surviving” more cycles and defining a smaller necessary set.

Other procedures may be used within the scope of the invention wherein only the highest weighted or ranking variables are stripped. Such an approach based on variable impact would likely result in a classifier “surviving” more cycles and defining a smaller necessary set.

In another alternative approach, the genes from signatures may be stripped from the dataset until it is unable to generate a signature capable of classifying the “true label set” with an LOR that is statistically different from its classification of the “random label set.” The “true label set” refers to a training set of compound treatment data that is correctly labeled (e.g., +1 class, −1 class) for the particular classification question. The “random label set” refers to the same set of compound treatment data where the class labels have been randomly assigned. Attempts to use a signature to classify a random label set will result in an average LOR of approximately zero and some standard deviation (SD). These values may be compared to the average LOR and SD for the classifying the true label set, where the SD is calculated based on LOR results across the 20 or 40 splits. The difference in classifying true and random label sets with valid signatures should be significantly greater than random. In such an alternative approach, the selected performance threshold for a signature is a p-value rather than a LOR cutoff.

The resulting fully-depleted set of variables that remains after a classifier is fully stripped from the full dataset cannot generate a classifier for the specific classification question (with the desired level of performance). Consequently, the set of all of the variables in the classifiers that were stripped from the full set are defined as “necessary” for generating a valid classifier.

The stripping method utilizes a classification algorithm at its core. The examples presented here use SPLP for this task. Other algorithms, provided that they are sparse with respect to genes could be employed. SPLR and SPMPM are two alternatives for this functionality (see e.g., El Ghaoui, L., G. R. G. Lanckriet, and G. Natsoulis, 2003, “Robust classifiers with interval data” Report # UCB/CSD-03-1279. Computer Science Division (EECS), University of California, Berkeley, Calif., and PCT publication WO 2005/017807 A2, published Feb. 24, 2005, which is hereby incorporated by reference herein).

In one embodiment, the stripping algorithm may be used on a chemogenomics dataset comprising DNA microarray data. The resulting necessary set of genes comprises a subset of highly informative genes for a particular classification question. Consequently, these genes may be incorporated in diagnostic devices (e.g., polynucleotide arrays) where that particular classification (e.g., renal tubule injury) is of interest. In other exemplary embodiments, the stripping method may be used with datasets from proteomic experiments.

D. Mining the Renal Tubule Injury Necessary Set for Signatures

Besides identifying the “necessary” set of genes for a particular signature (i.e., classifier), another important use of the stripping algorithm is the identification of multiple, non-overlapping sufficient sets of genes useful for answering a particular classification question. These non-overlapping sufficient sets are a direct product of the above-described general method of stripping valid classifiers. Where the application of the method results in a second validated classifier with the desired level of performance, that second classifier by definition does not include any genes in common with the first classifier. Typically, the earlier stripped non-overlapping gene signature yields higher performance with fewer genes. In other words, the earliest identified sufficient set usually comprises the highest impact, most information-rich genes with respect to the particular classification question. The valid classifiers that appear during later iterations of the stripping algorithm typically contain a larger number of genes. However, these later appearing classifiers may provide valuable information regarding normally unrecognized relationships between genes in the dataset. For example, in the case of non-overlapping gene signatures identified by stripping in a chemogenomics dataset, the later appearing signatures may include families of genes not previously recognized as involved in the particular metabolic pathway that is being affected by a particular compound treatment. Thus, functional analysis of a gene signature stripping procedure may identify new metabolic targets associated with a compound treatment.

The necessary set high impact genes generated by the stripping method itself represents a subset of genes that may be mined for further signatures. Hence, the complete set of genes in a necessary set for predicting renal tubule injury may used to randomly generate random subsets of genes of varying size that are capable of generating additional predictive signatures. One preferred method of selecting such subsets is based on percentage of total impact. Thus, subsets of genes are selected whose summed impact factors are a selected percentage of the total impact (i.e., the sum of the impacts of all genes in the necessary set). These percentage impact subsets may be used to generate new signatures for predicting renal tubule injury. For example, a random subset from the necessary set of 9 genes with 4% of the total impact may be used with one of the SVM algorithms to generate a new linear classifier of 8 genes, weighting factors and a bias term that may be used as a signature for renal tubule injury. Thus, the necessary set for a particular classification represents a greatly reduced dataset that can generate new signatures with varying properties such as shorter (or longer) gene lengths and higher (or lower) LOR performance values.

E. Functional Characterization of the Renal Tubule Injury Necessary Set

The stripping method described herein produces a necessary set of genes representing for answering the RTI classification question. The RTI necessary set of genes also may be characterized in functional terms based on the ability of the information rich genes in the set to supplement (i.e., “revive”) the ability of a fully “depleted” set of genes to generate valid RTI signatures. Thus, the necessary set for the RTI classification question corresponds to that set of genes from which any random selection when added to a depleted set (i.e., depleted for RTI classification question) restores the ability of that set to produce RTI signatures with an average LOR (avg. LOR) above a threshold level. The general method for functionally characterizing a necessary set in terms of its ability to revive its depleted set is described in U.S. Ser. No. 11/149,612, filed Jun. 10, 2005, and PCT/US2005/020695, filed Jun. 10, 2005, each of which is hereby incorporated in its entirety by reference herein.

Preferably, the threshold performance used is an avg. LOR greater than or equal to 4.00. Other values for performance, however, may be set. For example, avg. LOR may vary from about 1.0 to as high as 8.0. In preferred embodiments, the avg. LOR threshold may be 3.0 to as high as 7.0 including all integer and half-integer values in that range. The necessary set may then be defined in terms of percentage of randomly selected genes from the necessary set that restore the performance of a depleted set above a certain threshold. Typically, the avg. LOR of the depleted set is ˜1.20, although as mentioned above, datasets may be depleted more or less depending on the threshold set, and depleted sets with avg. LOR as low as 0.0 may be used. Generally, the depleted set will exhibit an avg. LOR between about 0.5 and 1.5.

The third parameter establishing the functional characteristics of the RTI necessary set of genes for answering the RTI classification question is the percentage of randomly selected genes from that set that result in reviving the threshold performance of the depleted set. Typically, where the threshold avg. LOR is at least 4.00 and the depleted set performs with an avg. LOR of ˜1.20, typically 16-36% of randomly selected genes from the necessary set are required to restore the average performance of the depleted set to the threshold value. In preferred embodiments, the random supplementation may be achieved using 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 or 36% of the necessary set.

Alternatively, as described above, the necessary set may be characterized based on its ability to randomly generate signatures capable of classifying a true label set with an average performance above those signatures ability to classify a random label set. In preferred embodiments, signatures generated from a random selection of at least 10% of the genes in the necessary set may perform at least 1 standard deviation, and preferably at least 2 standard deviations, better for classifying the true versus the random label set. In other embodiments, the random selection may be of at least 15%, 20%, 25%, 30%, 40%, 50%, and even higher percentages of genes from the set.

F. Using Signatures and the Necessary Set to Generate Diagnostic Assays and Devices for Predicting Renal Tubule Injury

A diagnostic usually consists in performing one or more assays and in assigning a sample to one or more categories based on the results of the assay(s). Desirable attributes of a diagnostic assays include high sensitivity and specificity measured in terms of low false negative and false positive rates and overall accuracy. Because diagnostic assays are often used to assign large number of samples to given categories, the issues of cost per assay and throughput (number of assays per unit time or per worker hour) are of paramount importance.

Typically the development of a diagnostic assay involves the following steps: (1) define the end point to diagnose, e.g., cholestasis, a pathology of the liver (2) identify one or more markers whose alteration correlates with the end point, e.g., elevation of bilirubin in the bloodstream as an indication of cholestasis; and (3) develop a specific, accurate, high-throughput and cost-effective assay for that marker. In order to increase throughput and decrease costs several diagnostics are often combined in a panel of assays, especially when the detection methodologies are compatible. For example several ELISA-based assays, each using different antibodies to ascertain different end points may be combined in a single panel and commercialized as a single kit. Even in this case, however, each of the ELISA-based assays had to be developed individually often requiring the generation of specific reagents.

The present invention provides signatures and methods for identifying additional signatures comprising as few as 4 genes that are useful for determining a therapeutic or toxicological end-point for renal tubule injury. These signatures (and the genes from which they are composed) may also be used in the design of improved diagnostic devices that answer the same questions as a large microarray but using a much smaller fraction of data. Generally, the reduction of information in a large chemogenomic dataset to a simple signature enables much simpler devices compatible with low cost high throughput multi-analyte measurement.

As described herein, a large chemogenomic dataset may be mined for a plurality of informative genes useful for answering classification questions. The size of the classifiers or signatures so generated may be varied according to experimental needs. In addition, multiple non-overlapping classifiers may be generated where independent experimental measures are required to confirm a classification. Generally, the sufficient classifiers result in a substantial reduction of data that needs to be measured to classify a sample. Consequently, the signatures and methods of the present invention provide the ability to produce cheaper, higher throughput, diagnostic measurement methods or strategies. In particular, the invention provides diagnostic reagent sets useful in diagnostic assays and the associated diagnostic devices and kits. As used herein, diagnostic assays includes assays that may be used for patient prognosis and therapeutic monitoring.

Diagnostic reagent sets may include reagents representing the subset of genes found in the necessary set of 186 consisting of less than 50%, 40%, 30%, 20%, 10%, or even less than 5% of the total genes. In one preferred embodiment, the diagnostic reagent set is a plurality of polynucleotides or polypeptides representing specific genes in a sufficient or necessary set of the invention. Such biopolymer reagent sets are immediately applicable in any of the diagnostic assay methods (and the associate kits) well known for polynucleotides and polypeptides (e.g., DNA arrays, RT-PCR, immunoassays or other receptor based assays for polypeptides or proteins). For example, by selecting only those genes found in a smaller yet “sufficient” gene signature, a faster, simpler and cheaper DNA array may be fabricated for that signature's specific classification task. Thus, a very simple diagnostic array may be designed that answers 3 or 4 specific classification questions and includes only 60-80 polynucleotides representing the approximately 20 genes in each of the signatures. Of course, depending on the level of accuracy required the LOR threshold for selecting a sufficient gene signature may be varied. A DNA array may be designed with many more genes per signature if the LOR threshold is set at e.g., 7.00 for a given classification question. The present invention includes diagnostic devices based on gene signatures exhibiting levels of performance varying from less than LOR=3.00 up to LOR=10.00 and greater.

The diagnostic reagent sets of the invention may be provided in kits, wherein the kits may or may not comprise additional reagents or components necessary for the particular diagnostic application in which the reagent set is to be employed. Thus, for a polynucleotide array applications, the diagnostic reagent sets may be provided in a kit which further comprises one or more of the additional requisite reagents for amplifying and/or labeling a microarray probe or target (e.g., polymerases, labeled nucleotides, and the like).

A variety of array formats (for either polynucleotides and/or polypeptides) are well-known in the art and may be used with the methods and subsets produced by the present invention. In one preferred embodiment, photolithographic or micromirror methods may be used to spatially direct light-induced chemical modifications of spacer units or functional groups resulting in attachment at specific localized regions on the surface of the substrate. Light-directed methods of controlling reactivity and immobilizing chemical compounds on solid substrates are well-known in the art and described in U.S. Pat. Nos. 4,562,157, 5,143,854, 5,556,961, 5,968,740, and 6,153,744, and PCT publication WO 99/42813, each of which is hereby incorporated by reference herein.

Alternatively, a plurality of molecules may be attached to a single substrate by precise deposition of chemical reagents. For example, methods for achieving high spatial resolution in depositing small volumes of a liquid reagent on a solid substrate are disclosed in U.S. Pat. Nos. 5,474,796 and 5,807,522, both of which are hereby incorporated by reference herein.

It should also be noted that in many cases a single diagnostic device may not satisfy all needs. However, even for an initial exploratory investigation (e.g., classifying drug-treated rats) DNA arrays with sufficient gene sets of varying size (number of genes), each adapted to a specific follow-up technology, can be created. In addition, in the case of drug-treated rats, different arrays may be defined for each tissue.

Alternatively, a single substrate may be produced with several different small arrays of genes in different areas on the surface of the substrate. Each of these different arrays may represent a sufficient set of genes for the same classification question but with a different optimal gene signature for each different tissue. Thus, a single array could be used for particular diagnostic question regardless of the tissue source of the sample (or even if the sample was from a mixture of tissue sources, e.g., in a forensic sample).

In addition, it may be desirable to investigate classification questions of a different nature in the same tissue using several arrays featuring different non-overlapping gene signatures for a particular classification question.

As described above, the methodology described here is not limited to chemogenomic datasets and DNA microarray data. The invention may be applied to other types of datasets to produce necessary and sufficient sets of variables useful for classifiers. For example, proteomics assay techniques, where protein levels are measured or protein interaction techniques such as yeast 2-hybrid or mass spectrometry also result in large, highly multivariate dataset, which could be classified in the same way described here. The result of all the classification tasks could be submitted to the same methods of signature generation and/or classifier stripping in order to define specific sets of proteins useful as signatures for specific classification questions.

In addition, the invention is useful for many traditional lower throughput diagnostic applications. Indeed the invention teaches methods for generating valid, high-performance classifiers consisting of 5% or less of the total variables in a dataset. This data reduction is critical to providing a useful analytical device. For example, a large chemogenomic dataset may be reduced to a signature comprising less than 5% of the genes in the full dataset. Further reductions of these genes may be made by identifying only those genes whose product is a secreted protein. These secreted proteins may be identified based on known annotation information regarding the genes in the subset. Because the secreted proteins are identified in the sufficient set useful as a signature for a particular classification question, they are most useful in protein based diagnostic assays related to that classification. For example, an antibody-based blood serum assay may be produced using the subset of the secreted proteins found in the sufficient signature set. Hence, the present invention may be used to generate improved protein-based diagnostic assays from DNA array information.

The general method of the invention as described above is exemplified below. The following examples are offered as illustrations of specific embodiments and are not intended to limit the inventions disclosed throughout the whole of the specification.

EXAMPLES Example 1 Construction of Chemogenomic Reference Database (DrugMatrix™)

This example illustrates the construction of a large multivariate chemogenomic dataset based on DNA microarray analysis of rat tissues from over 580 different in vivo compound treatments. This dataset was used to generate RTI signatures comprising genes and weights which subsequently were used to generate a necessary set of highly responsive genes that may be incorporated into high throughput diagnostic devices as described in Examples 2-7.

The detailed description of the construction of this chemogenomic dataset is described in Examples 1 and 2 of Published U.S. Pat. Appl. No. 2005/0060102 A1, published Mar. 17, 2005, which is hereby incorporated by reference for all purposes. Briefly, in vivo short-term repeat dose rat studies were conducted on over 580 test compounds, including marketed and withdrawn drugs, environmental and industrial toxicants, and standard biochemical reagents. Rats (three per group) were dosed daily at either a low or high dose. The low dose was an efficacious dose estimated from the literature and the high dose was an empirically-determined maximum tolerated dose, defined as the dose that causes a 50% decrease in body weight gain relative to controls during the course of the 5 day range finding study. Animals were necropsied on days 0.25, 1, 3, and 5 or 7. Up to 13 tissues (e.g., liver, kidney, heart, bone marrow, blood, spleen, brain, intestine, glandular and nonglandular stomach, lung, muscle, and gonads) were collected for histopathological evaluation and microarray expression profiling on the Amersham CodeLink™ RU1 platform. In addition, a clinical pathology panel consisting of 37 clinical chemistry and hematology parameters was generated from blood samples collected on days 3 and 5.

In order to assure that all of the dataset is of high quality a number of quality metrics and tests are employed. Failure on any test results in rejection of the array and exclusion from the data set. The first tests measure global array parameters: (1) average normalized signal to background, (2) median signal to threshold, (3) fraction of elements with below background signals, and (4) number of empty spots. The second battery of tests examines the array visually for unevenness and agreement of the signals to a tissue specific reference standard formed from a number of historical untreated animal control arrays (correlation coefficient>0.8). Arrays that pass all of these checks are further assessed using principle component analysis versus a dataset containing seven different tissue types; arrays not closely clustering with their appropriate tissue cloud are discarded.

Data collected from the scanner is processed by the Dewarping/Detrending™ normalization technique, which uses a non-linear centralization normalization procedure (see, Zien, A., T. Aigner, R. Zimmer, and T. Lengauer. 2001. Centralization: A new method for the normalization of gene expression data. Bioinformatics) adapted specifically for the CodeLink microarray platform. The procedure utilizes detrending and dewarping algorithms to adjust for non-biological trends and non-linear patterns in signal response, leading to significant improvements in array data quality.

Log₁₀-ratios are computed for each gene as the difference of the averaged logs of the experimental signals from (usually) three drug-treated animals and the averaged logs of the control signals from (usually) 20 mock vehicle-treated animals. To assign a significance level to each gene expression change, the standard error for the measured change between the experiments and controls is computed. An empirical Bayesian estimate of standard deviation for each measurement is used in calculating the standard error, which is a weighted average of the measurement standard deviation for each experimental condition and a global estimate of measurement standard deviation for each gene determined over thousands of arrays (Carlin, B. P. and T. A. Louis. 2000. “Bayes and empirical Bayes methods for data analysis,” Chapman & Hall/CRC, Boca Raton; Gelman, A. 1995. “Bayesian data analysis,” Chapman & Hall/CRC, Boca Raton). The standard error is used in a t-test to compute a p-value for the significance of each gene expression change. The coefficient of variation (CV) is defined as the ratio of the standard error to the average Log₁₀-ratio, as defined above.

Example 2 Preparation of a Chemogenomic Dataset for Late-Onset Renal Tubule Injury

This example describes methods used to prepare a chemogenomic dataset (i.e., a positive training set) for use deriving a signature for renal tubule injury (i.e., late-onset nephrotoxicity).

Overview

28-day repeat dose studies were conducted on known nephrotoxicants. Doses were chosen that would not cause histological or clinical evidence of renal tubular injury after 5 days of dosing, but would cause histological evidence of tubular injury after 28 days of dosing. Animals were assigned to groups such that mean body weights were within 10% of the mean vehicle control group. Test compounds were administered either orally (10 ml of corn oil/kg body weight) or by intra-peritoneal injection (5 ml of saline/kg body weight). Animals were dosed once daily starting on day 0, and necropsied 24 hrs after the last dose following an overnight fast on day 5 (n=5) and day 28 (n=10). An equivalent number of time- and vehicle-matched control rats were treated concurrently. Likewise, a large set of short-term (day 5/7) treatments that would not cause renal tubular injury (i.e., negative control data) after sub-chronic dosing conditions were selected from the chemogenomic reference database in-vivo studies described in Example 1 (above), to complete the training set. This assertion of the absence of nephrotoxicity for these compounds was based on thorough evaluation of human clinical studies curated in Physicians Desk Reference (PDR) as well as peer-reviewed published literature. Lastly, these treatments did not cause histological evidence of renal tubular injury on day 5/7. Appropriate time and vehicle-matched controls for these negative treatments were also derived from the reference database in vivo studies described in Example 1.

Compound Selection and Dosing

To derive a signature predictive of renal tubular injury, it is necessary to first define both nephrotoxic and non-nephrotoxic treatments from short-term studies devoid of tissue injury that can be used to model the early transcriptional effects that will be predictive of late-onset toxicity. To empirically confirm the late-onset nephrotoxicity of the positive treatments prior to inclusion in the training set, 28-day repeat dose studies were conducted on 15 known nephrotoxicants in adult male Sprague-Dawley rats according to the in vivo methods described in Example 1.

In addition, 49 short-term (day 5/7) compound treatments that would not cause renal tubular injury after sub-chronic dosing conditions were selected from chemogenomic reference database (DrugMatrix™) to complete the training set. This assertion of the absence of nephrotoxicity for these compounds was based on thorough evaluation of human clinical studies curated in Physicians Desk Reference (PDR) as well as peer-reviewed published literature. These treatments were experimentally confirmed not to cause histological evidence of renal tubular injury at the time of expression analysis.

Doses were chosen that would not cause histological or clinical evidence of renal tubular injury after 5 days of dosing, but would cause histological evidence of tubular injury after 28 days of dosing. This time course of injury was significant to deriving a predictive signature since the presence of injury on day 5 would bias the signature towards a gene expression pattern that are indicative of the presence of a lesion, rather than identifying gene expression events that will predict the future occurrence of the lesion.

The compounds and their doses are listed in Table 2. TABLE 2 64 in vivo compound treatments used in the training set. Dose Time Compound (mg/kg/d) (d) Vehicle Route Class 4-NONYLPHENOL 200 5 Corn oil PO Nephrotoxic AMIKACIN 160 5 Saline IP Nephrotoxic CADMIUM CHLORIDE 2 5 Saline IP Nephrotoxic CARBOPLATIN 5 5 Saline IP Nephrotoxic CISPLATIN 0.5 5 Saline IP Nephrotoxic COBALT (II) CHLORIDE 10 5 Saline IP Nephrotoxic CYCLOSPORIN A 70 5 Corn oil PO Nephrotoxic DAUNORUBICIN 4 5 Saline IV Nephrotoxic DOXORUBICIN 4 5 Saline IV Nephrotoxic GENTAMICIN 40 5 Saline IP Nephrotoxic IDARUBICIN 4 5 Saline IV Nephrotoxic LEAD (II) ACETATE 2 5 Saline IP Nephrotoxic NETILMICIN 40 5 Saline IP Nephrotoxic ROXARSONE 11 5 Corn oil PO Nephrotoxic TOBRAMYCIN 40 5 Saline IP Nephrotoxic 6-METHOXY-2-NAPHTHYLACETIC ACID 360 5 Saline PO Non-nephrotoxic ACARBOSE 2000 5 Water PO Non-nephrotoxic AMPRENAVIR 600 5 CMC PO Non-nephrotoxic ANTIPYRINE 1500 5 CMC PO Non-nephrotoxic ASPIRIN 375 5 Corn oil PO Non-nephrotoxic ATORVASTATIN 300 5 Corn oil PO Non-nephrotoxic AZATHIOPRINE 54 5 Water PO Non-nephrotoxic BENAZEPRIL 1750 5 CMC PO Non-nephrotoxic BETAHISTINE 1500 5 Water PO Non-nephrotoxic BISPHENOL A 610 5 Corn oil PO Non-nephrotoxic BITHIONOL 333 5 Corn oil PO Non-nephrotoxic CANDESARTAN 1300 5 CMC PO Non-nephrotoxic CAPTOPRIL 1750 5 Water PO Non-nephrotoxic CELECOXIB 263 5 Corn oil PO Non-nephrotoxic CLINDAMYCIN 161 5 Saline IV Non-nephrotoxic CLOFIBRATE 500 7 Corn oil PO Non-nephrotoxic CROMOLYN 1500 5 Water PO Non-nephrotoxic DEXIBUPROFEN 239 5 CMC PO Non-nephrotoxic ENROFLOXACIN 2000 5 CMC PO Non-nephrotoxic ETHANOL 6000 7 Saline PO Non-nephrotoxic EUCALYPTOL 930 5 Corn oil PO Non-nephrotoxic FENOFIBRATE 215 5 Corn oil PO Non-nephrotoxic FLUVASTATIN 94 5 Corn oil PO Non-nephrotoxic GADOPENTETATE DIMEGLUMINE 125 5 Saline IV Non-nephrotoxic GEMFIBROZIL 700 7 Corn oil PO Non-nephrotoxic GLICLAZIDE 1500 5 CMC PO Non-nephrotoxic GLYCINE 2000 5 CMC PO Non-nephrotoxic INDINAVIR 1000 5 CMC PO Non-nephrotoxic KETOPROFEN 20.4 5 Corn oil PO Non-nephrotoxic LEFLUNOMIDE 60 5 Corn oil PO Non-nephrotoxic LINCOMYCIN 1200 5 CMC PO Non-nephrotoxic LISINOPRIL 2000 5 CMC PO Non-nephrotoxic LOVASTATIN 1500 5 Corn oil PO Non-nephrotoxic N,N-DIMETHYLFORMAMIDE 1400 5 Saline PO Non-nephrotoxic N-NITROSODIETHYLAMINE 34 5 Saline PO Non-nephrotoxic RAMIPRIL 1500 5 CMC PO Non-nephrotoxic RAPAMYCIN 60 5 CMC PO Non-nephrotoxic RIFABUTIN 1500 5 CMC PO Non-nephrotoxic RIFAPENTINE 75 5 Corn oil PO Non-nephrotoxic SULFADIMETHOXINE 1100 5 CMC PO Non-nephrotoxic SULFAMETHOXAZOLE 1000 5 Water PO Non-nephrotoxic SULFINPYRAZONE 269 5 CMC PO Non-nephrotoxic TENIDAP 75 5 Corn oil PO Non-nephrotoxic THIAMPHENICOL 1500 5 Water PO Non-nephrotoxic TRANSPLATIN 0.5 5 Saline IP Non-nephrotoxic VALACYCLOVIR 88 5 CMC PO Non-nephrotoxic VALPROIC ACID 850 5 Water PO Non-nephrotoxic ZILEUTON 450 5 Corn oil PO Non-nephrotoxic ZOMEPIRAC 11 5 Saline PO Non-nephrotoxic

In Vivo Studies

Male Sprague-Dawley (Crl:CD® (SD)(IGS)BR) rats (Charles River Laboratories, Portage, Mich.), weight matched, 7 to 8 weeks of age, were housed individually in hanging, stainless steel, wire-bottom cages in a temperature (66-77° F.), light (12-hour dark/light cycle) and humidity (30-70%) controlled room. Water and Certified Rodent Diet #5002 (PMI Feeds, Inc, City, ST) were available ad libitum throughout the 5 day acclimatization period and during the 28 day treatment period. Housing and treatment of the animals were in accordance with regulations outlined in the USDA Animal Welfare Act (9 CFR Parts 1, 2 and 3).

Clinical and Post-Mortem Evaluation

All animals were monitored daily for clinical observations approximately 1 hr after dosing. For both the reference database studies (described in Example 1) and the sub-chronic study presented herein, gross necropsy observations and organ weights (liver, kidneys, heart, testes) were recorded for all animals following termination. Paired organs were weighed together. Body weights were recorded pre-test and daily thereafter for reference database (i.e., DrugMatrix™) studies, and on days 0, 3, 5, 7, 14 and 28 for the sub-chronic studies. Terminal body weights were measured at necropsy and used to calculate relative organ weights and percent body weight gain relative to day 0.

Clinical Pathology

Blood samples were collected at necropsy from the orbital sinus or abdominal aorta under CO₂/O₂ anesthesia prior to terminal necropsy by exsanguinations and pneumothorax. A panel of clinical chemistry and hematology parameters were analyzed on a Hitachi-911 and a Baker 9000 instrument, respectively.

Histopathology

The right kidney was preserved in 10% buffered formalin for tissue fixation and subsequently embedded in paraffin, sectioned and stained with hematoxylin and eosin. Sections (5 μm thick) were examined under light microscope by Board Certified Pathologists for histopathological lesions. The left kidney was snap frozen in liquid nitrogen for subsequent RNA extraction.

Statistical Analysis of Animal Data

Treatment group means for body and organ weights, and clinical chemistry and hematology measurements were compared to the time-matched vehicle control group by Student's T-test. Significance was declared at p<0.05.

Microarray Expression Profiling

Gene expression profiling, data processing and quality control were performed as previously described in Example 1. Briefly, kidney samples from 3 rats were chosen at random from each treatment and control group on day 5 for expression profile analysis on the Amersham CodeLink™ RU1 Bioarray (Amersham Biosciences, Piscataway, N.J.). Log transformed signal data for all probes were array-wise normalized used Array Qualifier (Novation Biosciences, Palo Alto, Calif.), a proprietary non-linear centralization normalization procedure adapted for the CodeLink RU1 microarray platform. Expression logratios of base 10 are computed as the difference between the logs of the averaged normalized experimental signals and the averaged normalized time-matched vehicle control signals for each gene.

Results

A few treated animals showed histopathological evidence of early chronic renal nephropathy on day 5, including minimal to mild regeneration of tubular epithelium, interstitial inflammation, pelvic dilation, focal thickening of basement membrane and focal infarcts. Cisplatin induced a high incidence of mild tubular basophilia (4 of 5 rats), while both cisplatin and carboplatin induced a high incidence of karyomegaly (3 and 5 rats, respectively). Mild tubular dilation and proteinaceous casts were also observed in one lead acetate-treated rat. Although considered early signs of tubular injury, these mild and infrequent observations are unlikely to bias the signature since the large majority of the animals treated with the 15 nephrotoxicants were unaffected on day 5. Furthermore, the incidence and severity of findings indicative of tubular injury were markedly increased after 4 weeks of treatment relative to the day 5 time point.

After 4 weeks of dosing, all 15 nephrotoxicants showed evidence of degenerative changes of the renal tubules or early signs of tubular toxicity. Histological findings included tubular necrosis, dilation, vacuolation, basophilia, mineralization and cysts. These lesions were also accompanied by a higher incidence and increased severity of epithelial regeneration and interstitial inflammation, as well as granular and proteinaceous casts. A high incidence of karyomegaly was also noted for cisplatin, carboplatin, lead and cobalt. Consist with the tubular injury was the concurrent observation of hypercholesterolemia and hypoalbuminemia for a number of the nephrotoxic treatments. Although weaker than most other nephrotoxicants, 4-nonylphenol and roxarsone induced clear evidence of tubular injury on day 28. For example, proteinaceous casts, tubular cysts and mineralization were only observed in one roxarsone or 4-nonylphenol treated rat on day 28, yet these treatments did induce a much higher incidence and severity of tubular regeneration (4-6 rats) and interstitial inflammation (6 rats) suggestive of future tubular injury. Since the nephrotoxicity of 4-nonylphenol and roxarsone have previously been described (see, Chapin et al., “The effects of 4-nonylphenol in rats: a multigeneration reproduction study,” Toxicological Science 52(1): 80-91 (1999); Latendresse et al., “Polycystic kidney disease induced in F(1) Sprague-Dawley rats fed para-nonylphenol in a soy-free, casein-containing diet,” Toxicological Science 62(1): 140-7 (2001); Abdo et al., “Toxic responses in F344 rats and B6C3F1 mice given roxarsone in their diets for up to 13 weeks.” Toxicology Letters 45(1): 55-66), and early signs of injury are apparent in the current study, these treatments were included in the positive class.

Example 3 Derivation of a Predictive Renal Tubule Injury Signature

Overview

The support vector machine algorithm was trained to classify experimentally confirmed nephrotoxicants from non-nephrotoxicants using the data acquired in Examples 1 and 2 above. A linear classifier (i.e., gene signature) was derived using kidney expression profiles from rats treated with 15 nephrotoxicants that induce renal tubular injury after 4 weeks of daily dosing, and 49 non-nephrotoxicants known not to induce renal tubular injury under subchronic dosing conditions.

Gene Signature Derivation

To derive the gene signature, a three-step process of data reduction, signature generation and cross-validation of the predictive signature was used. A total of 7478 gene probes from the total of 10,000 on the CodeLink™ RU1 microarray were pre-selected based on having less than 5% missing values (e.g., invalid measurement or below signal threshold) in either the positive or negative class of the training set. Pre-selection of these genes increases the quality of the starting dataset but is not necessary in order to generate valid signatures according to the methods disclosed herein. These pre-selected genes are listed in Table 3. TABLE 3 7478 genes used to derive RTI signatures Accession # Accession # Accession # Accession # Accession # NM_012939 AI180253 AF139809 X63369 U27518 NM_012657 J02657 AI717121 AI412259 AF159103 NM_012848 NM_012764 D17310 AI011505 D00753 U67914 AB040031 NM_019308 NM_012878 AF290213 AW915240 AA818643 X78997 NM_019298 AI010583 BF415939 D38381 AF055477 AB025431 AJ237852 L18948 X83231 NM_013052 M62832 AI410548 NM_017250 AB043981 NM_019242 AA849028 NM_013062 AF150082 NM_017288 U75924 AA858817 U56863 AI511090 U22520 M96674 AI175530 BF282409 AA859352 BE113181 BE105381 U16253 U25137 NM_017270 AB013732 NM_019322 AW917537 D38101 M63282 D50671 AF034577 AB042598 AI407163 M35992 AF202887 Z17239 M81681 AW916143 AB009636 BE114586 AI029460 AI172112 NM_012698 X59132 AJ011607 M11814 AF306458 AI575641 NM_012824 NM_019126 NM_013075 U24441 BF400833 NM_012777 D38494 NM_019150 U09838 J03863 U24174 M18847 AW913878 AF060173 Y13400 NM_013105 U04317 AI171219 NM_012603 NM_012639 AF057564 AJ276893 BF405468 U66707 AI236611 BE109667 AI233740 NM_019348 AI236696 AF120275 AF208288 BE100918 AW920818 BE109861 NM_019286 NM_013068 AF053312 BF399598 X05884 AI009597 NM_012682 AF044264 NM_019128 U94708 AW915049 NM_019233 NM_012633 AI412261 AF014503 NM_012567 NM_013197 AB032419 X06827 J02643 AB000215 AF151367 NM_012810 AF199333 AF058786 AF254802 BF555121 J03734 M74716 BE109018 AW141051 AI169311 J02635 NM_017014 NM_012803 BF403190 NM_012738 AA997397 K03501 AW916301 NM_017123 NM_012786 NM_012551 AA818120 BE113155 AF227439 BF522317 M22899 NM_019332 AF160798 BE107840 M26199 NM_017289 X56846 BF557871 U97146 AB036792 AF144756 BF551250 AW920017 AA893596 AW143005 M34052 NM_021680 NM_013029 AJ001713 NM_012498 AF086607 X06889 AF107723 AI180010 BF283270 AF112256 L19031 AW142962 NM_017215 BF387347 BE112719 NM_013086 BF525022 AI178784 AA891470 NM_012735 U08290 AI409934 BE112216 NM_012881 AI227829 AJ242926 NM_019344 D13555 AA925167 AA901342 AI412418 L05435 NM_020087 NM_019295 X76723 AJ011035 NM_017279 AA800292 AI234119 AF093567 M33936 NM_012614 BF399627 NM_017354 BF283413 X01976 AW143537 BE109691 D87351 NM_019310 BF289266 AI007992 J02752 AF285078 AI233888 D89731 AI008376 NM_012806 BF405086 NM_012879 M91563 AI012611 BF405917 U61729 AI105410 NM_012654 NM_013217 AI228222 BE105137 AA850034 NM_012870 U49066 AI010917 NM_017259 AA891826 AA819103 AF015304 NM_012533 BE113157 AI176677 NM_012757 AI101595 BF401614 AI574903 NM_012963 AF063103 AI137819 D90109 L17127 BF420018 AF312687 AW252871 BF542912 AW914342 BF283381 BE111688 NM_012580 U45965 AB012721 U57097 NM_012720 AI176730 AI172281 BF403552 BF416240 AI103158 AI603128 AW917780 U80076 NM_012565 X68640 U15425 AW917985 U59245 AB005900 AA998157 Z17223 M15882 AI598399 AF111268 AW251703 AA946230 BF284124 M94454 BE113285 NM_012584 BF286009 AW915415 NM_021693 BE113397 BE099881 U55995 AW523614 AI176739 BF388223 AA848355 X87107 AI407487 U48596 BE098827 AF158186 AF068268 M84416 AI412099 M58587 Y00065 U20796 AI180421 U46118 U10188 AF133037 U41663 AW142880 AF027331 AI144646 AW920606 AW434178 BE113060 NM_012829 M15327 NM_017195 AB022883 AI101117 X15741 NM_017117 AI171656 NM_017019 BF282796 U44091 X94186 AI598316 NM_017208 BF413152 AB017820 AF009329 AF109643 BF393825 X89603 AF121670 BF284899 AI411981 AA800341 X68878 NM_013060 BF285687 NM_019230 AA946485 AI412460 NM_013005 AF214647 NM_017331 AI144771 NM_012833 NM_012606 AI172259 AI071251 AI555029 AA945100 NM_013094 NM_020538 AW143506 AI407201 BF281697 AI233903 AA892299 AI408713 AI411941 AA850910 BE115621 AW921456 U26686 AF154114 U21871 L27843 AW917933 AW915739 NM_021869 NM_012564 L29259 BF281701 NM_017097 AA892549 AF089825 Y18567 U75402 AW144649 NM_012618 AI171800 BF287903 AW915454 J03886 AW917460 BF396132 NM_021836 BF567847 AF184983 U67082 AI176814 AI111796 BF395192 BF414043 X84039 NM_013064 AW917212 AF105368 D83231 NM_012597 AW527509 AI010950 BF283340 AI227912 AA819832 AW914004 NM_012771 AF247450 AI408286 AI111954 NM_017115 NM_017011 NM_013008 AA964744 AI716469 AW523875 X81395 U39943 BF288765 BE105618 AW919125 NM_012794 AW528830 AA817759 L19656 M35297 U44845 AW919210 D16237 NM_017261 BF566488 X83399 AI556458 AA892049 AF155910 AF036959 NM_021763 AA925375 BE109730 J03627 AF041374 AI008409 BE106971 BE117330 L36459 AI137683 D50664 AF179679 NM_012621 AB009686 AI412889 NM_017122 BE109520 AW520812 BE113132 AJ131848 AI172222 BF396293 AA800587 NM_012940 AJ224120 BF389915 Y17606 AF193014 NM_019358 NM_012687 AI549393 U35371 BF282980 AI008390 U09228 Z30584 U32679 AA858900 BE120346 AF001417 AF102854 AW526005 AW915775 X12355 AF286595 AI237640 BE109016 AF277452 AW142290 AI177015 L06821 NM_020084 AI102884 BF283610 AW862656 X14788 AI408348 AW919995 X91234 BF523561 AW918179 M37828 L46791 AI137339 L15453 AI716265 U15098 AF104362 BE108873 AA850740 BF551328 AI144797 BF415024 BE113252 AI179990 BF554744 AI176553 J03583 AI716560 AW918006 D49977 U65656 M26744 NM_013139 AF172446 NM_019329 NM_019339 NM_013126 AW915606 AI102047 U31866 BE108896 J03093 AW918169 AW918050 AI412108 AF249673 NM_012588 AJ302650 L14323 BF285185 AI171162 Y00090 U66470 NM_017180 BF556736 AW523849 AI228970 J03026 AW918529 NM_012627 BF400832 NM_019326 AI136740 AW921215 AF295535 AA849743 AI454612 NM_017167 BF285985 NM_012825 AW143179 BE107069 AI716512 AF148324 AI169596 NM_012842 AF157016 NM_013413 BF282282 AJ131563 U07971 AI411412 BE107234 AI576621 M16235 AW251791 AI556066 BF550033 X53427 NM_017237 NM_019204 AW916833 BF563113 AW144705 AW915996 U12309 X14159 NM_012851 AJ132008 BF283556 BE095878 AF198442 AA894092 AJ133104 BF413176 BF282961 AW913932 BF283631 AW143091 U41453 NM_021691 BE111710 M63122 BF556210 BF402407 NM_012708 NM_017074 AA894210 BF562701 AF086630 BF405035 U33500 AI411995 U81186 AI407719 AA955213 AI045288 AW913986 AI232183 NM_012938 M10161 AI101323 AW919092 BF411166 BF398155 NM_017275 AI548591 BF284803 M27223 AA817877 U07560 AA817798 AA965057 AW917546 AI172302 BE109271 AI230339 AF016297 NM_012835 BF562755 NM_021746 BE108282 BF284475 BF394332 AF029107 M19651 AA848499 NM_013057 NM_013176 AW862653 AF007212 AA892366 AW915287 X77797 NM_012779 AF015953 AI406538 BE113142 AA893184 J02627 AW915613 U17967 AI168968 AF155196 X97477 BE119628 AI408557 AA875301 AF171936 AF038591 BF285565 AI235942 AA964535 NM_012998 M94064 NM_012908 BE109661 AW921399 U40064 AI535126 AI170799 NM_012750 X91892 AI764464 AI059223 AW144399 AW251848 AW914178 BF285034 AI234024 U12623 NM_012676 AA850480 NM_012561 AI599016 AF009133 X65747 AI175457 AI012250 NM_017113 AI103572 AI406941 AI410352 AI408580 AW917133 Z78279 AI236771 BE120339 AW144039 AA851926 BF391604 AF077354 BF286916 AA800782 AB020520 BF566679 BE109531 AA892778 NM_019258 AI102591 AF010293 BF551331 AW535307 BF283056 D14015 D12769 NM_017330 NM_019289 NM_017211 NM_012489 M69138 BE095859 AI176591 X70223 NM_012493 NM_017327 BE113367 M26125 AA850347 AW915453 AA818759 M18340 X73371 AI176836 AA944169 AJ222971 M90661 NM_017222 AW142823 AF013144 AW252812 AB033771 NM_021664 NM_012845 AF169636 BE116233 AF111181 U26033 Y09945 AI071412 BF406291 AI237075 AB007689 AW918231 AI411400 D10699 AI454923 AF021854 NM_019309 D88586 AI104278 AW919284 AA800719 BF389519 NM_012964 BE111666 D85760 AI172189 BF41148 BF407456 X03369 NM_012668 BF555498 M13646 NM_017027 AA946394 AI044740 NM_017089 AB012139 AA850541 L19341 AW528864 NM_019239 AW251324 BF564217 NM_021747 AA799428 AW524733 AB000776 AA858862 AW917544 Y18965 AI409871 M80550 AW142828 U05675 M17412 BF288073 NM_012625 NM_017335 AI102771 AF248548 NM_017310 BF557923 NM_013106 BF409724 AI235546 U39546 AA851370 U30290 X13016 L25527 U61266 AW916826 AI010251 BF403184 NM_019904 AI171646 NM_013226 AI012235 AB000489 AI101924 NM_013043 AI176515 AW143771 AF136584 BF549650 AB023432 BF417292 BF549490 AI407141 AB039663 AW524724 D86383 AF009330 AW434228 AI234852 BF412073 AI176773 AW525762 BE106791 AW921038 BF405050 AW914097 AW919683 BF396602 NM_012701 AA859796 AA799676 BE117335 BF524971 Z34264 BE349698 AF08797 U22893 AI170400 AW918222 BF284692 BE116886 BE120016 AI411304 AW919395 X99723 AB027143 AA892250 BE103975 AB027155 AI230728 AI007666 AF055286 NM_021595 AI406747 AI236770 AI406697 AW529723 BF558694 AW915643 AI406948 NM_012522 AW913917 D87336 AW917481 BF404362 M83209 NM_013089 M15797 BE349770 M95058 AI176842 U66471 AW918776 BF550231 AA818471 L04527 AA955786 AI409218 U63740 AI176476 NM_019168 AI012434 AA891839 X55995 AI406342 X53724 AI575699 AF237778 AF327513 AF247451 AW525211 NM_021587 AI178875 AI177140 BF553139 AA866351 AF118651 AW523888 AB001075 NM_016998 AF041838 AI385364 U61373 BF556958 AW920082 AF297118 AI579216 AB043892 U93880 AW535233 AI406968 NM_017271 AF045564 AI171653 BE099774 BF404452 BE100748 AI011757 BF399489 L05175 NM_017185 BE106832 NM_017090 AW918022 NM_017029 AF182714 U62667 NM_017359 BF398845 AF214733 BF393972 AF082535 X85183 M55601 X89968 BF398716 BE121120 AF013241 NM_012505 AW918674 NM_012530 U23407 AI007919 NM_013200 NM_013036 U68725 AI409065 AI111579 AA799503 NM_019375 X78606 M77479 AW531805 AF072935 AW144670 D88666 X04644 AW921168 BF398063 BF282712 BE107169 BE116867 D85035 AI235674 BE107427 AW916745 AW917160 AW918417 L13600 NM_012942 D13927 NM_017135 AA848820 NM_017193 BF394166 NM_021688 AA945724 AF080106 AF199504 BF410183 U42975 AW143008 AW434109 AI102073 AB016425 AF011789 BE105967 BE119862 AI105049 BF525016 AI170249 BF551345 NM_016987 AW253907 D88250 AW529672 BF554752 NM_017292 BF400042 U52102 BF283390 U06755 AW918564 BF542426 AI412423 BF561659 U10303 NM_012959 U56936 BE095842 AB035306 AI410546 AI179101 AA900654 AW914408 AW921109 L11002 AW920764 AI009727 BE103689 NM_012880 AI169317 U64451 AA900261 AA819268 NM_021846 BF284190 AI502229 AI101181 AB011365 AW915558 BF409783 AB003587 AI102732 AF021348 X3015 Z14030 AA800260 BF395781 AF192366 AA891535 AI237403 AB011528 BF563517 AW527151 AA892500 NM_019192 AW914789 AA818353 BE098709 AW524433 X04310 J00705 AI176497 BF557244 AW916447 AF014827 U44750 AI227885 BF567710 BE107464 AA943824 AI179459 AW254369 NM_012501 BE108230 AF186469 BF412037 D25233 U89514 NM_012838 AW144673 D13963 L14617 U91539 NM_019370 BF290076 M60388 NM_012532 AA892798 AI169655 NM_021868 NM_013134 NM_019283 AI234149 BE106663 U74586 X05883 AB024398 AI171288 BE109059 L35921 AA891690 AF151373 AI716500 NM_012715 AF133731 AF251305 AI717736 AW528865 U73525 AA997881 AF163569 BE113224 BF288208 AA850319 AW916609 AI599801 BF420610 NM_012884 AA892852 BF282415 BF413513 AF230645 AI232272 AI229630 D13121 M55636 AI178171 AW144339 AI716086 U44129 NM_012667 AI716250 AW533508 BE106513 AF021343 NM_019240 AW434520 AW917427 BF401626 BE097240 AW916836 NM_019186 AY004290 BF404514 AI179988 AI103918 U23377 BE101480 BF415760 D90404 AW531368 AA848451 BE107465 BF420628 NM_017047 BE113242 AF067727 BF549703 BF556874 U47280 BF285921 AA998660 AF189019 NM_019143 AI412625 NM_017340 BE113620 BE108837 AW141939 AI411021 X70871 AA818392 AI010272 AW434239 BF416285 AI101396 AI071243 L22079 AI030179 AI172196 AI113104 AI177050 AA894335 BE110739 BE116946 BF281931 AW435011 AF036548 NM_012553 BF398367 U14907 AW918443 AF157498 NM_012689 NM_012999 AW253265 BE106598 AI105080 AA818796 BE108670 M31363 BF411113 AF320509 AI237118 BF287788 U30789 AA965219 AI012574 AI639168 BF404478 AF038388 AI555002 AW532606 BF282476 AW141130 AW526289 BE098212 AW915048 BF283760 NM_019306 BE101472 AF076183 BE108327 BF398053 AI009609 BF285109 BF558592 BF282370 BF410020 AW523642 BF400636 U17565 NM_017065 NM_020097 AA901337 BE117156 BF415786 NM_017276 AW917098 AI145991 BE120810 NM_017147 AI169289 NM_021585 BE113179 NM_013074 U24175 AW253947 AA957047 BF398114 AI072384 NM_019291 BF409296 AF188608 M38060 D16817 AF182949 AI227945 AI169105 U89608 NM_012679 AW141292 NM_012678 AW918717 NM_012920 AA848821 AI168941 BF418630 AA850896 AF063102 AA943576 AI411510 NM_017337 AI171098 AF149118 AI409040 AA899704 NM_021842 AI179021 AI011501 AI598976 AA945761 BE110514 AW917461 AI235960 U60282 AI406809 AF184921 NM_012923 AW916210 AA945869 AA874859 AI176970 AI412936 AW917663 AW918611 AI102026 BE115041 BE098743 BE115280 AF190458 AI176993 AA817769 U94709 BF413244 NM_019153 L78306 AA955926 AF223677 U15408 AA946474 U10357 AB012933 AW529756 AA955579 AF007818 AA799664 AI172465 M35106 AJ293617 X66539 AW913998 BE104266 NM_021775 L19927 C06844 X69716 BE116564 S57864 X99470 AI070270 AF118816 BF562675 AA955206 AA819481 AW520754 AI234012 NM_013003 AW532179 AI172146 AW918029 BE108973 AI599126 NM_019620 AW915254 NM_019369 BF550769 U89873 AI172057 AW920478 X95507 NM_019262 BE109665 AW252815 BF550822 AF022085 NM_019282 BF556327 BF285046 U39571 BF284809 U92010 D83036 AA848826 U75920 M34643 AF003835 AI178527 AI175508 AA893172 X76168 AI111802 AA943995 U58466 AF314540 AI170766 AI230699 AI406646 AB036421 NM_019243 BF289272 D12678 AI412304 AI104545 BF548454 BF389876 AA848311 AI599520 BF404935 J05266 BF406752 AF286534 BF397840 AB017260 AA800222 NM_012549 AF011790 AA801208 AB021980 AB011533 NM_016995 AI234142 AA849975 AI012231 AI103924 U95368 AI236084 AI045904 BE120595 AW529808 X60370 NM_013004 AI411580 AW533822 AW916093 X74815 AW917823 M55049 BE106398 BF282239 AA800184 BF406312 X78461 AA817812 BF420074 AF306457 NM_012661 BF403410 BE106693 L29232 AW144456 NM_012967 NM_012563 L09656 NM_017144 BE101108 AA866419 AI413060 BE108277 NM_019214 BF411134 BE119802 BF408325 AA944061 NM_020096 Z11690 AI104484 X06338 AA945771 X58465 AF025670 AI144644 AA892325 AB024930 U42627 AW921149 AI411971 AF207605 AI010965 AA925353 AA944556 AW435041 AF263368 AW143130 AF059258 AI010281 BF556879 AW916182 AW523899 NM_021682 AI011455 NM_012693 BF419280 BE111805 AA799526 BF282149 AB017696 BF556833 BF282313 AW25115 BF403319 BF282034 NM_019293 M17086 AW915925 BF416794 D85100 BE101619 AI010948 AI177397 D10926 AF100960 AW144663 AW251681 BE120725 AI104478 AJ011811 BF412296 D70816 BF564940 AW144344 BF418869 BF416115 NM_017038 AB002801 AW534329 NM_017235 X69834 AA944518 AI009657 U59486 AA946430 AI235784 AI411149 M65148 AA799993 AI104125 AW535151 BF558676 NM_019216 AI406660 AI144863 AW919320 Y14933 AA892770 AI704771 AI409756 BE104321 AA850509 AI556534 AW144347 AW140637 AB002111 AI232565 AW914277 AW913888 AW918085 Y18208 AI407560 BF248137 J05499 BF283003 BF420720 AI501497 BF563117 AB035201 BF408444 NM_017204 AW251416 AW914809 BF404557 AI412054 AB052170 BF551283 BF287191 M95768 BF282646 AI598407 D49836 BF414010 X06564 BF396955 AJ132846 M18467 BF566546 BE097587 BF419234 AW141993 NM_013091 L22191 BG153269 BF556836 L19118 AA891734 L36884 AA891742 AI045635 NM_013148 AI145328 L43592 AF030423 AW144346 NM_019155 AI171655 NM_017143 AF181259 AW917390 AI105101 AW917475 U06436 AI410906 AW920271 AI599133 U50185 AA850333 AJ242649 BF281754 BE107503 NM_017068 AI169058 AW441131 J03190 BF419138 NM_017260 AW143818 NM_019333 NM_012666 NM_012869 AI237622 U85512 U69279 NM_013167 AW143834 NM_017322 X07365 X60789 AB011529 AW535377 NM_017332 AW525184 BF284889 AW531919 BE109179 U69702 D12516 BF398564 AI228528 M37394 U77697 AA800029 NM_013012 AI171994 U13396 AF004218 AI179538 NM_017034 AI231808 U17901 AF058787 AI227894 X82152 AI412662 AI409316 D31873 BE116816 AI232098 AW524460 AW917557 AF043345 NM_012739 AF090306 AW917674 BE113545 U05014 X59037 AF097887 BF287209 BF405134 AA891447 AF043642 AI235923 NM_019257 AA819488 AI412169 AI231761 BF405417 AB033830 D88450 U55816 BF559190 D13962 AI409182 AA866477 X55969 AF259981 L13445 BF289240 AI102735 AA848951 BF396614 NM_019205 BF396295 AI227769 AI071288 D88035 AF046886 BF412673 BE106459 AW530415 NM_012972 AI598942 NM_017217 BE113152 AW915057 AA799476 BE102426 NM_021856 BF283382 BE107033 AA891746 BE328941 AF111160 D25224 BF283353 AI170114 BF563262 AI104292 AA850987 BF404908 AI407982 NM_019203 AI603127 BF400611 BF407675 AW914850 X68199 X07320 D28754 L07315 BF550847 AF021935 BE113369 M80601 NM_017131 X66366 BF403098 BE120386 NM_012524 AI406369 AI710683 AI011610 BF399607 X17037 AF106659 AW916287 NM_012841 BF409977 AW526352 AF277900 NM_012558 NM_020072 NM_017325 AI044316 AI172003 AI235047 AF095576 U60096 AW915106 AI411352 BF396316 AW918640 AF273025 AW914808 AW921986 BF418597 BE119482 AI411225 BF283797 BE107674 AA963234 U96921 BE107250 BF403853 BF285066 AF071003 AA818184 AW915650 BF555793 D49955 AF182717 AI168986 BF285467 NM_012816 NM_012497 AI574743 AW915209 BF398403 U60835 AI233257 AI599339 BF286131 M29853 AI169629 NM_017075 AW914966 NM_019199 NM_012725 AW140983 NM_021740 AW915217 U16655 X51991 AW916321 BF413765 AW917653 AW919239 X57970 D50568 BF550866 BE113656 BE109746 X92069 NM_012903 BF555899 BF284918 BF558086 AA892522 AI228236 M21208 NM_012499 L23204 AF160978 AW143256 AF036537 NM_013145 BE098326 AI711516 BE107147 AI600221 BE107259 BF398684 BE119676 AF030091 AW915518 BF283261 AI072493 AA996836 BF287099 AW917510 BF400209 AF099093 NM_017124 BF550883 BE097210 BF388763 BF524872 AF228917 NM_021703 AW142560 BF550217 NM_013001 AI171736 AA944542 BF420172 M55045 U61157 AW915404 AF001896 BF557300 NM_012704 AF030253 AW917389 AI010954 BF559836 U73458 M83676 BE114160 AI012498 BF567496 BF557672 AF163477 BF283798 AI176695 D25290 X57228 AI175555 BF567631 AI180420 M88709 BF291167 BF416236 L02530 AI406310 U32314 AI599349 U20195 AF080468 AW531361 X16359 AW520770 U31668 AI176944 AW916592 AA801139 BF555127 AA850037 AI179372 BE112933 AI407016 D12498 AB020757 AJ003065 BF290834 AI412627 J05132 AI009371 AW143887 BF412769 AI555466 U48249 AI231799 AW916474 BF555129 AJ011608 AW918418 BF396682 AW917766 BF557296 NM_017181 BF281400 BF417187 NM_013071 D13126 AB004329 D16308 M63574 NM_017345 M17527 AF205438 AW917550 AA799741 X71068 U17604 AI407017 BF400606 AA799751 AI411997 AA819306 AW143149 BF547620 AF106860 AA800507 AF005099 AW918238 BF563077 BF281149 AA875261 AW918548 BF386716 M61726 AB019791 AI231776 X74549 U53855 NM_017212 AW142328 AI599077 AA850490 X57523 AA800476 BF396180 AW526320 AW251878 AF044201 AI231210 BF399385 BE116976 AW531902 AW914119 AI235446 D00403 BE117878 BF392577 AI102739 AW531735 NM_017040 U18771 AI044865 AW920722 BE111795 AA850725 AF065161 AI059079 NM_013070 BE349699 AB041998 AF150091 AI454134 AA800062 BF284919 AW144170 AI231716 AI454913 AA818952 BF396319 AW920501 BE113635 AW919929 AI012608 AF087696 BE108882 BF546202 D16479 AI137286 AI009647 BF389244 U04738 NM_012545 AI234678 X74832 BF408285 AI012120 NM_012555 AI406707 AF002281 NM_019386 AI178229 Y00480 AI411501 AI013919 Y17048 AW253043 AF068202 AW915713 AJ295748 AA944314 AA818438 AI406502 BE105713 AW144385 AI172618 AI103634 AW253742 BE107247 AW252087 AI180353 AW918605 AW919881 U19967 AW920527 AI235467 BE115947 U62326 U35775 BE111888 AI407999 BE116569 X57764 AF037071 AA875143 AI547463 BE118450 BE112952 AI009599 AF202265 NM_013137 BF389910 NM_013153 AI172198 AI231444 U37058 BF397834 AA874924 AI227748 BF555116 AF157026 NM_012503 AA943817 AW143395 D87839 AI009074 NM_012936 AI175978 BE113449 AW142811 AW526039 NM_019305 AI177748 BF396079 AW915601 BE109164 X97376 AI178923 M17069 BF288273 NM_012514 BE106816 NM_012974 U01914 NM_012721 AI175871 BE118122 NM_013215 X52498 AA892791 AI411930 BF403852 U09583 AF315378 AA899304 AI602125 D63648 AI233769 BF284065 AI176505 BF522885 NM_021859 AI385171 AI007922 AI410099 BF288063 AA944006 AI409259 AI013500 AI709768 BF565795 AB017702 BE108949 AI170394 BE111762 NM_012862 BE100018 BE103916 AI556941 BF282458 AA800455 BF415061 AI227890 AW141985 BF409042 M18028 BF389856 AI059493 AA800010 U06864 NM_012733 BF393807 AA942765 AA891944 U08136 X83579 D16348 AI137297 AF000577 U50707 AA997412 NM_017316 AI169001 AF017393 AF245172 AF151982 U10279 AW252664 AF065147 AF272892 AI137817 AF290194 BF397998 AI100769 AI103040 AI411605 AI170797 AF021923 AI170067 AI227907 AW143854 AI179993 AI230762 AI170405 AI412317 AW507078 AI713159 AW141128 AI236618 BF404556 AW525122 AW917818 AW534159 AW918017 NM_013049 AW916054 J00741 AW915055 BE096387 U67884 AW918208 AW251204 AW915084 BF288129 AW914944 BE109208 BE095833 AW916127 BF403009 AW916786 BE113233 BE110525 BF404842 BF555971 NM_012828 BE118580 BF400666 BF418582 NM_019273 AA900400 BF396948 NM_012763 L37380 X02904 AF306394 BF549525 U67080 AA943742 AA800273 AW533663 NM_019363 AF059530 AI168952 AI102064 AW915554 AF239674 AI009650 AI556408 AI171802 AW917516 AW915161 AI555351 D50559 AI230430 BE110577 BE105872 AI711114 AA945320 AW917132 BF281848 NM_012819 AW918076 AF247452 BE108178 D86711 NM_019237 BF284878 AI070113 BE108857 J03819 AI406821 BF399083 AW915174 BF397872 NM_017077 AF084576 BF419406 BE111769 BF543356 AW142947 AI060205 NM_013115 BE116370 BF543478 AW434045 AI179609 NM_021744 BF406344 NM_012655 AI232337 AI408442 AB043870 BF554877 NM_019279 AJ277747 AW915550 AI598442 BF556614 U16858 AW918255 BE113312 AW253880 U29174 AA851728 AW919873 BF387255 AW917588 X85184 AI137188 BF286478 BF394261 BE112998 BF566580 AI177431 BF388422 AA964824 U41853 AI176632 AI555341 NM_012562 AF184883 AA817841 AI178935 AI600037 NM_019211 AI231792 AA849966 AI406531 AW526346 U42209 AW521352 AF220760 AW144006 BE108174 AI412190 AW917064 AI102512 NM_017141 BE111925 AI716642 AW918585 AI231088 X04240 BF282876 BF555161 BE101088 AI598315 AB023634 BF557821 NM_012527 U72353 AI713206 AI175008 D31838 NM_021584 NM_020106 AW144044 AI237657 L27081 AB021645 X71071 BE117902 AI717113 NM_019167 AI169116 AA955396 BF282238 AW252879 AA849738 AW919190 AI176056 BF410755 AW532489 AI235219 BE098463 AW916119 M22323 AW916092 BE107395 NM_012590 AA998964 M81784 BF564219 BE108776 NM_019364 AB012759 Z48444 NM_013065 BF282217 U11038 AI179901 AA799832 U49057 BF550270 AA850505 AI407827 AF096835 AA800483 AA859010 AA892818 AI716077 AI008701 AB042407 AI600035 AI177408 BE098955 AI176212 AI170313 AI716255 AI227612 BF388440 AI176625 AW252251 BE102621 AI412150 AF277903 AI180275 AW917256 BF284716 AW523647 AI058960 AI412673 AW919062 BF397805 AW917504 AI409077 BE113146 BF389884 BF400811 BE095865 AW141921 BF403136 BF396282 L18889 BE103444 BF285451 NM_021589 NM_012671 NM_013132 U68168 AI229849 BF283898 BF401593 NM_013223 AF053317 AW918000 BF284303 BF413556 U40819 AI169878 BE120513 BF555924 NM_012916 AA800025 AI178796 BF419158 NM_012795 AA946011 AA850358 BE107485 NM_017269 NM_013135 AI170668 AI011497 AA943552 NM_017365 U40603 AI230723 AI070137 AA943564 NM_019219 U43175 AI598405 AW532074 AF017437 NM_021771 AJ000696 AW143111 NM_017186 AI172175 U30381 BF548957 AW434242 NM_021759 AW142913 AA892370 BF549697 AW920179 U50194 AW143093 AB022014 L38615 BF406407 AA866426 AW528898 AF020618 AF226993 BF413396 AI408960 AW915175 AF059311 BE112913 D00252 AW142588 BF287814 AF090867 D88364 AA799400 BE113966 U61261 AI172386 NM_013114 AA848776 BE117883 AB009463 BF284171 NM_019255 AI176611 AF075382 AB032164 NM_017220 U38253 BE116768 AF087454 AF031483 AA925490 U49055 M77362 AI175048 D29969 AW142307 AA998662 AA850728 AI407222 M34083 AW435429 AI104846 AI178761 AI599104 AA848470 AB012233 BF406522 AW916628 AW141280 AF058791 AI175440 BF413631 BE098366 BF419602 AI176665 AI409380 D38072 BF281544 L02896 AI178491 AW520758 U75916 BF523059 NM_017262 AI232898 AW524559 AI227843 D16302 AI406693 AI233288 AW534383 AI411425 NM_021660 NM_021762 AW532652 AW915350 AW531412 AI230918 AA955175 AW915437 BE113217 BE115635 BE110626 AW915491 U06099 BE116973 AI232321 AF169409 K03250 U83112 BF282030 AI236624 AW535358 AA891859 AA965063 BF284994 NM_012984 BE100202 AF106657 AB009999 AI009603 AI009623 BF282629 AI105272 AF023657 AI011034 AI010235 BF556943 AI170757 AF135059 AI011713 AI179979 BF563933 AI233199 AW144034 AI171480 AI599143 NM_019362 AI409501 AW251238 AI232365 AJ245707 U55765 AI410700 AW254429 AI408357 AJ306292 AI103327 AI598467 AW915944 AI716103 AW917197 AW144790 NM_017199 BF401313 BE111634 BE103937 BE108865 U09793 J05122 BE112615 BF545951 BF395678 AA851327 NM_019135 BF393611 BF556845 M11563 AA945202 U12187 BF408081 AA944161 NM_017194 AA945634 X03475 NM_012601 AF021936 NM_017267 AB000491 AA849719 NM_017342 AF087674 NM_017344 AI102065 AF268030 NM_021764 AI232370 U71293 AI232205 AI009594 U75689 AI579023 AI716115 AW916594 AI136848 X60822 AW141186 AW141000 AW921320 AW143233 AF063939 AW916805 BE109756 BE114154 AW144502 AI179974 BF291161 BF284075 AI411071 AW251339 BF398016 D14908 AI716289 AW142171 AW435110 BF525193 AI176016 AA956784 AW434007 AW916721 D10665 BE109747 AF058714 AW915587 BF544951 AB014089 BF282271 AF090113 BE109596 NM_017005 AI175820 D78482 AF127390 NM_017189 U77933 AI237593 AA893708 BE113175 AA899898 AA998160 AI409747 AB001982 BE113372 AI410203 AI176825 AW253010 AI716516 BF288088 AI705687 AW535229 AW143285 AI172159 AI231206 BF409759 AW915543 AW916783 AI409738 BE108849 AA859585 BF284679 AW917522 AW915402 BF389882 AF109393 BF285207 NM_012685 L07073 BF550292 AI009274 BF392605 NM_012728 U34985 AI010241 AI013361 BF398046 X53003 AI556488 BF558976 AI013475 AI008125 AF098301 BE115058 AW915795 AW525285 AI172184 AF199411 BF283742 AA894080 BE103518 BF550875 AI231432 AI103682 BE097615 BE114137 AF009603 AI236772 AW534533 BE108899 BF289044 AI009591 AI408517 AW535909 BE113057 J05030 BF392344 BE126739 BE098266 BF396082 U77038 BF404539 BF288138 D90166 M35052 U95727 AF000423 BF396678 U07201 M84009 AA943100 AI010267 BF558506 AA891834 NM_017178 AF022729 AI101199 BE111625 AA997458 NM_019379 AI137488 AI231787 BF558467 AI044229 NM_021576 AI145359 AI715452 NM_017152 AI175551 AF267197 AI172450 AJ002940 BF419635 AW921797 AF276940 AI175031 AW525049 D21799 BF412792 AI454081 AI234810 AW919666 AI069912 D13127 AW141938 AI408705 BE107334 AW914758 D89514 AW918816 BE099401 NM_012636 AW914939 U55192 BE103359 BE120608 NM_019284 BF284700 AI045819 BE118465 BF550426 AA997435 BF404603 AW144075 NM_017159 BF561727 AI236090 BF555890 AA945706 NM_017311 BF567649 AI575940 M64301 AA945734 AI103954 NM_013103 BE349755 Y00102 AF106945 AA819871 AI103456 BF281802 AA858509 AF142629 AF083418 BF284887 U56732 AI105215 AF176784 AW918470 BF409560 AF292116 AI237580 AI102248 BF551138 AI235238 AW918457 AJ293697 BE095605 AA800701 BE109510 BF408873 BF565344 BE121438 AF052042 BF525211 BF409812 NM_012581 BE329061 AI013104 AI172460 AA800241 AI170786 BF550271 AI407821 AI233875 AF050159 AI231438 L31840 AI598402 AW916561 AF313411 BF408022 X64411 AI599376 BE108405 AI317840 AI598462 AA998893 BF285247 BF282009 AI412209 BF281386 AI101490 BF285980 BF555349 AW919129 AI112622 AW915318 U68726 BF556162 M20406 AI172033 AW915609 X78604 BF562149 NM_021857 AI175383 BF407740 X90710 NM_017241 AF131294 AI409049 D00680 AI179119 U26397 AI234849 AW533060 AF010131 AI411742 AA900983 BF415080 AW919094 X79860 AW142808 AA965117 X58375 AW920600 AA943981 AA817907 AI171654 AI102037 BE101138 AW916468 AI179443 AI177089 AW251849 BE107520 NM_017101 AB019693 AI408686 AW527217 NM_012674 AA943600 AI578861 M97754 NM_017066 AA801218 AF314960 NM_017213 NM_017006 AF007549 AF037199 AI008988 U78889 BE107747 AI008386 AI145784 AI233241 AA891790 AB006461 AI104546 AI177867 AW143117 AA925922 AI234008 AI176039 BF283802 BE101096 BF408391 AA944483 AI235512 BF396424 BE108272 BF525153 AF322224 AI407464 BF405032 L34821 AI407903 AI763565 AI549323 BF416249 AI177887 AW914881 AW916701 BE103152 BF283736 AI410438 AI407483 BF282212 BE108583 NM_017021 AI230134 AI535483 BF401710 NM_017099 AI138061 AI410822 AW433595 J02997 AA817863 AI412244 BE099629 BE108976 AA848338 AB030644 AW915966 AA801434 M59742 AI454466 AB042887 BE105397 AA819679 NM_012613 AI555844 AI103943 BF417391 AF084241 BE113624 BE098873 AI170377 U18942 AW915444 BF406637 BF395080 AI179991 U75973 AW918431 U92803 BF414124 AW435010 X62952 BE098309 AA850785 BF546361 AW526079 AA848834 BF407209 AB020759 AW144002 BE108249 AA894259 BF407452 AF036344 BF419074 BE109637 AF022952 BF550795 AI137471 BF552916 BE113111 AI408852 BF555867 AI145625 M64711 BF398605 AJ005113 D13871 AI172211 AA800210 NM_012836 BE109161 NM_019220 AW919132 AA850498 NM_013216 BF549710 U72994 BE112948 AA893230 BF389352 NM_012839 AI170827 BF283612 AF115282 AI071698 NM_021653 BE113005 BF284840 AI169619 AI175474 NM_021865 BE117511 BF414261 AW531530 AW917280 AW536019 BF389478 BF522056 AW919429 BF551315 BE099732 BF412016 D13061 BE102505 AB016532 D12770 U57362 U46034 BF419925 AI230220 AW143273 AI012356 AA799661 M76591 AW915159 AW523874 AI169243 AA875055 NM_013063 BE108853 NM_019180 BF281787 AA943094 AF072124 AA891830 AA874838 BF287768 AF037350 AI177645 AI411897 AF228049 BF396114 AF244349 AW918369 BE110722 AI412591 U68544 AI180400 BE120038 BE112999 AW434329 AA800232 AI603627 BF284819 D26179 AW914982 AI104857 BE095490 BF406693 L06238 AW917734 AI105461 BE109529 NM_012578 NM_017050 BE111098 AI230228 BE113119 NM_017353 U03708 BF386111 AI412612 NM_020089 AI101475 AW915834 BF397542 AW140530 AW140531 AI176781 BF284693 BF549877 BF555370 AI176792 AI411194 AA944036 AI172191 AI170769 AI236760 AI705731 AI102429 AI232217 AI170280 AI598324 AW141990 AI171775 AW528823 AI179677 BE107173 AW253902 AI406506 BF285991 AI410505 L46865 AW524517 AW531891 BF565628 BF403332 NM_012987 BE113371 BE107157 AI235353 AW142852 NM_017175 BF285393 BF404868 AJ300162 BF286955 AA817895 L26450 D12771 AW918833 NM_012515 AA859508 M34384 AA893610 D90102 AI013928 AI010432 NM_020306 AB038387 U87305 AI176626 AI169228 U15211 AI170859 AA892330 AI233205 AW534781 AA850551 AI234035 AI407409 AW142713 BF390657 AF051895 BE105286 AW144331 AW142877 NM_017207 AI406290 BE111776 AW915847 AW915294 AF090347 AI412323 BF281438 BF557668 BF392695 AF030377 U65007 BF404419 AA848342 BF397773 AI102519 X66842 L36388 AA942695 M32061 AI177143 AB026288 X86789 AA955630 X62528 AI232354 AI717447 AA849782 AF020045 AA849497 AW522044 AW142440 AA874906 AI137298 AB026291 AW917726 AW527204 AI169368 AI179370 AI317813 BE106275 AW915676 BE109266 AI575703 AW918480 U53475 AI409024 BF390003 AW141463 BE111685 AA850801 AW253750 AI103914 AW143992 BF281285 AF012714 AW535136 AI170783 AW918108 BF396317 AF146738 AW917211 AI713210 BE105452 BF548520 BE103926 NM_017356 BE098845 U19485 D50580 BE109586 AF061266 BE102816 AA946490 U34841 BF396467 AI012352 BF283510 AB040807 Y17319 NM_019381 AI060043 BF391673 AF039033 AW918273 U72660 AI412018 X56541 AF092207 BE121325 U83897 AI600031 AA800172 AI072958 NM_012980 AA851296 AW433866 AF327562 AI178489 NM_019187 AA893237 AW917796 AJ238717 AW434972 NM_020976 AF277902 BE107459 AW918775 AA848526 X96488 AI145039 BF399791 BE104931 AF063447 AF272662 AW143197 L31884 BE119692 AF218575 AW144391 AW918637 AI012263 BF283247 AI170251 BE099953 BF284879 AI233726 BF555980 AI235480 BF282288 BF565705 AI408104 BF564461 AW144226 BF282645 U11685 AI555237 NM_013058 AW251666 BF413969 U13253 BF285079 U48246 AI013913 AA874952 AB017793 BF417363 AI013699 AI137301 AW915060 AI230988 M84488 AI409741 AJ001184 BE104111 AI385140 NM_021997 AW142955 AW917946 BF283001 AI407991 AA858786 BE096047 BE112415 BF284914 AW434026 AA894084 BE101311 AF245040 L32591 BE100014 AW918999 BE109604 AI136871 AI010234 BE109057 D90036 BF289328 AI177706 AI233766 BE119961 NM_021684 BF393085 AI180454 AI716240 BF397933 AA800597 BF551339 AI231601 AW254017 AF034214 AA892281 L37293 BE108326 AW919336 AF190798 AI169225 AI010342 BE115880 BF415023 AI010660 AI234095 AA851945 BF394214 J05029 AI170570 AI411077 AA943868 BF399328 NM_019385 AW526160 AI639139 AA963282 L10072 AA799515 AW531675 AW433942 AJ293948 NM_012592 AA925559 BE111118 AA892483 AW143480 NM_012793 AI011736 BE118222 AI104485 AW915268 AB042599 AI102877 BF555119 AI407945 BE107438 AF156981 AI176623 NM_017025 AI409108 BF556273 AI176323 BE098468 AA892339 BE095970 BF559875 AI317817 BF550402 AB002406 BE101099 M23984 AI599641 NM_021770 AF203906 BE107434 NM_012997 AW920443 AA819398 AI010233 D32207 AA892298 BE097245 AA946128 AI175028 NM_013034 AI029960 BE109513 AF151377 AI406667 X89963 AI409930 AA801206 AI177663 AI407482 AI231190 AI716131 AF231010 AI412090 AJ242554 AI412736 AW526697 AI413033 AI412292 AW434419 AW433944 BE100193 AW143939 BE102889 AW521367 AW917545 BE108131 AW531093 BF408844 BF283772 BF283384 BE113228 BF282636 BF564899 BF388772 BF420685 BF567904 U48247 NM_012634 BF400697 AA944568 M81766 AA849715 AA924526 BF550302 AI072892 Y08981 AF020046 AA944278 NM_017225 AI105210 AW144637 AI412580 AF094821 AB026057 AI236773 AI009167 AI600237 AW144383 AI172214 AI406363 AI408865 AW915560 NM_017251 AI235950 AI408954 AI412011 AI598414 AA892364 AW916305 AW915466 AW915292 AW915580 AB020022 BE100201 BF417386 AW915499 BF550554 AF051561 BE105305 BF551118 BE113053 D63665 AF177478 D17447 D14013 BF282223 AW254190 AF323615 L02121 NM_012947 AI169291 BF555084 AI071688 M20133 AA998435 BF399098 NM_021754 AJ006295 M34253 AF080568 AA946357 AI009029 AW915256 AW919017 AI045590 AI008952 AI227700 AI178647 AA875129 AI070591 AI103937 AI409145 AF072509 AA900046 AW915160 AI227742 AW525288 AI172156 AA946441 BF285089 AI411999 BF396534 AI176848 AF139830 BF547641 BE109075 BF404409 AI407459 AF205604 U93197 BF399614 J03753 AI411005 AW252550 AA924945 M29295 NM_013006 AW142370 AW916799 AF000942 NM_012665 AA817867 AW252152 BE111887 AW535349 Z83868 AA819812 AW916013 AI102290 BF558075 AI101393 AI169599 AW916792 AI233162 AI411332 AI547421 AI227919 BF387153 AA799789 BF285720 AW143757 AW919050 NM_019341 AI011711 BF557889 AW525128 NM_013076 BE111801 AI102236 AA944526 BE108832 U09229 AA892271 AI411240 AB049189 BF403323 AA945103 AI008961 AA799301 AI101322 BF407165 AB018546 AW918092 AI236816 AI102495 BF555033 AF182946 BF282185 AI409186 AJ277881 M58716 AI180081 BF395777 AI012573 BF409313 NM_017188 AI407985 BF398045 AI172116 AA818820 AB047002 AI410886 BF420629 BF282323 AI102873 AI232269 AW915104 BF557739 BF283075 AI179142 AW918541 BF407878 J03637 M69056 AI230778 BF523077 BF414947 Y12009 AI105441 BF285078 L11319 D10655 AI175375 AI407500 NM_012659 M23601 M92042 AI230185 AI170752 U18650 NM_017305 NM_017231 AW251213 AI172417 AI013775 AI411520 NM_019335 M81639 AI412239 AI411964 BE108919 NM_020073 AA945090 D85580 BE109603 BF558507 NM_021847 BE111755 J03933 BE114159 NM_013090 BE109039 BF419380 L27513 M86870 Z83035 AA850736 AI409032 NM_012911 AB005549 AB002466 AI407932 AW144517 AF281018 AI231193 AI230056 AJ005425 AW525342 AI013788 AI385277 AI410833 AW143263 AW914215 BF399587 AI409841 AI555566 AW917908 BE103434 M81687 AW915241 AI598648 BE106888 BF389721 AI413058 BF398378 AI716218 BE111752 BF397663 AF069525 J05214 BE101448 BF282437 BF411381 AI060118 NM_012818 BE102671 BF290638 NM_012846 AI407064 AF019109 BE118605 AF016049 NM_017216 BF558513 AI104376 BF555974 AA892897 AW435310 AA875011 AI228233 AA817722 AB015433 AW917572 AA891774 AI639162 AI233194 AI234830 BE108192 AA892554 AW917587 AI408375 AW141787 U76997 AI715257 BE100208 BE109600 AW143141 AA892567 BE113288 BE108905 BF567692 BF548116 AA999042 BF551361 NM_019280 NM_013147 NM_012571 AI232065 AA892346 NM_019622 AF085693 AI175536 AI599031 AI234858 AA944162 AI171807 BF554895 AW915803 AI602172 AI137972 AW528847 BF563786 BF396191 AI172579 AF192757 AW920802 J00696 M64300 AI717053 AI170933 L35767 NM_012966 NM_017187 AW918732 AW529588 AW143336 AI236376 AW915800 BF283743 AW530272 AW144084 AI407946 BF282620 AI144583 AW918408 AW252169 AW144223 BF401275 BE102535 BF283302 AW528454 BF283130 AW917258 AA849729 L20821 AW915763 L19658 AI233133 NM_017200 U04319 BF419241 AA801116 AI408930 AW913858 BF410753 BF557396 AI011704 AW918153 AI012474 AF286006 M58340 AW144504 BE109152 AI412614 AW252511 NM_013190 AW527880 BF288288 BE109201 AI170384 NM_021750 BE113354 BF562779 BE109644 AI410837 AI175586 BF407799 U54632 BF281325 AA894189 AI411060 U07181 AW915140 BF523098 AF119667 AJ001529 AB020504 BE109575 D30795 AF228307 BF282544 BF283685 AA899489 L09653 AI234719 BF408448 BF405110 AI111840 NM_017105 AI410917 AA851280 U58858 AI412967 BE103894 AJ001044 AA944380 AI172274 AI575671 AA799981 BE107298 AI176442 AF159626 BE100155 AA943811 AW916684 AI237621 BE115860 NM_013055 AF077195 BF389719 AI409180 NM_013028 NM_019246 AI236778 BE108876 AI410943 AW140640 AI231333 AW143201 AI411399 AI411979 BF393884 AW523114 AW254246 BE118972 BE108923 NM_013185 AW523679 AW916618 H35082 BF386302 NM_017024 BF284300 X04959 L34039 D30035 AW916148 U06713 AA800199 AW143157 NM_012586 BE113380 AI105154 AA819716 AW533321 X56228 BF285301 BE109143 AA946074 BF412594 AF003944 D90035 BF567763 BF396729 BF567585 AI013474 AF220455 NM_019208 U39044 AW142367 AI101500 AI104326 U04933 AI104251 BE121429 BF284242 AW140537 BE096021 AI231564 BF407916 U58857 M94548 BE113323 AI231789 M86235 AI029291 AA924352 BE121314 AW253339 AI009759 AI170751 AW916619 BF407511 AW524478 AI407545 BE112253 AW917712 NM_017079 BE110652 AW918385 NM_021848 BE108877 NM_017174 BE117114 BE101157 AI071187 BF284713 AA849031 BF404464 AA799507 BF405880 AA799636 AA859343 BF563403 AA818132 BF548241 AI407904 AA943765 D50564 AI102046 M93271 AW254590 AI175728 NM_017033 AI171975 NM_019222 AW917661 AI228548 AI101900 AI172271 U82623 BE104941 AI230073 AI413051 AI230110 AI410415 BF393950 AW433847 AW917849 BE102814 AW142953 X87885 AW915824 BE100016 BE118552 AW434978 AI169383 BE098021 BF404932 BF404472 BE100035 AI412413 U79661 BF416377 NM_013221 BE108780 NM_012528 AI175762 U23443 NM_021592 NM_021760 AI412230 AW918595 AI408984 AA944463 AA849752 AW525071 BF281282 AI411771 BF281215 AB003042 AF061947 X78949 AF065387 AA894318 AI236861 BF389157 AA963096 AI176933 AI009656 BE099603 AI008969 AA998971 BE101089 AI010721 BF400873 AW142549 U84038 M22631 AI012456 BF551369 BE098806 AI071470 NM_012609 AI137208 AI176483 AW144499 BF555429 BF564158 A1598988 NM_013042 AI010430 AI598321 AA800290 BE112781 AA818571 AI706767 BE111696 AW434213 BF393577 AA943149 AW915737 L20822 AI231846 BF414252 AI169160 AW918850 U08141 AI408197 BF558120 AI411217 BF283053 AA800519 AW525033 Y17325 BF282194 AA799614 AF016047 BF284076 AI105265 BF401587 AB032899 AI233267 M36074 AI112074 NM_021594 AI406853 AW527592 U60063 BE099063 AA891221 AW527606 AI071703 AI169278 BE101628 BF556691 BE112252 AI145019 AA801230 BF549638 AB010467 BF416533 AI412626 AA892319 M97380 AI102685 NM_017246 AJ130946 AF065438 U40628 AI177409 AA946356 BF558459 AI102139 AW914919 AI229166 AB017711 X16481 AI236798 BE107373 AW918105 AI178752 AI410901 AW916666 NM_017274 BE113010 AI599125 AW915787 BE113034 AB008161 BF281834 AW144760 BE108235 BF284695 BF288270 BF386665 BE108884 BE108381 U36786 BF397445 BF394140 BF284699 BF549121 AF036760 BF416387 X13549 AA956764 BF559056 AI177061 NM_013111 U82626 AI112512 AF051155 NM_019372 NM_019123 AA943793 BE107281 AI412014 AA892300 AF121893 AI105167 AI176713 BE107155 AF032872 Y15748 AW144315 AI178763 BE109130 AI103962 AA800044 AI236054 AJ299016 Y08172 AI176002 AW144441 BF389493 BF406240 AI598359 AW916151 BF414262 BF400662 AF184920 NM_017151 BE111638 AA848367 AI230729 AI072236 AW528874 AB031014 AI178206 BE115551 AW917568 BF550453 AA892294 AI229655 AI012951 BE112921 AA893193 AI177845 AI406371 AW917662 M73714 AF181992 AI411497 BE117002 BE113247 AI102744 AW144745 AW253895 BF282296 BE099563 AI232494 AW252105 AW915264 AW433959 BF548170 AI233702 AW526756 AW916138 AF029310 AA849756 BF284127 BF399124 AB020879 AI103375 AI229596 BF405996 U87627 AI171276 AI176541 AF158379 BF522695 AI104348 AI1712840 AI227815 AI170263 AI412601 AI231785 AJ000347 AI411985 AI234844 BF412389 AI411141 AJ292524 AW142847 AI639157 BF414338 BE110537 AW142931 BE113048 AW915774 AA799576 M11185 AW144646 AI179335 AI232784 AF296131 AF029690 BF403923 AA801136 AW916344 AI385216 AI010722 BF420067 AA817945 BF408552 BE110949 AW252820 NM_019275 AA850525 AI233916 BF284939 AW914860 BE107208 AA850909 AI409258 BF555949 BF405883 AI103616 AA891818 BE098359 BF564549 L16532 AW144313 AI104296 BF418913 L20900 AI012438 AW529753 AI231812 J04112 Z16415 BE329046 AW915952 AW252855 AA945604 AI229684 AI136513 AW918376 BE103222 AB017544 AI406527 AI169330 BF404589 BF288776 AI170948 AI409951 AI171772 BF410846 BF394038 AW143214 BE098713 AI407001 BF419489 BF397229 BF283454 M31788 AI548694 BF567996 BF558902 BF523555 U14533 AW920624 X62322 NM_012804 U70825 AI178912 BE115875 AI044638 NM_016988 AI176331 AI408244 BF397523 AW529960 X94351 AI013800 AI704755 BF408216 BE095474 AA893217 AI412560 BF282119 BF558463 BE108346 AA943578 AW914984 BF392959 NM_017112 BE109672 AB028934 AW919694 BF409371 AA849991 BE110542 AI172177 BE113234 NM_013166 AA892496 NM_019299 AW251501 BE113330 X87106 AA894233 AA893811 AW919497 BF398543 AI013041 AI010295 AI178257 BE111972 M57299 AI172285 AI011448 AI711105 BE118440 NM_016986 AI411057 AI229529 AW142280 BF283418 NM_017153 AW524453 BE105699 AW915107 BF420144 BE101101 AW915155 BF413204 AW915928 BF550580 AA799666 BE108840 M94040 U21662 U25808 AA944403 H35178 NM_012669 AA893505 AA924151 AI704799 M11942 Y12517 AI058276 AB003400 BF398009 M73808 AA819729 AI172267 AI227672 D85435 Y12708 AF054826 AI177016 AI406500 AI233765 AB017638 AI180337 AI233728 AW253963 AA800539 AI169242 AI234533 AI406932 AW914642 AA892044 AI233232 BE105565 AI412180 AW918527 AA942808 AI237681 BF564263 AW143212 BE101505 AA946508 AW143114 NM_012866 BE108162 BF282984 AW915559 AW913929 NM_019152 BE111673 C06665 BF282349 BE113268 AA944438 AI060197 U44979 BF398332 NM_017048 AB011531 AI230388 AA942726 AW143568 AA957492 AF110025 AI408502 AA944828 AW916347 AF094609 AI145630 BE108850 AI169053 BF408957 AI009654 AI176996 BE329450 AI171242 AW915669 AI013906 AW141869 BF398626 AW915015 AA800699 AI171617 M54926 AA819234 BE110412 AI011749 AW531909 AI169607 AI103467 BE113269 AI104431 BF393126 AI169746 AI177412 U78977 AI170825 X13058 AW915955 AI229902 AA848503 AI575445 Y17326 BF282899 AW915152 AF244895 AW251630 AA801094 BF400575 AW916942 AW435017 BF287135 AI169140 U64030 AW917815 BE108968 BF420680 AI232722 AF259504 AW919586 BF405135 BF548086 AI236270 AI171230 BF291214 AA850872 AA942949 AW915791 AI229647 AA943831 AA944332 BF388434 U41803 AI235502 AF034582 AI600085 AA892829 AA893241 AW523709 AF077000 AI600108 AB002151 AI228540 BE108860 AI412298 AW433865 AI170414 AI317827 BF419854 L12384 AW913942 AI233729 AI575026 L25331 AI102688 AW916661 AI236101 BE104107 AA818113 AI232248 AW921139 AI412255 BF282890 AF056034 BE103304 BE101171 BE101485 BF287032 AI407095 BE109671 BE106523 BE110671 BF398047 AW915655 BE112899 BE107223 BF283122 BF419646 BF387477 NM_017361 BF522863 BF414192 NM_017348 BF549379 AA849734 BF563261 NM_017013 AB024333 BF555532 AA924717 AI406651 AI102745 AI105205 L37085 AI232347 BE096104 NM_021676 AW918593 AA817752 AJ004912 BE101124 AA799550 BE100453 AA858600 BE095620 BE109118 AB008538 BE102815 AI169490 BF398121 BF284014 AF334379 BE103430 AI575402 BF417396 BF396629 AI235934 BF282594 AW143173 NM_017015 BF403937 BF411031 AW919578 BE108396 AI103129 BF289928 NM_013222 BE095971 D21800 AI234816 BF565365 NM_019259 BE109900 AA799499 AI175507 AI111991 AI412015 BF283091 AA892127 BE119615 BF286941 AI169353 NM_019206 AA893171 BF408841 AF200359 AW252811 AA963094 AF311055 AI137756 AI009363 NM_012619 AI012074 AI169365 AW434991 AW915716 NM_012946 AI236754 AI407130 NM_019238 BF284754 AA851239 AW918097 AW527971 AF069306 BF523646 AA899150 AW919037 AW916168 AI599945 AA894030 AI171607 AW919937 NM_021745 AI137114 AI713140 AI172029 BE118683 BE115558 AI232357 AW915146 AI180458 AI598320 AA964789 AI412958 BF412293 BE102485 BF281741 AI169729 AW251310 AB037424 BF550566 BF285339 AI172272 BF417793 BE110618 BF556846 BF549027 AI179472 BF419240 NM_017326 NM_013033 X15958 BF284775 U19614 AI073176 AF030358 AA818203 BF398680 AW525945 AI411198 AI176121 AW916939 BF410951 AA801212 BF398587 AI598881 BE113338 AI175767 AI639285 AA955157 AW143543 BF408856 AI599956 AA800191 AI105145 AW915481 BF548630 BE100802 AA800535 AI231011 BF399447 BF557395 BF407563 AW142925 AI236640 NM_017201 BF568009 AA893590 BE108810 AI412002 NM_017281 M29472 AA944576 BF399618 BE110561 Z83044 U75928 AI169375 X67654 BE111986 AI058938 AI009818 AW521376 AA893532 U15138 AI137569 AI317880 AW918620 AA944158 BF397956 AW527421 AI412086 AW918940 AI105243 AA799709 NM_012776 AW917096 BE110557 AI233763 AI070397 AI177863 BF285334 NM_012875 AA851386 AI102943 AI406964 BF288060 AF095741 AA866432 AI231777 AI411212 BF290997 AI231196 AA946017 BF551377 AI556246 BF407158 AJ245646 AI105117 AB018791 U62940 BF420447 AW525089 AI598410 AI008971 AA800570 BF556463 AW528792 AW141364 BE102266 AA946434 AA998047 BF410042 AW532663 BF399504 AI407954 AI231781 NM_017169 AA800763 AA800001 AI170671 AI236726 AI227832 AA998468 AB010954 AI409070 AJ003004 AI104378 AW142276 AF179370 BE113315 AW531275 AI170657 AW914992 AI171990 AA818128 AW918257 AI230061 BF285344 AW915681 AB028626 BE108494 AW921738 BF561196 AW918311 AW915815 BE111850 BF419366 AB017188 NM_017182 BE101212 BE113375 AA892780 AI406280 X93352 BF559919 BE120015 AA875425 AW915764 AA924980 AA875045 NM_017264 AW917015 AA945568 AF172640 AI137420 AA926279 BF398144 AI176477 AI101380 AW251313 AA946382 BE101784 AI599407 AI179992 AW915638 AB008571 AI111559 BE113340 AI717425 AW917594 AI013657 AI169149 BF549893 AW916433 BF524281 AI176468 AI175019 AA892273 BE098799 BF556698 AW520324 AI177410 AA899959 BF397603 AI233262 BF283406 BE107245 AF285103 AI102027 AI233718 BF418890 BE118650 AI176465 AI104258 AI598371 BF420754 NM_012985 AI411365 AI454943 AW141873 BE106191 BF407964 BE100986 AI059108 BE101766 BE099950 U61696 AA946375 BE110530 BF282301 BF407170 AA800277 AA955172 BF410389 BF415017 AF110195 AA819086 AF255305 AI412276 BF420639 AI012785 AI172459 AI169359 AW433846 NM_012789 AI412143 BF397894 AI408455 AF002251 NM_017299 AW253985 AI407555 BF396218 AI104146 AI411436 AW914085 AI556546 BF548597 AI454536 AJ303456 BE112582 AI577393 BF557304 AJ005424 AF044058 BF286237 BF281749 U93692 AI233276 AI410001 BF399633 AF144701 AI232657 AI716471 AW525660 AA945062 AW141326 BF414143 AI230758 BE349725 AI103988 BF557792 NM_012960 AI412949 BF282686 BE109599 BF420654 AA891821 AI600036 BF549603 BF523605 AI059234 AW917596 AW253367 BF407149 AI175803 AI232643 AI100850 BE104143 AA924654 AI556502 BE113423 AI102689 AA799783 AW144382 AI599995 AA892993 AI179136 AI716491 AW915749 AW917738 X13817 AW253642 AW921162 BF281388 BF284345 AW915662 BE118414 AF110026 BF282084 M62388 AB006450 BF404027 AI013011 BF283385 AA924152 AI233857 BF414266 AI411227 BF400719 AI600216 AW915056 AI412024 AI101580 AI177621 AW523737 AI171211 AW919474 AI598381 AI575104 NM_019144 AW140925 AA801308 AW920761 BE112007 Y00350 AF032120 AA818914 BF558116 AA848795 AA893208 AI169648 AF120111 AI555567 AA894262 AI703715 AW918604 AI102947 BE099224 AI230432 AW916925 BF397588 AI409731 BE112202 AI548620 BE099060 NM_019213 AW254068 BE117946 AW917543 J05405 AA894297 AW913868 BF282388 BE115626 AA799331 BE104415 BF398537 AA800521 AI009222 AA944053 BF282678 AW526283 AA849788 BE108018 AF184893 NM_019334 AI412192 AF281304 AI235192 AI172269 AI169328 AI412537 AI010455 BF283084 BE112892 AI172092 AI716902 AI144663 NM_012595 BF419731 AW528057 AW434064 AW915194 AI178818 D50696 AF026476 BF396493 BF544320 AW525229 AB032178 AF136585 AA800576 AA944449 C06787 AI012381 AW918068 AI579376 AW142350 D83948 AI180252 NM_019331 BE113316 AW531382 Z71925 AI228249 AA925303 BF406661 AW915412 AA945915 AI230278 AI007987 AI233172 AY017337 BF287826 AI408770 AI229046 AF110732 BE096311 M75153 AI409748 BF420055 AI102991 BF417071 M83675 AW433870 AW143287 AA891940 AF315374 AA858879 BF419628 AI105345 BE100586 NM_017177 AI231773 M61142 BF413977 AI233751 BF404344 AI232273 NM_021849 BF398712 AW916097 AI555009 BE107540 U66322 AI408162 BE109950 AW919046 BE113490 AI406508 AW523409 AI172301 BF549833 BE120629 AW915566 BF283600 AW520767 AA850288 L11004 BE115600 U69485 BE109512 AI411153 X74226 BE116507 BE109521 BF420279 AW916463 AA858867 AI171632 AA944494 BF393934 BF282695 AA859922 AI007841 BF282132 AA800258 AI410079 AF067728 AI599286 BF417400 AI171764 AI411278 AW920774 BE349648 NM_012891 AI706892 M62763 AI412491 AW143711 NM_013021 NM_021264 J02811 AW915621 NM_019359 AI406655 X52477 NM_013098 BE101165 AI411113 U02096 NM_013104 BF396151 AI145899 AW913987 M31176 NM_020088 AI408380 AW917752 BE095840 U22830 AI009128 AF035963 BE115557 BF411317 AW143269 NM_012629 AI231805 AA819400 BE101129 M55050 NM_013041 BF282647 AB049151 BE100823 AI548036 J04731 AF054586 AI172464 BE101292 M98820 NM_013178 AB037937 AW141870 U53512 AI007936 BE111869 NM_017280 NM_019252 BE113035 AW141286 AF012891 AI599294 BE112384 AI410481 BF556841 BE109711 AI007877 BF285023 AB041723 NM_013092 NM_017170 AF311886 AA800665 BF281200 AF176351 AI177747 AA859768 AI178806 AA943011 AA943126 AI176502 AF168795 AI406906 BE096986 AW143102 AI105086 BF284341 AJ225623 AI044721 X78689 NM_012971 BE110633 AW918039 BE116383 BF550800 AW916756 M14952 BF407819 BE111699 NM_013023 L29419 AI411426 AA849757 AI104034 NM_012844 BF410589 BF285557 AI170714 AI548730 NM_013191 X65083 U34843 BE109614 BE113022 M22926 BE111296 AF007789 BE116918 BE113201 AI408780 M63991 D10693 AI011510 NM_013102 NM_012822 NM_017044 D88672 BE115034 AI170354 U53449 U76551 AW918103 NM_012670 BF411424 BF285022 D00569 AF003598 X96663 J03624 M96548 BF399655 NM_019241 AI145851 NM_012556 NM_012521 Z50144 NM_012694 BF547710 AW143082 AI715955 AI170387 AI233253 AW528625 AF199322 BF404304 NM_013154 NM_012702 BE349838 Z46957 U21954 AW915339 NM_012716 BF389726 L06040 Z96106 AW919159 NM_019223 BF523622 AF180350 BF550451 AI172174 Y07704 BE111787 AB040802 AF135115 U04998 X06423 AI170768 BE109138 X92097 AF069770 Z18877 BE113043 NM_021695 AW918419 D12978 AI170265 BF282314 NM_019125 AW251839 BF288153 U28356 M57547 X92495 AW915423 AI172352 AA945099 AA858518 AW141928 AA893251 NM_012744 X95096 AI575433 X00469 AI229720 U57063 J04628 AA818520 AA799329 D49494 NM_019189 BF405027 AA893517 AA818947 U44125 L26009 NM_013100 AF165892 AI178768 X67859 BE096501 D63834 AI179365 AI010317 BF394161 AW918276 AW920575 AI230346 NM_013165 NM_021669 AW918684 AF203374 BF406604 BF563201 AI406856 NM_012826 BE110695 BE113454 D10041 BE107032 BF420059 M31155 AI171781 AF097723 NM_017158 AF324043 BE113362 AI179316 U89744 NM_017081 NM_017076 NM_017058 AI171367 M58364 BF549748 AF013598 AW920993 BE109901 BF398051 NM_017136 AF242391 AI176592 BE329347 AW434139 AW143169 AI170665 X54467 AI410096 NM_021656 AF082533 AB018049 AF150106 AI411531 AF205717 Z14119 AA801173 AJ002745 BE110545 L33916 BE113272 AA818949 BE104375 BE111677 AW527564 BE121346 AJ132352 D83792 AW141664 L27059 D14048 AA996961 AF082534 AF000973 BF289566 U31203 AA800501 BE118055 BE109616 BF410786 AF024622 AI169399 AF008554 BF419319 AI105417 BF405059 BF281357 D50864 AF136583 V01224 BF563404 AW918387 AF020346 J03621 U07609 BF400779 BF408867 NM_019145 U02315 AI168935 NM_019314 BF420653 NM_021766 AW919325 BF281135 BF419671 U61184 BE101094 BF282951 L12025 NM_019179 AB006614 BE109569 NM_020080 U10697 BF397726 AW920729 BE117893 X98746 BF564840 NM_020301 U86635 L33413 AF154914 AF163321 D38104 AA819339 AA818892 L27651 U38938 NM_019157 AW918535 BF558524 AA875041 X06942 AI409500 NM_012587 AI232085 AW919685 BF404901 AF100421 NM_013069 AW143890 D14437 D45920 NM_019290 AW251335 AI175907 X99338 NM_020074 X68400 AW251633 BE097102 AF016180 AJ000555 AF141386 BF542467 BE111729 AI500969 AA859556 BF403998 BF565649 AI172498 BE105541 U69550 NM_019272 AA892824 AW915002 BE108368 AI071605 U12402 BE120309 AW140991 U49235 BF557670 AI598429 BF388912 BE107195 U66292 AF188699 BF414004 AW434670 BE117687 AI236780 BF284311 BF549324 BE110658 U41164 AI599365 AB000216 Z49762 NM_012900 BF284897 NM_012896 D79981 Z50051 AF062594 AI228240 AI176810 AW919217 U37026 BF420163 BF392884 NM_012918 NM_012526 AI577501 U00964 BF546209 BF415072 AW921292 AI235610 AI044845 AW918841 AB020019 NM_013078 NM_013224 BE113165 U25967 AI170357 BF555189 BE108347 BF393078 AI137259 AI716535 AI045026 AI137751 BF558742 AA944308 BF405610 U79031 AW917981 Z19087 AI407975 AI176718 M60753 BE116152 AF150741 AF168362 L27112 BE113295 BE120545 U57049 AI406533 U08255 AI111803 AW919982 AA800382 AW141129 Y11490 AI233752 BE109277 AW917673 AW915546 BF408271 L07736 U93851 J04811 BF288240 D16829 BF401764 M87053 AW918559 U22424 AA946492 AF072835 BF283410 BE099796 AA800389 AI598346 X63995 M91597 AB046606 AJ223599 U28504 BF407531 AF030378 BE098930 NM_019147 NM_013196 NM_012699 AJ305049 AF079864 AI045083 AA946350 AA891949 M22253 BF557269 AJ132230 BE108246 NM_019371 AA799450 AA851305 NM_017020 AW141135 BF417565 BE108756 AF201901 BE120578 U81037 NM_012892 AF115435 AI411955 NM_017010 AA946467 BE107187 BE109242 AW143142 BF282689 AI412189 BE108224 AW533482 BE109664 D17309 AI180349 L01702 BE111827 AA900180 L36088 X95189 AI177168 NM_017149 AF230638 NM_012700 BE117941 M59967 AI598306 BE101140 NM_021593 AW916860 X98517 BE103482 D37979 U48245 BF523660 AJ002556 BE104535 NM_012608 NM_017154 NM_017192 NM_013172 AA924724 AI711110 U89695 U92802 NM_017320 NM_013179 NM_017286 AI233818 BF285568 AA943114 X13722 NM_019137 BE113599 BF281914 BF401491 AI178476 AI411375 J03025 U59672 BF287843 U56241 AI236120 AA946014 U90829 BE095997 U67137 AW915825 BF287827 AA858794 BE109638 BE108748 BE113365 BE098800 AI317854 L14851 AI172248 BF393902 AI712686 AJ009698 M83679 AW526136 BF556880 BF404426 NM_012742 U14647 BE107192 AA894099 J02962 AB019120 BF399595 U17253 BF417476 NM_020471 AW918468 BE112983 X95577 U53882 X89383 J04147 AI232716 AI600081 AF153012 U25651 NM_017129 BE100617 AA819316 BF288244 AB015308 U25055 BE101148 BE113655 NM_012773 AW434998 NM_017278 BF405932 AI233213 M30596 BF284768 BF398182 BF399649 AI178556 AW142966 BF406261 AW915563 NM_012707 BF393799 AI228955 D30666 AA851914 BF398696 BF408425 AW523755 Y00697 U56859 M88469 AW142667 AW918188 AB022714 AA848534 AI236753 BF404316 BF522212 AF132046 AA944398 M83196 BF555947 AF036335 AI178938 AF022247 AF067793 NM_019165 BE120354 M22923 AW434092 AI137506 U92072 AF083269 NM_012591 BE108809 U48592 AF156878 AI235493 AF093536 BF404853 BE113616 BE114418 AI411056 AI406525 AB021971 X07467 AI179460 L27058 AI408017 BE113076 BF285915 NM_020081 AW253040 BF284776 BF414136 BF563467 AI102524 AA818020 BE113205 AI145380 D16465 NM_017150 AW141878 M14050 AA943794 NM_019318 AB022209 AW527440 AA892918 AI146056 U90888 BF285150 BE113660 NM_013050 AI178808 AA899951 AI411991 BF389120 U42413 BE109381 BF556350 NM_012734 AI411270 AB016160 M55534 U17971 AW142654 AW918441 AI410127 BE329415 NM_019196 NM_012610 BE102251 NM_019384 AB003478 AA874975 AI176548 BE109561 AI102061 AF157511 AF110023 AA850242 NM_017003 AA946349 BF408990 AJ225654 BF396462 AI236928 NM_019256 BF551318 AW915004 NM_012913 AA891213 AF008114 L05084 BE097085 AI145761 AI407992 AI230591 NM_021741 BF285071 AI411297 Y09164 BE101290 BF553500 AA801331 NM_017060 BF550737 NM_021661 BF564759 BE109744 AF281635 X05341 NM_017062 AI176478 AI713217 U42388 AI411422 AI408969 AI454928 BF396314 BF409208 AW919170 AW918198 AI599484 NM_012921 AW142170 AI763826 AA800744 AW917650 U89280 AW143820 BF288140 AB028461 AB001089 AW917574 BF282574 X96589 AW143077 BE098025 BE105864 AF178689 BF406991 BE101126 BE101151 U14914 BE107098 AA817836 BF555858 BF282700 AI227916 BF407134 X15834 BF556693 M74067 AW920324 L39018 BF555544 AI717140 AI232138 BF281577 BE097840 AB046544 AF240784 BE110691 AI600068 BE107410 L13041 AW916911 BF282674 BF282471 AI227686 AF009511 BF284509 AF015949 BF396350 AW916943 BF567426 BF418775 AF054870 M91214 AF227741 NM_017161 BF568015 AI009608 X82021 NM_021670 U90312 AA800737 AI411793 AF062389 X52196 AF063851 AI146063 NM_012600 BE116153 AB025784 BF415013 AI407061 BF282483 AA851302 NM_021776 AI009427 BE115604 AA800364 AW914045 U03491 AI233343 BE116180 AA945579 BE113101 X02610 BE109221 BF419010 BF392911 BF407194 AA818377 D78610 BF557276 NM_019122 D86345 AI599232 AW917185 NM_012761 AA818602 AI703713 AW915797 NM_019368 NM_020077 AI172262 BE109919 BF285528 AA800815 AA818342 M85299 BE096027 BF566689 AF061873 AI230596 NM_012770 AI409037 AI574745 AW918233 AI406712 AA955527 AW143190 BE112950 BF542548 AI410452 AF222712 BF396115 X65948 AA851282 AI548615 AA943573 Y15054 AW252115 AW918031 AW251686 AI412866 AA946222 BE097244 BE096652 NM_017300 BF388797 AI511282 NM_021590 BF551160 M64381 BF403842 AW915567 BF282395 NM_021866 AI104432 NM_012624 BE108177 BE116554 AW527690 AW919837 U78090 BE115948 U55836 AI180050 NM_017238 AI176298 AW915148 X16262 AW917831 AI012336 AW523419 BE107295 BF550679 BE109095 AW919892 AW917114 BF395101 AI170390 BF408792 NM_017243 M22756 AI146156 AW915776 AF221622 AF194371 U48702 AI599410 BF284067 BF388220 AI102802 NM_012780 AW144095 NM_019376 D00036 AI138048 AA944552 AW915236 AI072251 AI178019 L38644 AI408249 NM_012969 U96490 BE111361 NM_013124 U25281 AW253398 AI007768 BE111820 X54862 NM_012889 BF282987 AW921975 AW915041 AI178452 AB009372 AF234260 AA925469 AW915273 AI578745 J00750 BF416935 AI102804 AI556256 L22294 NM_012834 BF550779 AW141615 AA817802 AI178361 AA848305 BF553981 BF404819 AI176838 AW520781 AI406532 U30831 NM_012807 AI412114 BE113015 NM_017110 AI172415 BE104961 BE109712 BF283407 NM_021774 M64780 BF281284 AF254800 AI639411 AI103955 AI407187 AW915886 AI406670 AW526270 AA818197 BF408452 BE120498 U20999 U08257 AW520354 BF413245 AI175533 AB006137 AI716159 Z21513 M88096 NM_020308 AW433947 AW143164 BE097309 NM_017179 AI145869 BF400588 AW919130 BE118454 AF279918 AW142932 BE097982 BE107279 BF290106 AI007974 AW143294 M85183 AI236615 M31837 AW144302 AW251657 AA892987 BF291260 AA955605 BF402472 AW525099 AF106325 NM_019350 AW918716 BF416877 AW523504 BE117939 AA858745 BF288254 AI411670 AW915685 BE119991 AI598946 NM_012811 X62660 BE115417 BE126380 AJ245648 AB010960 NM_017323 AA945882 AB033418 AW530332 AF081582 X73653 AI177360 AF068861 AA957010 BF393949 AW251852 NM_021586 AI231450 AW915165 AI009820 BF281178 AI598507 AW918920 BF564460 AI229209 AJ002942 AW915843 X73292 AA849731 NM_012907 NM_017214 AI172024 AW143907 BF543359 NM_016994 AF177430 AI176646 BE113277 AA944327 AW533098 NM_017035 AI409051 BF389143 AW918368 BF404778 AF100172 AI409861 AI105450 BE100015 AF032925 AW142717 BF281872 AW526673 BE100965 AA800046 AI409727 AF026505 AA848804 BE110621 NM_012653 AI231433 BE103793 AI411527 BE112971 NM_013151 AI602613 AI169749 AI235294 AI102009 AI176727 AW140397 AI454845 U66461 AW915541 AW143676 BE108985 M25073 AA945069 AW921544 BE109246 BF285313 AW916692 AF081503 BE100576 AF176072 BF289100 AI177083 AI408928 BE113248 AI170289 D10554 AI228159 AW920454 Z29486 U27186 M83107 AW434103 BF414412 AI169653 AW530292 AI411222 BE108388 BF419792 AI172320 BF387258 BE107075 BF282088 AW252109 AI76972 AI175556 AF218826 BF420183 NM_012904 AI502952 AW143156 AI102758 AI409150 NM_021757 NM_017168 AW917977 AI231782 AW915035 AW916774 AW918991 X14773 D88190 BF284983 AW915540 BF551808 AI230732 AI555819 AW435159 BE096098 U36482 AI412740 D21158 Y00047 AI104256 AA997745 BF406286 M77246 AI411360 AI179391 AI069922 NM_020101 AI171651 X78855 AI556315 BE107622 U81160 AI548655 AW251401 BE109108 BF567869 AI113186 AI555457 Z49858 BF417010 AW919868 AA893584 BF404590 AA944079 BF548406 BE118251 AF161588 BF411162 AI172266 NM_012749 AW915682 NM_013129 NM_016996 BE107489 BF417442 AI136709 AI170410 AI101373 BE116220 AI407858 BE110614 BE096257 AW918990 AA945713 BF282381 AA899160 M29294 BE107805 AW920687 D29960 AB029559 U36992 AI177022 BF415222 L26267 AI409045 X66022 AI411391 AI177058 AI229821 AF117330 AA848437 AA891551 AW532870 AI230362 BF523591 AA850317 BE106307 BE108835 AA891733 AI411845 D13518 BF393917 NM_020075 BE109055 AI502504 AI008964 BE110638 AI102743 BF281852 AW143215 AI639504 M69246 AI169386 AA799700 BE098555 AW919920 AI227943 BE109681 BF414012 AI009644 AW920557 BF524978 AI599479 BF393863 D87950 AI008371 U31352 BF283237 AB018253 AA893640 AI230578 AI010423 NM_012797 AI072292 AI009197 AW915692 M13979 AI171794 M34477 AI171088 BE099875 AI177590 U27191 AI236691 AW921523 BF282648 AI111863 L27339 AI406487 BE113399 AA850576 AI235282 AW916023 BF283073 AF016252 AW915782 AW919696 BE098778 AI411772 BF420684 BE102100 BF553948 AF136943 AW251612 BF557013 D17711 AA858925 AI178272 AW525370 AI103146 AA998252 AF033027 AI231505 BF551370 AI501407 AW531386 J05035 BE096516 BF393595 AW528778 BF402375 AI710879 NM_012853 AW143323 NM_017282 AI101189 NM_019163 U69487 L28801 AA893192 AI410802 U71294 AA944485 NM_017037 AF208499 AI599568 AA849987 U26595 BF285026 BE107103 L14684 BE101435 AA818910 AA849958 BF415001 AF324255 NM_020076 AI232346 BF550748 NM_017209 U82591 BF283735 AB048711 AI409857 BE111727 X59601 BF394563 BE121333 BF394528 BE116914 AF214568 AW917562 AJ225647 AI235367 BF398071 AI406304 AW918237 BF283417 BE104454 AI007924 U57715 NM_012827 BF558071 AW915120 AI233773 BE097153 U73503 AF216807 BE117683 BF281865 BF281969 AI170258 AF323174 AF025424 AI175544 AI716436 AW914009 AA849774 AA859141 AW914973 BF417252 AW914041 AF003926 BE116512 AW916823 AI010312 BE109628 BF557691 AA946032 BE099999 BE111694 BF555169 NM_013027 AI070399 BE110645 BE113210 AI179795 AA848530 BE108886 AF002705 BE117891 BE102427 AW529231 BF551148 AW918614 AW435036 BE111811 BF557674 AA942690 AW917503 AA943752 NM_017313 AA800803 AW914062 BE113989 AA800739 AA819318 AW919277 BF408129 BF284855 AI070523 AW524523 AW918452 BF550572 AW915142 AI177379 BF411622 BE100774 AW253429 AW915484 AI406469 BF558866 BF396644 AF223951 AI411205 AI598307 U57391 AA892362 AF277899 AF036255 L19699 X62277 AI227985 BF557299 AI579643 AA901066 AA892240 BE108201 AW915121 AA799544 BF412565 AW251483 AA799313 NM_017349 BF414146 M84719 AW525372 AI236027 AI406938 AI102643 BE110574 X67156 BE120602 AI010033 AF302085 BE120360 AI231309 X04070 AI407930 AW251641 BF282675 BF420064 X54640 AI599023 AA943815 AI408993 D50695 AA894305 NM_012680 AW253646 NM_019201 U96638 AI229183 Y00826 AF221952 AW144669 NM_017283 AI411790 AW254166 BE109709 BE110128 AF274057 AW143855 BF411147 BF549441 BE113321 AI409506 BE118562 AI408520 AI172472 BF392443 AI412429 AA892772 BF283250 NM_013113 BF556332 BE116848 AA892922 AW917768 AI228624 X66370 BF551342 AA800249 BF396485 BE112237 AI178214 AI137218 AA858572 BF401591 BF281954 AI230884 AI171769 AW918182 AI169706 AF170253 AI556402 AI412763 D84667 BE109678 AI012264 U35245 AA818692 U89282 NM_017163 BF281319 U40188 AI178158 AI010433 AA799691 D38082 AI169635 AI231286 BE113013 BE104865 AA946389 AI410456 AB006914 BF396371 BF284093 BF523723 BF288651 AI411156 D13124 AI013075 M57728 BF397951 AW916461 AA996628 AW433875 AA818582 AF000578 BF403712 AB047556 AW433883 BE097279 AW520760 AI102486 AI137161 BF418588 BF550623 BE104290 AI137233 AW252891 AA955616 BF407480 BE117164 AI175494 BE111879 AF227200 AF087431 BF406590 BE109633 BE115051 BE097298 AI232979 AI229833 AB000199 AA945898 AW914090 AW251107 AI009089 AI009094 AI012613 M61219 AW253004 AI012598 NM_017166 AI407067 BF406413 BF419187 AI228598 AI408482 BE116889 AW143981 AA891860 BF399993 Z11994 X71873 AW919527 AI172500 L12382 AI178922 AA900562 AA893621 AA945753 AI176042 AI236063 AI170409 AW141940 AW252110 BF562819 AW526015 BF400995 AI137912 AW254010 X52140 BE109952 M27893 BF406514 AW434299 AA996888 D26180 BF284313 U00926 M23674 AI105088 AA851369 AI230697 AI178155 AI169176 AI172150 AI227996 AI575056 AI716607 AA851241 BE109232 AA858649 AW914867 BG153368 BE116927 BF420717 BE096995 M33648 AF269283 AI548722 BF282933 AI716456 AB032243 NM_021678 AA818954 AI228642 AA957770 L07578 X68101 BE109116 AI599819 AA945696 NM_017210 BF567821 AW522132 BF411461 BF397012 D14046 AJ238278 AW916153 AA963071 BF550545 X79807 J04487 AJ301677 AI171951 D10854 AW530379 AF008197 BF566748 AI410391 AA818089 NM_012743 BF396279 NM_017139 NM_012552 BF284830 X68282 M59814 BF406213 AI009200 Y07744 AF062402 AI230548 D10233 BF281133 BE114123 AW251683 L20823 BE111690 NM_021752 AW141131 NM_012852 BF396478 BF410771 AW915445 BF289154 U12571 AW143086 AI045074 BF284328 BE111731 NM_017304 AF304429 AI137283 BF285068 BE119400 NM_019175 AF073379 NM_017049 BF288092 BF393862 AI013038 U23438 AA891922 AW918538 AW251199 X70706 NM_021701 M95738 BF282327 AW526089 AB032827 AW534166 AI170382 BE101579 AW919172 BF286192 L15619 BF398540 BE116560 BE110609 AA892531 BF398602 AI145586 NM_012758 AW142642 U52103 X15800 BE110674 AA996543 AW434308 BF412297 M81642 BF419044 BF415031 BF554891 AI144958 NM_012790 U67138 AI410349 AW254375 AF291437 AB030947 BF283759 AF134054 AI235510 U73174 L08814 L11007 AW916920 AF219904 AI176327 X58828 NM_017248 AI385370 BE115570 U06273 NM_017017 AW918345 BE100607 AI234173 AF095449 AF035156 AB001321 AI233786 AW525042 AF269251 AI715321 AI406494 AI713324 BE104891 NM_013127 AW528005 BE097282 BF290678 X71429 X97831 X52590 AW435315 BF414193 BF283351 X53477 BE102840 D37920 AI406350 BF415054 NM_017284 NM_017333 AA892864 AI411530 BF282715 NM_013225 AW141761 BF400782 BE111849 AI010351 U66566 AF011788 AI231089 AW916376 AI112973 S79760 AB032551 BF417360 AA799532 BF558479 AW143231 BF549260 NM_017173 AI170763 X53232 BF564152 U53706 X98399 AW141730 AW144324 AW915661 X68191 Y13588 BE111512 NM_017257 NM_012957 M14053 BF283107 AI102788 AI169374 BE115943 NM_019352 AA799358 BF284711 AI555565 AW920769 BF403999 BE116101 AI103993 AA800637 BE110731 NM_012930 AI575254 BF557930 AI009796 Y16641 AW920609 AF016387 BF563406 AI407449 M87067 AW918854 AW918052 BF288328 BF287028 AF016183 NM_013174 L35771 L26288 AI145385 D86373 AA964289 AF007108 M34043 H35156 J05181 AB015746 AW142311 AB046442 BF284885 BE110547 U78517 AA819501 AF239045 AI010413 NM_021696 AJ223355 AW144294 AI639012 NM_012500 NM_021758 AF104034 Y00752 AA942681 AI175064 NM_017230 BF396709 NM_012651 AF276774 BE111765 NM_017127 BF404959 AW251942 BE099976 V01222 BF557572 U93306 BF399135 AI412079 BE116947 U05989 AJ010750 BF289492 AW507304 NM_012883 M35270 BF281419 AA946518 M75148 NM_017094 BF406646 AI715893 BE107610 NM_012594 AI237077 AI406390 BF407203 AW143162 AW143513 BF407501 AI237636 BF566346 AF187814 BE109573 AF095740 BE101876 U51583 AI009156 AI179711 BF551593 BF567845 AW917598 AW527815 AF087433 AW920343 BF289001 AA945149 AA943764 BE105589 BF281975 AF234765 NM_012747 AI233266 D83538 BE110624 AI179315 AW913871 AI177053 BF406562 BF548006 AI009007 BF393285 D00859 AI175454 D21132 D82928 BE109704 AF013967 AW253843 M29293 AI407113 L22022 BE109532 BF291213 BF396256 NM_017190 AA945866 AF017756 AI180187 AI575072 AW919439 BE118425 BE109634 BE111659 BE098855 BF556755 AA944176 BF283830 AA848420 BF282147 BF395125 BE109642 AI406499 BE108922 AI070732 AI406520 BF402664 BF283754 BF410170 L22339 BF405725 AI232332 NM_013177 NM_013186 U67140 AF110024 BF420043 AA893191 AW143526 M55250 AA817813 BF555225 AA799784 BE111345 X71916 AI013110 AA817817 AI070303 BF412643 AI179413 AA965185 AI170664 AI231827 BE109656 M94043 AI579555 NM_017026 AI406275 U46149 D89375 AF039203 BF390970 BE100771 AA818364 BF405581 U54807 BF393486 AI045035 X99326 BE128566 AW141446 NM_019234 BF563114 AW915616 AI598719 AI231290 BE116574 AA801133 BF414997 NM_019124 U10894 AW921546 BE100609 AI170303 AI044124 NM_013130 NM_019281 AA848639 M35495 L39991 BF395067 L14936 AA817968 AW918011 AI408827 BF548743 AI072218 AI410818 AI716480 BF553984 BF411842 AB028933 AI235222 AI178134 AA859631 NM_017160 BE107324 D85189 U78875 BE111609 NM_017104 BE111770 AI411088 AA900434 AA800708 AI407320 AF049344 M27905 AI233452 AI170376 AI172075 AA850487 AJ007704 M55075 BF283861 Y13380 AA944549 AA800291 AA893164 AA800004 BF397919 AA894306 X51707 D50694 AF051943 AI179640 AI412931 BF558780 X74125 NM_017355 X61677

The signature used to predict the presence or absence of future renal tubular injury was derived using a robust linear programming support vector machine (SVM) algorithm as previously described (see e.g., El Ghaoui, L., G. R. G. Lanckriet, and G. Natsoulis, 2003, “Robust classifiers with interval data” Report # UCB/CSD-03-1279. Computer Science Division (EECS), University of California, Berkeley, Calif.; and U.S. provisional applications US Ser. No. 60/495,975, filed Aug. 13, 2003 and U.S. Ser. No. 60/495,081, filed Aug. 13, 2003, each of which is hereby incorporated by reference herein). Briefly, the SVM algorithm finds an optimal linear combination of variables (i.e., gene expression measurements) that best separate the two classes of experiments in m dimensional space, where m is equal to 7479. The general form of this linear-discriminant based classifier is defined by n variables: x₁, x₂, . . . x_(n) and n associated constants (i.e., weights): a₁, a₂, . . . a_(n), such that: $S = {{\sum\limits_{i}^{n}{a_{i}x_{i}}} - b}$ where S is the scalar product and b is the bias term. Evaluation of S for a test experiment across the n genes in the signature determines what side of the hyperplane in m dimensional space the test experiment lies, and thus the result of the classification. Experiments with scalar products greater than 0 are considered positive for sub-chronic nephrotoxicity.

Signature Validation

Cross-validation provides a reasonable approximation of the estimated performance on independent test samples. The signature was trained and validated using a split sample cross validation procedure. Within each partition of the data set, 80% of the positives and 20% of the negatives were randomly selected and used as a training set to derive a unique signature, which was subsequently used to classify the remaining test cases of known label. This process was repeated 40 times, and the overall performance of the signature was measured as the percent true positive and true negative rate averaged over the 40 partitions of the data set, which is equivalent to testing 392 samples. Splitting the dataset by other fractions or by leave-one-out cross validation gave similar performance estimates.

Cross validation using 40 random iterative splits (80:20 training:test) resulted in an estimated sensitivity, or true positive rate, of 83.3%, and a specificity, or true negative rate, of 94.0%. Leave-one-out cross-validation produced similar results.

To test whether the algorithm is identifying a true pattern in the training set, but not a random data set, the labels for the 64 experiments were randomly assigned and a signature was derived and subject to cross-validation as above. This process was repeated 99 times. As expected, the average test log odds closely centered about zero (−0.004±0.86), with a range of −2.3 to 2.9. By comparison, the true label set had a log odds ratio of 4.4, which was significantly greater than expected by chance (p<0.0001).

Results

Using 7478 pre-selected genes whose accession numbers are listed in Table 3, the SVM algorithm was trained to produce a gene signature for renal tubule injury comprising 35 genes, their associated weights and a bias term that perfectly classified the training set. The 35 genes and the parameters of the signature are depicted in FIG. 1. Average impact represents the contribution of each gene towards the scalar product, and is calculated as the product of the average log₁₀ ratio and the weight calculated across the 15 nephrotoxicants in the positive class listed in Table 2.

As shown in FIG. 1, the genes are ranked in descending order of percent contribution, which is calculated as the fraction of the average positive impact each gene in the positive training class has relative to the sum of all positive impacts. Genes with a negative average impact are considered penalty genes. The expression log₁₀ ratio of each gene was plotted in the depicted “heat map” across all 15 treatments in the training set. The sum of the impact across all 35 genes for each treatment, and the resulting scalar product are presented along the two rows below the plot. The bias term for the 35 gene signature was 0.58.

The 35 genes identified represent 35 unique Unigene clusters. This 35 gene signature identifies compound treatments that are predicted to cause future renal tubular injury in the rat based on kidney expression data from short term (<=5 days) in vivo studies.

The product of the weight and the average log₁₀ ratio across the 15 positive experiments in the training set indicated that 31 of the 35 genes are considered “reward” genes, as they represent expression changes that positively contribute to the signature score (i.e., the scalar product). The reward genes assure sensitivity of the signature by rewarding expression changes consistent with nephrotoxicity. A positive scalar product indicates the experiment is predicted to be positive for future renal tubular injury, while a negative scalar product indicates the experiment is negative for future renal tubular injury. The remaining 4 genes in the signature are considered “penalty” genes as they represent expression changes that negatively contribute to a scalar product. Penalty genes assure specificity of the signature by penalizing expression changes not consistent with nephrotoxicity.

The genes and bias term in the signature are weighted such that the classification threshold (i.e., zero) is equidistant, by one unit, between the positive class and negative class experiments in the training set.

Of the 31 reward genes, 15 have an average expression log₁₀ ratio greater than zero and are therefore induced on average by the nephrotoxicants, while the remaining 16 are on averaged repressed by the nephrotoxicants. Examination of the expression changes across the 15 nephrotoxicants in the training set reveals that most genes are not consistently altered in the same direction by all treatments (FIG. 1). Instead, it is the sum of the product of the weight and log₁₀ ratio (i.e., impact) across all 35 signature genes, less the bias, that results in an accurate classification. For example, Cyclin-dependent kinase inhibitor 1A (U24174) or the EST AW143082 are induced and repressed to varying degrees by compounds in the positive class, thus indicating that individual genes would be poor classifiers when used individually. This highlights the limitations of using single genes for classification and also illustrates the basis for signature robustness since classification decisions are not dependent on any one gene that may be subject to experimental error.

Example 4 Stripping of Renal Tubule Injury Signatures to Produce a Necessary Set of Genes

In order to understand the biological basis of classification and provide a subset of genes useful in alternative signatures for renal tubule injury, an iterative approach was taken in order to identify all the genes that are necessary and sufficient to classify the training set.

Starting with the 7478 pre-selected genes on the Codelink RU1 microarray, a signature was generated with the SVM algorithm and cross-validated using multiple random partitions (80% training: 20% test) of the data set. The 35 genes identified previously in the first signature (i.e., “iteration 1” in Table 4) as being sufficient to classify the training set were removed and the algorithm repeated to identify additional genes. This identified an additional 37 genes (i.e., the genes in “iteration 2” in Table 4) that were able to classify the training set with a log odds of 3.80. This approach was repeated until the test LOR of the model reached zero, which occurred after 14 iterations and which consumed 622 genes. Based on the first 5 iterations, 186 genes were identified to be necessary to classify the training set with a test LOR of 1.64 (Table 4), which is approximately 2 standard deviations greater than the average LOR achieved with random label sets. Importantly though, it identifies a reasonable number of genes with a demonstrated ability to uniquely discriminate nephrotoxicants with an approximate accuracy of 76%. These genes are listed in Table 4. TABLE 4 186 genes identified to be necessary and sufficient to classify the training set. Mean Mean Logratio Logratio Positive Negative Unigene Probe Iteration Weight Impact Class Class ID UniGene Description AI105417 1 −0.89 0.261 −0.294 −0.172 Rn.8180 neuronal regeneration related protein BF404557 1 −1.36 0.213 −0.156 0.077 Rn.50972 ESTs U08257 1 0.88 0.149 0.170 0.029 Rn.10049 Glutamate receptor, ionotropic, kainate 4 BF285022 1 1.46 0.143 0.097 −0.013 Rn.24387 ESTs AF155910 1 0.55 0.125 0.226 0.002 Rn.92316 heat shock 27 kD protein family, member 7 (cardiovascular) AI144646 1 0.63 0.108 0.171 −0.075 Rn.36522 gap junction protein, alpha 12, 47 kDa (Hs.) (DBSS_strong) AI105049 1 0.82 0.104 0.126 −0.018 Rn.23565 ESTs AI227912 1 0.46 0.074 0.160 −0.026 Rn.873 Sorting nexin 3 (SDP3 protein) (Hs.) (DBSS_strong) AW916023 1 −0.64 0.074 −0.116 −0.011 Rn.6788 Kelch-like ECH-associated protein 1 (Cytosolic inhibitor of Nrf2) (INrf2) (Rn.) (DBSS_weak) BF403410 1 0.42 0.068 0.163 0.020 Rn.23087 Homo sapiens clone 25048 mRNA sequence (Hs.) (DBSS) Y00697 1 0.63 0.067 0.106 0.048 Rn.1294 Cathepsin L AW143082 1 −0.30 0.056 −0.186 0.361 Rn.22057 ESTs AI599126 1 0.36 0.044 0.122 −0.061 Rn.8452 inner centromere protein (Mm.) (DBSS_strong) AI102732 1 −0.31 0.035 −0.113 0.064 Rn.7539 ESTs AI176933 1 0.46 0.035 0.076 −0.048 Rn.23658 ajuba (Mm.) (DBSS) AF208288 1 −0.27 0.034 −0.127 0.043 Rn.48779 G protein-coupled receptor 26 AF281635 1 0.43 0.021 0.049 0.002 Rn.9264 zinc finger protein 22 (KOX 15) U24174 1 0.09 0.021 0.219 0.133 Rn.10089 cyclin-dependent kinase inhibitor 1A AW142947 1 −0.22 0.019 −0.085 −0.030 Rn.61563 ESTs BF396132 1 −0.26 0.014 −0.055 0.004 Rn.76362 echinoderm microtubule associated protein like 2 NM_012610 1 −0.08 0.014 −0.164 0.054 Rn.10980 nerve growth factor receptor U57049 1 −0.17 0.013 −0.080 0.000 Rn.10494 methylenetetrahydrofolate reductase AW520754 1 −0.08 0.010 −0.124 0.021 Rn.15536 potassium channel, subfamily K, member 3 (Hs.) (DBSS) AI231846 1 −0.13 0.008 −0.059 0.032 Rn.27 ESTs BE116947 1 0.05 0.006 0.126 −0.078 Rn.8045 ESTs AW917933 1 −0.04 0.005 −0.124 0.039 Rn.28424 ESTs AW144517 1 −0.05 0.005 −0.097 −0.004 Rn.13780 ESTs AW920818 1 0.03 0.005 0.177 −0.078 Rn.11702 macrophage activation 2 (Mm.) (DBSS) AB021980 1 −0.05 0.003 −0.057 0.054 Rn.32872 delta-6 fatty acid desaturase AF087454 1 −0.29 0.001 −0.004 0.033 Rn.30019 potassium voltage-gated channel, subfamily Q, member 3 BE097309 1 0.41 0.000 0.001 0.004 Rn.46694 Peregrin (Bromodomain and PHD finger-containing protein 1) (Hs.) (DBSS_strong) AW919837 1 −0.05 0.000 0.010 0.042 Rn.23432 adrenergic, alpha-2A-, receptor (Hs.) (DBSS) NM_013197 1 0.03 −0.007 −0.259 −0.286 Rn.32517 aminolevulinic acid synthase 2 BF396955 1 0.77 −0.050 −0.065 −0.228 Rn.41236 PC4035 cell-cycle- dependent 350K nuclear protein (Hs.) (DBSS_weak) BF281149 1 1.34 −0.057 −0.042 −0.226 Rn.3137 Hypothetical protein KIAA0008 (Hs.) (DBSS_weak) AI412011 2 3.38 0.279 0.082 0.005 Rn.3738 RIKEN cDNA 0610012G03; expressed sequence AI839730 (Mm.) (DBSS_weak) BF419406 2 −0.94 0.159 −0.168 −0.026 Rn.26560 ESTs NM_021682 2 −0.53 0.125 −0.234 −0.032 Rn.42884 kilon AF136583 2 0.66 0.115 0.174 −0.024 Rn.12100 serum-inducible kinase NM_020308 2 0.94 0.111 0.118 −0.025 Rn.28393 a disintegrin and metalloproteinase domain (ADAM) 15 (metargidin) BE109152 2 1.60 0.103 0.064 0.011 Rn.19642 Red protein (RER protein) (Mm.) (DBSS_strong) AI176739 2 0.41 0.083 0.205 0.005 Rn.22359 KIAA1002 protein (Hs.) (DBSS_moderate) AI228233 2 0.67 0.076 0.113 −0.017 Rn.25139 epsin 2 (Hs.) (DBSS) AF007549 2 0.55 0.075 0.136 0.026 Rn.10734 golgi SNAP receptor complex member 2 AI232347 2 −2.15 0.070 −0.032 0.012 Rn.102 chromosome 14 open reading frame 114 (Hs.) (DBSS_moderate) AW915996 2 −0.48 0.054 −0.114 0.094 Rn.19250 T00260 hypothetical protein KIAA0605 (Hs.) (DBSS_strong) AA819832 2 −0.40 0.054 −0.136 0.141 Rn.34433 period homolog 1 (Drosophila) (Hs.) (DBSS) AW524724 2 −0.34 0.052 −0.156 −0.002 Rn.95059 ryanodine receptor type 1 (Mm.) (DBSS_strong) BE103916 2 −0.72 0.046 −0.064 0.020 Rn.26832 ESTs BF283302 2 0.56 0.046 0.081 −0.008 Rn.226 ESTs X68878 2 −0.17 0.040 −0.244 −0.050 Rn.11022 synaptosomal-associated protein, 91 kDa D00403 2 −0.44 0.039 −0.088 0.031 Rn.12300 Interleukin 1 alpha AI145385 2 −0.79 0.035 −0.044 −0.025 Rn.3580 ESTs AI317854 2 −0.22 0.032 −0.143 0.012 Rn.20362 ESTs AI231432 2 0.58 0.030 0.051 −0.025 Rn.6983 hypermethylated in cancer 1 (Mm.) (DBSS_moderate) AA996961 2 −0.34 0.029 −0.088 0.071 Rn.12469 DNA-repair protein complementing XP-A cells (Hs.) (DBSS_moderate) NM_012971 2 −0.26 0.025 −0.098 0.058 Rn.9884 potassium voltage gated channel, shaker related subfamily, member 4 BF397726 2 0.43 0.020 0.047 −0.076 Rn.18639 NF-E2-related factor 2 (Rn.) (DBSS_weak) AW527217 2 −0.20 0.017 −0.088 −0.027 Rn.23378 ESTs AA799789 2 0.25 0.016 0.065 −0.026 Rn.30163 ESTs NM_013190 2 −0.59 0.015 −0.026 0.001 Rn.4212 Phosphofructokinase, liver, B-type AI576621 2 0.16 0.013 0.082 0.027 Rn.24920 ESTs AA943149 2 0.81 0.010 0.012 −0.002 Rn.7346 ALEX3 protein (Hs.) (DBSS_strong) AW253895 2 −0.12 0.006 −0.055 0.011 Rn.3382 BRCA1 associated protein- 1 (ubiquitin carboxy- terminal hydrolase) (Hs.) (DBSS_strong) BF283340 2 −0.09 0.005 −0.057 0.028 Rn.20857 ESTs AF073379 2 −0.11 0.005 −0.046 0.015 Rn.10169 glutamate receptor, ionotropic, N-methyl-D- aspartate 3A AA799981 2 −0.14 0.005 −0.034 0.032 Rn.6263 ESTs AF237778 2 −0.18 0.003 −0.017 0.086 Rn.88349 calcium/calm odulin- dependent protein kinase II alpha subunit AI175375 2 −0.14 0.003 −0.019 −0.025 Rn.24087 ESTs AJ130946 2 0.13 0.002 0.014 −0.096 Rn.2949 karyopherin (importin) alpha 2 AI012120 2 0.25 −0.004 −0.016 −0.149 Rn.17809 ESTs AW252871 2 0.54 −0.078 −0.145 −0.370 Rn.12774 cell proliferation antigen Ki-67 (Mm.) (DBSS_moderate) J03863 3 0.70 0.163 0.233 0.208 Rn.9918 serine dehydratase U19614 3 2.55 0.161 0.063 −0.005 Rn.11373 lamina-associated polypeptide 1C M19651 3 0.78 0.131 0.168 0.052 Rn.11306 Fos-like antigen 1 AI407719 3 −1.78 0.111 −0.063 0.161 Rn.20359 ubiquitin specific protease 2 (Hs.) (DBSS) BF396629 3 2.54 0.111 0.044 −0.051 Rn.16544 patched homolog (Drosophila) (Hs.) (DBSS) BF290678 3 2.25 0.109 0.049 −0.015 Rn.40449 heterogeneous nuclear ribonucleoprotein G (Mm.) (DBSS) BE101099 3 −1.84 0.109 −0.059 −0.008 Rn.35019 parathyroid hormone regulated sequence (215 bp) AI070303 3 −1.13 0.098 −0.086 0.019 Rn.21284 pancreasin (Hs.) (DBSS_moderate) AA925559 3 −1.06 0.078 −0.074 0.031 Rn.25196 RIKEN cDNA 2610027L16 [(Mm.) (DBSS_strong) AB005549 3 0.58 0.056 0.097 −0.026 Rn.31803 three-PDZ containing protein similar to C. elegans PAR3 (partitioning defect) AI717140 3 −0.59 0.043 −0.072 −0.001 Rn.22400 ESTs AA858817 3 −0.23 0.040 −0.171 0.079 Rn.22047 T46271 hypothetical protein DKFZp564P1263.1 (Hs.) (DBSS_moderate) BF284897 3 0.54 0.035 0.064 0.027 Rn.18772 hypothetical protein FLJ10579 (Hs.) (DBSS_moderate) AW914881 3 0.27 0.034 0.123 0.036 Rn.22383 ESTs BE106459 3 −0.21 0.033 −0.157 −0.037 Rn.20259 ESTs BF283556 3 −0.14 0.027 −0.188 0.019 Rn.7829 Homo sapiens clone 23785 mRNA sequence (Hs.) (DBSS) M63282 3 0.31 0.016 0.050 0.084 Rn.9664 Activating transcription factor 3 AW533663 3 0.08 0.014 0.174 0.124 Rn.41672 Proline oxidase, mitochondrial precursor (Mm.) (DBSS_strong) L19656 3 −0.92 0.013 −0.014 0.048 Rn.10552 5-hydroxytryptamine (serotonin) receptor 6 NM_012852 3 0.11 0.009 0.083 −0.008 Rn.34834 5-Hydroxytryptamine (serotonin) receptor ID AA946230 3 −0.22 0.008 −0.039 −0.023 Rn.47222 ESTs BF405135 3 −0.36 0.008 −0.022 0.018 Rn.51262 ESTs AA818949 3 −0.14 0.007 −0.052 0.002 Rn.20419 DnaJ homolog subfamily B member 12 (Hs.) (DBSS_moderate) X79860 3 −0.36 0.006 −0.017 0.066 Rn.65877 H1SHR mRNA AW253907 3 −0.08 0.005 −0.064 0.066 Rn.98601 ESTs X89603 3 0.05 0.004 0.091 −0.049 Rn.11325 metallothionein 3 AA858649 3 −0.50 −0.002 0.004 0.004 Rn.16864 chromosome 13 open reading frame 9 (Hs.) (DBSS_strong) AW529588 3 0.61 −0.003 −0.005 −0.040 Rn.28180 ESTs BF550800 3 0.16 −0.004 −0.023 −0.307 Rn.36317 ESTs BE111296 3 0.18 −0.014 −0.079 −0.174 Rn.19339 ESTs AI113104 3 1.77 −0.086 −0.048 −0.262 Rn.12343 protein regulator of cytokinesis 1 (Hs.) (DBSS_moderate) U53706 4 −1.14 0.159 −0.139 −0.021 Rn.10288 mevalonate pyrophosphate decarboxylase L36459 4 0.89 0.152 0.171 −0.036 Rn.10045 Interleukin 9 receptor BF410042 4 4.02 0.151 0.038 −0.030 Rn.31227 cardiac lineage protein 1 (Mm.) (DBSS) AW915655 4 −2.26 0.129 −0.057 0.000 Rn.14962 ESTs AA944518 4 −1.07 0.102 −0.096 0.019 Rn.34351 ESTs NM_012939 4 −0.19 0.079 −0.408 −0.002 Rn.1997 Cathepsin H BF408867 4 −0.37 0.059 −0.157 0.013 Rn.35618 mitochondrial translational release factor 1-like (Hs.) (DBSS_moderate) AW915454 4 −0.26 0.052 −0.204 −0.028 Rn.14822 ESTs BE113132 4 −0.37 0.042 −0.112 0.124 Rn.22381 guanine nucleotide exchange factor for Rap1; M-Ras-regulated GEF (Hs.) (DBSS) AW143273 4 0.72 0.040 0.056 −0.020 Rn.11888 Rec8p, a meiotic recombination and sister chromatid cohesion phosphoprotein of the rad21p family (Hs.) (DBSS) AW915107 4 0.70 0.039 0.055 −0.023 Rn.19003 ESTs BE110577 4 0.96 0.038 0.040 −0.008 Rn.14584 ESTs AW141985 4 0.39 0.034 0.088 −0.008 Rn.13195 ATP-binding cassette, sub- family C (CFTR/MRP), member 4 AW140530 4 −0.35 0.029 −0.083 0.005 Rn.7679 tumor susceptibility protein 101 (tsg101) gene (Mm.) (DBSS) BF420720 4 −0.31 0.026 −0.083 0.030 Rn.23998 ESTs AW144399 4 −0.78 0.025 −0.032 0.068 Rn.15255 hypothetical protein FLJ10652 (Hs.) (DBSS_moderate) AI411605 4 −0.30 0.024 −0.079 −0.095 Rn.20056 ESTs NM_019123 4 0.38 0.021 0.055 −0.025 Rn.88072 sialyltransferase 7c AW920802 4 0.50 0.019 0.037 −0.021 Rn.36609 ribosomal protein L5 (Hs.) (DBSS) AI228598 4 −0.70 0.018 −0.026 0.036 Rn.11771 ESTs AI175454 4 0.18 0.013 0.072 −0.002 Rn.17244 procollagen-proline, 2- oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II (Hs.) (DBSS_strong) AI009623 4 −0.08 0.011 −0.135 −0.073 Rn.13924 ESTs AI235282 4 −0.20 0.011 −0.053 0.004 Rn.22436 Low-density lipoprotein receptor-related protein 1 precursor (Hs.) (DBSS_strong) NM_012564 4 −0.06 0.009 −0.159 −0.100 Rn.1437 Group-specific component (vitamin D-binding protein) BE095865 4 −0.35 0.009 −0.025 0.104 Rn.21852 calcium channel, voltage- dependent, alpha 1I subunit (Hs.) (DBSS) AF291437 4 −0.40 0.009 −0.022 −0.058 Rn.39124 leucine rich repeat protein 3, neuronal AF176351 4 −0.26 0.009 −0.032 0.017 Rn.54003 nuclear receptor coactivator 6 AB027155 4 0.15 0.008 0.057 0.027 Rn.44869 phosphodiesterase 10A BE116569 4 0.34 0.008 0.024 −0.009 Rn.15835 zinc-finger protein AY163807 (Hs.) (DBSS_strong) AA894210 4 0.05 0.004 0.091 0.082 Rn.85480 ESTs AJ237852 4 −0.04 0.003 −0.058 0.065 Rn.30023 sodium channel, voltage- gated, type1 1, alpha polypeptide AJ305049 4 −1.09 0.002 −0.002 0.075 Rn.64632 interleukin 10 receptor, alpha NM_017186 4 −0.03 0.002 −0.070 −0.015 Rn.30042 glial cells missing (Drosophila) homolog a AA800004 4 0.04 0.001 0.024 −0.063 Rn.6269 Septin 4 (Peanut-like protein 2) (Brain protein H5) (Hs.) (DBSS_strong) NM_012614 4 0.05 0.001 0.012 0.040 Rn.9714 Neuropeptide Y BF285985 4 −0.06 −0.001 0.016 0.074 Rn.42366 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4 AI412889 4 −0.08 −0.001 0.012 0.105 Rn.23659 monocyte to macrophage differentiation-associated 2 (Mm.) (DBSS) AJ002556 4 −0.54 −0.003 0.006 0.050 Rn.37490 microtubule-associated protein 6 AI179459 4 0.12 −0.011 −0.094 −0.152 Rn.31366 Kell blood group (Mm.) (DBSS_moderate) AI603128 4 0.15 −0.019 −0.127 −0.330 Rn.13094 Cyclin A2 (Cyclin A) (Mm.) (DBSS_strong) BE111688 4 1.72 −0.082 −0.048 −0.343 Rn.23351 cyclin B2 (Hs.) (DBSS_strong) NM_012892 5 −0.70 0.128 −0.184 −0.127 Rn.37523 amiloride-sensitive cation channel 1 BE098463 5 2.30 0.101 0.044 −0.100 Rn.18203 ESTs C06844 5 −0.94 0.095 −0.101 0.075 Rn.7159 S49158 complement protein C1q beta chain precursor (Rn.) (DBSS_weak) AI170114 5 −0.42 0.078 −0.183 −0.112 Rn.91697 ESTs AI105265 5 −1.53 0.073 −0.048 0.009 Rn.5911 hypothetical protein FLJ10315 (Hs.) (DBSS_strong) BF394214 5 −0.79 0.071 −0.090 −0.014 Rn.58227 ESTs AA946356 5 −1.08 0.063 −0.058 −0.017 Rn.1435 CGG triplet repeat binding protein 1 (Hs.) (DBSS) AW919159 5 1.09 0.056 0.051 −0.022 Rn.41574 A38135 ADP- ribosylarginine hydrolase (Rn.) (DBSS_weak) AI230884 5 1.61 0.053 0.033 −0.034 Rn.9797 Fibroblast growth factor receptor 1 BF406522 5 0.92 0.052 0.056 −0.019 Rn.3537 cerebellar degeneration- related protein 2, 62 kDa (Hs.) (DBSS) NM_012848 5 0.14 0.048 0.350 0.110 Rn.54447 ferritin, heavy polypeptide 1 AW914090 5 −1.61 0.046 −0.029 0.002 Rn.973 60S acidic ribosomal protein P1 (Rn.) (DBSS_strong) AW142828 5 −0.65 0.044 −0.068 −0.034 Rn.23877 ESTs AI705731 5 −0.95 0.040 −0.042 0.058 Rn.24919 transcription factor MTSG1 NM_019126 5 −0.33 0.037 −0.112 0.140 Rn.25723 Carcinoembryonic antigen gene family (CGM3) U73503 5 0.64 0.037 0.057 −0.014 Rn.10961 calcium/calmodulin- dependent protein kinase (CaM kinase) II gamma AF017437 5 0.55 0.036 0.066 −0.010 Rn.7409 integrin-associated protein NM_021869 5 −0.42 0.035 −0.083 0.057 Rn.1993 syntaxin 7 AI144644 5 −0.34 0.030 −0.087 0.024 Rn.12319 ESTs AA818377 5 0.79 0.029 0.037 −0.033 Rn.34063 hypothetical protein FLJ22419 (Hs.) (DBSS_weak) AI171994 5 0.13 0.027 0.198 0.008 Rn.22380 ESTs AA925167 5 −0.12 0.022 −0.180 0.106 Rn.8672 ESTs BF398051 5 −0.38 0.020 −0.053 0.080 Rn.97322 ESTs AW144075 5 0.48 0.019 0.040 −0.024 Rn.19790 ESTs U26686 5 −0.09 0.015 −0.158 −0.045 Rn.10400 nitric oxide synthase 2 BF404426 5 −0.07 0.009 −0.128 −0.032 Rn.63325 ESTs U31866 5 0.24 0.007 0.029 −0.037 Rn.32307 Nclone10 mRNA AW917475 5 −0.07 0.006 −0.087 0.055 Rn.16643 high-affinity immunoglobulin gamma Fc receptor I AI408517 5 0.44 0.006 0.013 0.021 Rn.2773 protein phosphatase 1, regulatory (inhibitor) 5 subunit 14B AF207605 5 −0.34 0.005 −0.015 0.000 Rn.42674 tubulin tyrosine ligase AI178922 5 −0.41 0.005 −0.012 −0.023 Rn.18670 leucine zipper and CTNNBIP1 domain containing (Hs.) (DBSS_moderate) BF398403 5 0.41 0.005 0.011 −0.037 Rn.20421 mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase (EC 3.2.1.114) (Mm.) (DBSS_moderate) M22923 5 0.05 0.004 0.091 −0.019 Rn.10922 membrane-spanning 4- domains, subfamily A, member 2 BE107747 5 −0.05 0.004 −0.077 0.041 Rn.29176 ESTs BF281697 5 0.57 0.004 0.007 −0.024 Rn.7770 potassium voltage-gated channel, Isk-related family, member 1-like (Hs.) (DBSS) AB006461 5 0.03 0.002 0.059 −0.009 Rn.5653 neurochondrin AF100960 5 0.03 0.001 0.051 −0.038 Rn.8633 FAT tumor suppressor (Drosophila) homolog U79031 5 −0.07 0.000 0.006 0.048 Rn.44299 adrenergic receptor, alpha 2a NM_017353 5 −0.21 −0.004 0.019 0.045 Rn.32261 tumor-associated protein 1 AI231716 5 1.81 −0.007 −0.004 −0.138 Rn.24598 ESTs NM_012964 5 0.67 −0.024 −0.036 −0.298 Rn.92304 Hyaluronan mediated motility receptor (RHAMM) L06040 5 0.19 −0.035 −0.183 −0.306 Rn.11318 arachidonate 12- lipoxygenase

The 186 genes of the necessary set listed in Table 4 correspond to 164 reward genes, of which 72 are induced on average across the nephrotoxicants. Additional genes not necessary for classification, but nonetheless differentially regulated by the nephrotoxicants relative to the negative class, were also considered.

Example 5 Using a Necessary Set to Generate New Signatures for Renal Tubule Injury

As shown above in Examples 1-3, a predictive signature for renal tubule injury comprising 35 genes may be derived using gene expression data from a microarray in the context of a chemogenomic database. Using the signature stripping method described above, four additional high performing predictive signatures for renal tubule injury may also be derived wherein each of the signatures is non-overlapping, i.e., comprises genes not used in any of the other signatures. Together, the union of the genes in these five signatures comprises a set of 186 genes that is necessary for deriving a predictive signature for renal tubule injury capable of classifying the training set above a selected threshold level of LOR=1.64.

This example demonstrates that additional signatures for renal tubule injury may be generated based on the necessary set of 186 genes. In addition, it is shown that at least four genes must be selected from the necessary set in order to generate a signature for renal tubule injury capable of performing above a selected threshold LOR of 4.00.

As listed in Table 4, for each gene from the necessary set of 186, an impact factor was calculated, corresponding to the product of the gene's weight and the gene's expression mean logratio in the positive class (i.e., nephrotoxicants). Subsets of genes were chosen randomly from the necessary set of 186 so that the sum of the impacts of all genes in the subset accounted for 1, 2, 4, 8, 16, 32, or 64% of the total impact. Total impact was defined as the sum of the individual impacts of all 186 genes in the necessary set. This random subset selection procedure was repeated 20 times resulting in 140 gene subsets (i.e., 7 impact thresholds times 20 random choices).

Table 5 shows the average number of genes for each of these seven impact thresholds. This number increases regularly reaching an average of 116 genes for those subsets that account for 64% of the total impact. Each of these random subsets was used as input to compute a renal tubule injury signature using the SPLP algorithm as described in Example 3 above. A training LOR and a 10-fold cross-validated test LOR were calculated for each signature. Table 5 lists average LOR values for the signatures generated in each of the seven percent of total impact thresholds.

Based on the results tabulated in Table 5 it may be concluded that signatures for renal tubule injury capable of performing with an average training LOR of 4.30 may be generated starting with random subsets having an average of 4.4 genes that together have only 2% of the total impact of the necessary set. Similarly signatures capable of performing with an average test LOR of 4.41 may be derived from random subsets of the necessary set having an average of 9.15 genes with only 4% of the total impact. Significantly, the average training LOR never drops below 4.00 when a random set of genes having at least 4% impact are selected. As shown in Table 5, comparably higher performing signatures are derived from the necessary set when the random subsets have a percent impact of 8% or higher. TABLE 5 RTI signatures generated based on randomly selecting necessary set genes with minimal percentage impact # input genes Signature Length LOR (training) LOR (test) percent impact* avg min max avg min max avg stdev avg stdev 1 2.85 1 5 2.8 1 5 3.42 1.61 3.01 1.34 2 4.4 1 9 4.3 1 8 4.30 1.61 3.20 1.00 4 9.15 3 17 8.05 3 13 6.82 2.34 4.41 2.43 8 17.3 8 27 12.8 8 18 8.54 0.61 5.91 1.99 16 33.4 22 42 19.2 14 25 8.68 0.00 7.85 2.01 32 61.6 49 76 26.5 22 30 8.68 0.00 7.35 2.03 64 116 100 134 30.7 28 36 8.68 0.00 7.07 1.50 *average of 20 lists chosen from the necessary set

Table 6 shows the parameters for 20 signatures generated from random subsets of genes with 2% of the total impact of the 186 gene necessary set. Tables 7 (subset 8) and 8 (subset 14) illustrate two specific 5 gene signatures (including values for gene weights and bias) for predicting renal tubule injury onset that perform with a training LOR of 4.00 and 7.3, respectively. TABLE 6 RTI signatures generated based on random selections of necessary set genes with 2% impact # Input Signature Training Test Subset # Genes Length LOR LOR 14 5 5 7.3 5.0 9 7 7 6.8 3.4 15 5 5 6.2 4.1 7 6 6 6.0 3.2 18 5 5 5.8 3.7 3 4 4 5.5 4.0 10 9 8 5.0 2.8 2 4 3 4.7 1.7 13 3 3 4.5 3.2 19 6 6 4.4 2.6 8 5 5 4.0 2.8 11 5 5 3.8 4.5 4 4 4 3.8 4.0 12 4 4 3.8 5.1 20 4 4 3.2 2.7 5 3 3 2.8 2.6 1 4 4 2.6 2.4 17 3 3 2.2 2.4 6 1 1 2.1 1.6 16 1 1 1.7 2.3

TABLE 7 Subset 8 BF283302 15.5 AW920818 5.88 AW141985 5.48 BF403410 4.28 AA858649 −2.3 Bias 1.13

TABLE 8 Subset 14 AI176933 43.1 U08257 33.7 BE116947 18.4 AI408517 12.7 AA819832 −2.9 Bias 8.49

Similarly Table 9 shows the parameters for 20 signatures generated from random subsets of genes with 4% of the total impact of the 186 gene necessary set. Tables 10 (subset 18) and 11 (subset 5) illustrate specific 9 and 13 gene signatures for predicting renal tubule injury onset that perform with a test LOR of 4.1 and 10.2, respectively. TABLE 9 # Input Signature Training Test Subset # Genes Length LOR LOR 5 13 13 8.7 10.2 2 14 11 8.7 8.9 7 11 10 8.7 8.9 9 17 11 8.7 6.2 20 11 9 8.7 5.3 10 14 12 8.7 4.7 11 13 12 8.7 4.6 14 7 6 8.7 4.5 12 9 8 8.7 4.3 18 9 9 8.7 4.1 15 11 9 8.7 3.8 3 6 6 6.2 3.3 19 7 6 6.2 3.2 13 6 6 4.7 3.1 8 11 9 6.8 2.7 4 5 5 4.3 2.7 17 5 5 3.7 2.1 1 7 7 3.7 2.1 6 4 4 3.4 2.0 16 3 3 1.9 1.5

TABLE 10 Subset 18 AW143273 55.95 AI599126 29.8 AI705731 19.05 BF406522 16.71 AB027155 −4.12 AW253895 −13.53 AA819832 −14.81 X68878 −17.57 AW140530 −19.85 Bias 8.96

TABLE 11 Subset 5 AW144075 4.82 AI113104 4.58 AI171994 4.25 AW920818 3.39 BF281697 3.11 AI012120 1.76 BE110577 1.08 NM 012964 0.87 AI227912 0.74 AW144399 −0.2 AI232347 −2.9 AA944518 −6.4 AW914090 −6.6 Bias 0.68

The results tabulated in Table 5 may also be illustrated graphically. As shown in FIG. 2, which plots training LOR and test LOR versus signature length, a signature performing with an average training LOR of 4.00 may be achieved by randomly selecting on average 4 genes from the necessary set. Similarly, an average test LOR of 4.00 may be achieved by randomly selecting on average 7 genes from the necessary set.

Example 6 Functional Characterization of the Necessary Set of Genes for Renal Tubule Injury by Random Supplementation of a Fully Depleted Set

This example illustrates how the set of 186 genes necessary for classifying renal tubule injury may be functionally characterized by randomly supplementing and thereby restoring the ability of a depleted gene set to generate RTI signatures capable of performing on average above a threshold LOR. In addition to demonstrating the power of the 186 information rich genes in the RTI necessary set, this example illustrates a system for describing any necessary set of genes in terms of its performance parameters.

As described in Example 4, a necessary set of 186 genes (see Table 4) for the RTI classification question was generated via the stripping method. In the process, a corresponding fully depleted set of 7292 genes (i.e., the full dataset of 7478 genes minus 186 genes) was also generated. The fully depleted set of 7292 genes was not able to generate an RTI signature capable of performing with a LOR greater than or equal to 1.28 (based on cross-validation using 40 random 80:20 training:test splits).

A further 186 genes were randomly removed from the fully depleted set. Then a randomly selected set including 10, 20, 40 or 80% of the genes from either: (a) the necessary set; or (b) the set of 186 randomly removed from the fully depleted set; is added back to the depleted set minus 186. The resulting “supplemented” depleted set was then used to generate an RTI signature, and the performance of this signature is cross-validated using 3 random 60:40 training:test splits. This process was repeated 20 times for each of the different percentage supplementations of genes from the necessary set and the random 186 genes removed from the original depleted set. Twenty cross-validated RTI signatures were obtained for each of the various percentage supplementations of the depleted set. Average LOR values were calculated based on the 20 signatures generated for each percentage supplementation.

Results

As shown in Table 12, supplementing the fully depleted set (minus random 186) with as few as 10% of the randomly chosen genes from the necessary set results in significantly improved performance for classifying RTI. The random 10% of genes selected from the depleted 186 yielded signatures performing with an avg. LOR=1.4. In contrast, supplementing the depleted set (minus random 186) with 10% from the necessary set yields RTI signatures performing with an avg. LOR=4.5 (based on 3-fold cross-validation using random 60:40 splits). TABLE 12 Supplementation with random genes from necessary or depleted sets Necessary Set Depleted Set % Avg. LOR Avg. LOR 10 4.51 1.43 20 4.93 2.32 40 4.73 2.63 80 4.10 3.28

Although increasing the percentage of random “depleted” set genes used to supplement resulted in an increase in average performance, even at 80%, the average LOR remained below 4.00, while supplementation with the random 80% “necessary” set genes yielded an average LOR above 4.00.

These results demonstrate how supplementation with a percentage of randomly selected genes from the RTI necessary set of 186 “revives” the performance of a fully depleted set for generating classifiers. Thus, the RTI necessary set of genes may be functionally characterized as the set of genes for which a randomly selected 10% will supplement a set of genes fully depleted for RTI classification (i.e., not capable of producing RTI signatures with avg. LOR>˜1.4), such that the resulting “revived” gene set generates RTI signatures with an average LOR greater than or equal to 4.00.

Example 7 Functional Characterization of the RTI Necessary Set by Random Supplementation with Rigorous Signature Cross-Validation

In a further exemplification of the method of Example 6, a randomly selected set including 1, 2, 5, 10, 20, 40, 80, 90, or 99% of the genes from either: (a) the necessary set; or (b) the set of 186 randomly removed from the fully depleted set; was added back to the depleted set minus 186. The resulting “supplemented” depleted set was then used to generate an RTI signature, and the performance of this signature was cross-validated using 40 random 80:20 training:test splits. This process was repeated 100 times for each of the different percentage supplementations of genes from (a) the necessary set, and (b) the random 186 genes removed from the original depleted set. Twenty cross-validated RTI signatures were obtained for each of the various percentage supplementations of the depleted set. Average LOR values were calculated based on the 20 signatures generated for each percentage supplementation.

Results

Based on cross-validation using 40 random 80:20 training:test splits, the fully depleted set of 7292 genes was not able to generate an RTI signature capable of performing with a LOR greater than or equal to 1.28. As shown in Table 13, supplementing the fully depleted set (minus random 186) with as few as 5% of the randomly chosen genes from the necessary set results in substantially improved performance for classifying RTI (avg. LOR ˜2.2). In contrast, the random 5% of genes selected from the depleted 186 yielded signatures performing with an avg. LOR ˜1.3. Significantly, increasing the percentage of random “depleted” set genes used to supplement did not result in an increase in average performance—even at 99%, the average LOR remained at ˜1.3, while supplementation with the random 99% “necessary” set genes yielded an average LOR of ˜4.3. TABLE 13 Supplementation with random genes from necessary or depleted sets % Necessary Set Random Set Supplementation Avg LOR Avg LOR 1 1.44 1.31 2 1.72 1.31 5 2.19 1.31 10 2.68 1.31 20 3.38 1.30 40 4.00 1.30 80 4.39 1.28 90 4.32 1.28 99 4.32 1.28

These results further demonstrate how supplementation with even a small percentage of randomly selected genes from the RTI necessary set “revives” the performance of a fully depleted set for generating classifiers. It also demonstrates that more rigorous cross-validation (40-fold random 80:20 training:test splits) provides a more consistent average performance of the signatures generated by the random supplementations from depleted set. Thus, the RTI necessary set of genes may be functionally characterized as the set of genes for which a randomly selected 5% will supplement a set of genes fully depleted for RTI classification (i.e., not capable of producing RTI signatures with avg. LOR>˜1.3), such that the resulting “revived” gene set generates RTI signatures with an average LOR of greater than or equal to about 2.00. Further, a random supplementation of at least 40% of the necessary set genes will produce a revived gene set capable of generating RTI signatures with an average LOR greater than or equal to about 4.00.

Example 8 Construction and Use of a DNA Array for Predicting Renal Tubule Injury

The necessary subset of 186 genes identified to be necessary and sufficient to classify the renal tubule injury training set listed in Table 4 may be used as the basis for a DNA array diagnostic device for predicting renal tubule injury. The device may be used in a therapeutic monitoring context, such as for monitoring the response of an individual to a compound that is suspected of possibly causing renal tubule injury (or related nephrotoxic side effects). Alternatively, smaller sufficient subsets of genes the necessary set, which may be selected according to the methods of Examples 4 and 5 described above, may be used as the basis for a DNA array.

The probe sequences used to represent the 186 (or fewer) genes on the array may be the same ones used on the Amersham CodeLink™ RU1 platform DNA array used to derive the renal tubule injury signature as described in Examples 1-3. The 186 probes are pre-synthesized in a standard oligonucleotide synthesizer and purified according to standard techniques. The pre-synthesized probes are then deposited onto treated glass slides according to standard methods for array spotting. For example, large numbers of slides, each containing the set of 186 probes, are prepared simultaneously using a robotic pen spotting device as described in U.S. Pat. No. 5,807,522. Alternatively, the 186 probes may be synthesized in situ one or more glass slides from nucleoside precursors according to standard methods well known in the art such as ink-jet deposition or photoactivated synthesis.

The DNA probe arrays made according to this method are then each hybridized with a fluorescently labeled nucleic acid sample. The nucleic acid may be derived from mRNA obtained from a biological fluid (e.g., blood) or a tissue sample from a compound treated individual. Any of the well-known methods for preparing labeled samples for DNA probe array hybridization may be used. The fluorescence intensity data from hybridization of the sample to the DNA array of 186 (or fewer) genes of the necessary set is used to calculate expression log ratios for each of the genes. Depending on the specific gene signature selected for use in predicting renal tubule injury (e.g., the genes in iteration 1 of Table 4), the scalar product for that signature is calculated (i.e., sum of the products of expression log₁₀ ratio and weight for each gene less the bias). If the scalar product is greater than zero then the sample is classified as positive (i.e., onset of renal tubule injury is predicted).

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for clarity and understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit and scope of the appended claims. 

1. A reagent set for testing whether renal tubule injury will occur in a test subject comprising a plurality of polynucleotides or polypeptides representing a plurality of genes selected from Table
 4. 2. The reagent set of claim 1, wherein the plurality of genes is the set of genes in any one of iterations 1 through 5 in Table
 4. 3. The reagent set of claim 1, wherein the plurality of genes are selected from a linear classifier capable of classifying renal tubule injury with a training log odds ratio of greater than or equal to 4.35.
 4. The reagent set of claim 1, wherein the plurality of genes includes at least 4 genes having at least 2% of the total impact of all of the genes in Table
 4. 5. The reagent set of claim 1, wherein the plurality of genes includes at least 8 genes having at least 4% of the total impact of the genes in Table
 4. 6. The reagent set of claim 1, wherein the reagents are polynucleotide probes capable of hybridizing to the plurality of genes selected from Table
 4. 7. The reagent set of claim 6, wherein the polynucleotide probes are primers for amplification of the plurality of genes.
 8. The reagent set of claim 6, wherein the polynucleotide probes are immobilized on one or more solid surfaces.
 9. The reagent set of claim 1, wherein the reagents are polypeptides that bind to a plurality of proteins encoded by the plurality of genes selected from Table
 4. 10. The reagent set of claim 9, wherein the proteins are secreted proteins.
 11. An apparatus for predicting whether renal tubule injury will occur in a test subject comprising a reagent set according to claim
 1. 12. The apparatus of claim 11, wherein the reagents are polynucleotides.
 13. The apparatus of claim 11, wherein the reagents are polypeptides.
 14. A set of genes useful for testing whether a compound will induce renal tubule injury comprising a random selection of at least about 10% of the genes from Table 4, wherein the addition of said randomly selected genes to a fully depleted gene set for the renal tubule injury classification question increases the average logodds ratio of the linear classifiers generated by the depleted set to at least about 2.5.
 15. The set of claim 14, wherein the randomly selected percentage of genes from the necessary set is at least 20% and the average logodds ratio is increased to at least about 3.3.
 16. The set of claim 14, wherein the randomly selected percentage of genes from the necessary set is at least 40% and the average logodds ratio is increased to at least about 4.0.
 17. A reagent set for classifying renal tubule injury comprising a set of polynucleotides or polypeptides representing a plurality of genes selected from Table 4, wherein the addition of a random selection of at least 10% of said plurality of genes to the fully depleted set for the renal tubule injury classification question increases the average logodds ratio of the linear classifiers generated by the depleted set by at least 2-fold.
 18. The reagent set of claim 17, wherein the random selection is of at least 40% of said plurality of genes and the average logodds ratio of the linear classifiers generated by the depleted set by at least 3-fold.
 19. An apparatus comprising a set of polynucleotides capable of specifically binding to the reagent set of claim
 17. 